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Chapter 1
Introduction
1.1 De novo Design
De novo protein design is a branch in the ﬁeld of protein engineering that started at
the end of the ’70s. Following many successful cases it developed quickly, and nowadays
more than 100 papers are published every year on the subject. The number of publications
per year on “de novo protein design” according to PubMed is reported in Figure 1.1.
























Figure 1.1: De novo protein design publications
Number of articles published every year with the key-words “de novo protein design”. The results were
taken from PubMed in January 2019.
Despite its large diﬀusion, it is quite diﬃcult to describe and explain what exactly
protein design is. In general, everything that brings something new (from Latin, de novo)
in the ﬁeld of protein science can be classiﬁed in this branch: the creation of a new protein
topology [7], a new enzymatic activity [8] or an amino acid sequence that is not present
in nature [9]. However, the boundaries between protein design and protein engineering
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are blurred. For example, a single point mutation in a protein might yield a sequence
that is not present in nature, but it will not be deﬁned as de novo design. The lack of
clear deﬁnitions and boundaries is mainly due to its recent development. Moreover the
deﬁnition of “de novo” is time-dependent: designs and methodologies of the ’80s may be
considered obsolete nowadays thanks to the acquired knowledge and the development of
new technologies.
1.1.1 The origins of the de novo design
The scientiﬁc community generally attributes to Brend Gutte the beginning of the de
novo design era. In fact, he is considered as the father of the ﬁeld since he published
three publications between the end of the ’70s and the beginning of the ’80s.
The ﬁrst article, published in 1975, reports the synthesis by solid phase method of an
analog of Ribonuclease S [10]. The wild-type protein is 124 residue long and presents a
wide loop on its surface. In order to study the importance of loops in protein folding,
Gutte reduced Ribonuclease S to a 70-residue analog, which misses 5 loops not involved in
the enzymatic activity. Surprisingly, despite the removal of 54 residues, the ﬁrst “de novo”
protein retained 4% of the enzymatic activity and speciﬁcity of the wild type enzyme.
The second article was published in 1979 [11]. The group wanted to design an artiﬁcial
peptide with nucleic acid binding activity. They designed a 34-residue peptide in two
steps: ﬁrst they determined that the minimal structure for DNA-binding should contain
a β-strand, a reverse turn, an anti-parallel β-strand, another reverse turn and an α-helix
(shown in Figure 1.2). Following the design of the backbone model, they applied the rules
for secondary structure prediction in order to ﬁnd the best amino acid sequence to ﬁt the
model.
Figure 1.2: Model of an artiﬁcial peptide
Model representation of an artiﬁcial 34-residues polypeptide interacting with the trinucleotide GAA (from
Gutte et al., 1979 [11]).
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The peptide was produced by solid phase synthesis and showed binding to single strand
DNA. Furthermore, the dimeric peptide also showed ribonuclease activity. Despite the
lack of a 3D structure to conﬁrm the design, the results that were obtained at that time
are extremely remarkable, especially considering that: 1- computers were not used, 2-
the number of available pdb structures was limited (42 according to RCBS-PDB) and
3- the advances in molecular biology, such as recombinant DNA, cloning, sequencing or
DNA synthesis were not well-established. Not only they designed and produced artiﬁcial
sequences, but they were also able to retain the original activity and to introduce a new
functionality.
The third major achievement of Gutte was published in 1983 [12]. It describes the
design of a 24 residue β-sheet able to bind DTT on both sides of the sheet. A Kd value
of 20 µM was determined and crystals were obtained, thus leading to the ﬁrst artiﬁcial
crystallized protein. However, the structure of the protein, if any, was never deposited on
RSCB-PDB.
1.1.2 Inverse protein folding
In the three de novo works of Gutte, we can discriminate among two kinds of designs:
in the ﬁrst example there is a simple deletion of parts of the protein (the loops) that
brought to a new sequence; in the remaining two examples there is a rational design of
the structure ﬁrst, and then of the sequence. This last approach was deﬁned by Pabo as
“inverted” [13], and later on took the name of “inverse protein folding”. In the classic
Anﬁnsen view of protein folding, the amino acid sequence of a protein deﬁnes its ﬁnal 3D
structure (Figure 1.3), while in the inverse protein folding concept, a sequence is designed
to achieve a given backbone structure [14].
Figure 1.3: Inverse protein folding
Schematic representation of folding vs inverse folding: on the left, an amino acid sequence and on the
right its protein structure. Arrows describe the relationships among sequence and structure in the normal
folding and in the inverse protein folding approach. The picture was designed for this thesis by Ruth
Kellner.
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Most examples of de novo design that are reported in the literature fall in the inverse
protein folding domain. The target backbone may belong to a natural protein or it may
be designed from scratch, but the sequence is always optimized according to the structure.
The research work presented in this manuscript, fully refers to the inverse protein
folding domain, and the following sections will describe some examples of this class of
designs. However, for completeness, we should mention that there are other options
for generating artiﬁcial proteins, i.e. the directed evolution. This method is widely
used to improve properties of natural proteins and enzymes, such as the solubility, the
stability and the activity. Ward and co-workers used directed evolution to create an
artiﬁcial metalloenzyme able to catalyze a reaction that is not present in nature, the oleﬁn
metathesis [15]. Another example of alternative de novo design is the screening of libraries
of artiﬁcial sequences for in vivo activity [16]. The libraries are inserted in auxotrophs
mutants of E. coli and only the sequences that recover the lacking functionality allows
the survival of the cell. In this way it was possible to select new sequences with enzymatic
activity and also to discover alternative metabolic pathways that are not present in nature.
These two examples are deﬁned as combinatorial designs because they imply the exper-
imental screening of a large number of sequence combinations (up to 106 for the directed
evolution). In comparison to the inverse protein design approach, the combinatorial one
has more chances of success thanks to its strong selection method. However, due to its
experimental nature (intended as wet-lab experience), it is time consuming and more
expensive. For this reason, there are much more examples in the literature of inverse
folding designs (often less successful) than combinatorial ones. For example, a PubMed
search for “Protein engineering [title]” gave 935 outputs (March 2019). The words “Pro-
tein engineering [title] AND design”, mainly used for inverse folding designs, found 190
outputs, while “Protein engineering [title] AND libraries”, mainly used for combinatorial
designs, found only 50 outputs. If both words are restricted to be present in the title
of the articles (“Protein engineering [title] AND design [title]” and “Protein engineering
[title] AND libraries [title]”), the output numbers are reduced to 44 and 9, respectively,
showing that the combinatorial approach is less used compared to the rational one.
Manual design
As described in the previous section, the inverse protein folding is the design of ar-
tiﬁcial sequences starting from a 3D structure. After Gutte, many other examples were
published in the literature: the design of helix-bundles (Figure 1.4a) [17, 18], β-sheet folds
(Figure 1.4b) [19], ﬁbrous proteins [20, 21], coiled coil [22] and membrane channels [23].
Attempts to design artiﬁcial TIM-barrels have been carried out by the group of Joseph
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Martial, at the University of Lie`ge, and they are described in Chapter 1.3, page 19) [1–3].
(a) (b)
Figure 1.4: Examples of manual designs
(a) The model of the protein Felix, an artiﬁcial 4-helix bundle (from Hecht et al. 1990 [18]) and (b) the
model of the Betabellin, and artiﬁcial β-sheet protein (from Yan and Erickson, 1994 [19]).
All these examples are classiﬁed as “manual” de novo designs, in opposition to the
“computational” ones that arrived later on (described in the next section). Until 1997,
researchers in the ﬁeld performed manually all the steps of design, from the alignment of
protein sequences, to the creation of backbone models (Figure 1.4) and the optimization of
the sequence. The reasons are bound to the technological limitation of that time: despite
computers with discrete computational power were available, specialized programs for
protein manipulation were missing or had a limited diﬀusion in the scientiﬁc community.
For example, the ﬁrst algorithms for global sequence alignment of proteins was pub-
lished in 1970 [24], the ﬁrst one for local sequence alignment in 1981 [25], and the ﬁrst one
for multiple sequence alignment in 1986 [26]. The ﬁrst program for homology modelling
is dated 1988 [27]; the ﬁrst one for structural alignment is in 1989 [28], and the ﬁrst
computational method to design proteins de novo was published in 1994 [29]. Many of
these programs are widely used nowadays, and they are essential to the ﬁeld of de novo
design.
Computational design
The jump from “manual” to “computational” designs dates back in 1997. In this year,
Dahiyat and Mayo published the ﬁrst paper describing a revolutionary method for de novo
design and sequence selection [9]. As mentioned in the previous section, an algorithm for
de novo design was already published in 1994 [29]. However it was based exclusively on
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statistic data extracted from native structures deposited on RCSB-Protein Data Bank.
This means that the designs are biased by the database content (i.e. proteins that are
soluble enough for the crystallization process only). As a consequence, many folds or
proteins were excluded (i.e. membrane proteins). The revolutionary algorithm proposed
by Dahiyat and Mayo is based on physical and chemical properties of amino acids, in order
to determine with high precision the structure and the stability of any kind of fold. In
particular, they introduced the concepts of “scoring functions” and “energy calculation”
that are widely used nowadays.
Diﬀerences among manual and computational design are not limited to the historical
period or the technological advances only. In the manual design there is a limited number
of sequence combinations that researchers may take into account. In the computational
approach this number is limited only by the computational power. Dahiyat and Mayo
calculated the energy score for 1.9 x 1027 sequences for the target fold (a zinc binding
domain of 28 residues). It took 90 hours of computational calculations. It is not possible
to obtain the same results by manual design.
Following the work of Dahiyat and Mayo, software for energy calculations and protein
design were developed,that gave rise to the computational era of de novo protein design.
Some of the most interesting examples are: the re-design of globular proteins [30] and
enzymes [31, 32], the design of a new protein fold [7], of an enzyme with new activity [33] or
with an unnatural reaction [8], the thermo-stabilization of enzymes [34], the incorporation
of unnatural amino acids [35] and the self-assembling of protein nanostructures [36]. The
review of Woolfson [37] summarizes most of the successful design obtained so far. In
general, small proteins (less than 100 aa) or repeat proteins have an higher rate of success
compared to larger ones. Proteins designed by inverse protein folding usually do not
have an enzymatic function. Once the structure of the designed protein is experimentally
validated, it is possible to add a function, as an enzymatic activity or a binding site.
However the success rate in the design is very low. For example, in almost 30 years of
design of the TIM-barrel fold, only 1 design out of 43 was successful (see Chapter 1.3,
page 19). Regarding the thioredoxin fold (see Section 1.1.2, page 7), only 1 protein out of
48 was experimentally validated. The reasons of this low rate are probably bound to the
limitation in our knowledge of proteins. Many aspects in the stability, solubility, folding
and function of proteins are not yet fully understood, in particular for protein larger
than 100 residues. This led to limitations in software and tools for protein modelling and
design. However, these software are constantly improved, with information obtained by
both natural and artiﬁcial proteins.
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Thioredoxin re-design
Among all the available examples on the de novo protein design, I will describe in more
details the work of Winther and co-workers on the re-design of the thioredoxin protein
[31]. The goal of their research was to test the capabilities of a modelling software, Rosetta
[38], to recreate the target fold.
The thioredoxin fold was chosen because it is a small and rigid protein (106-112 aa),
highly conserved in nature, with 90% of well-deﬁned secondary structures. As for the
TIM-barrel fold, the amino acid sequences of the thioredoxin family may be highly dif-
ferent (thus, have low sequence identity). Moreover, the protein was already successfully
engineered in previous works. The researchers selected 8 natural structures with a thiore-
doxin fold from Protein Data Bank (shown in Figure 1.5a), and they performed geometry




Figure 1.5: Thioredoxin fold, design and expression
(a) Structural overlay of 8 natural thioredoxin folds and (b) Dendrogram showing the distance relation-
ships after sequence alignment of the 960 designs and (c) Analysis of the expression and of the solubility
of the 48 designs of the thioredoxin. The gray bars indicate the insoluble fraction (inclusion bodies) while
the black bars indicate the soluble fraction of the crude extract. Two pmol of protein corresponds to ∼0.2
mg/mL of protein. The nomenclature used is dNyxx, where d is design, N the ﬁrst(s) letter in the PDB
ID code of the initial templates, y the geometry optimization output and xx the sequence optimization
output (from Winther et al., 2016 [31]).
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For each of the 48 backbone structures, the sequence optimization generated 20 models,
for a total of 960 designs. The sequence relationship of the models after alignment is
shown in Figure 1.5b. For each of the 8 initial templates, the group chose six designs for
experimental validation according to the lowest Rosetta energy score (so, the ones with
higher stability), for a total of 48 models. Their synthetic genes were inserted in a plasmid
with an HisTag at the C-terminal part of the protein, and cloned in E. coli. Expression
trials couppled to western blot analysis indicates that 16 out of the 48 proteins did not
expressed at all, 11 were expressed in inclusion bodies only and the remaining ones were
partially found in the soluble fraction of the crude extract (Figure 1.5c).
Among the soluble ones, only 2 were successfully puriﬁed. The other ones were not
stable or soluble enough, with some of them aggregating on-column. Only one of the
two puriﬁed proteins was able to form crystals, and its structure was solved. The X-ray
structure is in good agreement with the computational model, and the average RMSD is
of 1.8-2.0A˚ (Figure 1.6).
Figure 1.6: Structure resolution of the thioredoxin design
Overlay of thioredoxin structures: the initial template (obtained from Protein Data Bank) is shown in
green, in red the designed model and in blue the X-ray structure. Its resolution is 2.4A˚ (from Winther,
2016 [31]).
This work on the redesign of the thioredoxin protein is an excellent example of inverse
protein folding. Moreover it is one of the few publications on de novo protein design in
which both the positive and the negative results are reported. In general, only successful
designs are published and this makes more complicated to understand and discuss any
unexpected results.
The design of Winther has also many similarities with the work presented in this thesis,
for example the use of the Rosetta software. Thanks to these similarities it is possible to
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compare and discuss the two designs despite of signiﬁcant diﬀerences in the target folds,
thioredoxin on the one side and TIM-barrel on the other.
In the next chapters I will ﬁrst describe the subject of this thesis project, the TIM-
barrel fold, and then I will illustrate results that were obtained in the group of Joseph
Martial (the Octarellin project) at the University of Lie`ge.
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1.2 Natural TIM-barrels
The TIM-barrel fold can be found in 10% of all known proteins and in 5 out of 6
classes of enzymes, representing the most common fold in nature [39, 40]. This chapter
will describe features such as structure, function, folding, stability and evolution of the
TIM-barrel fold.
1.2.1 Structure, topology and classiﬁcation
The TIM-barrel fold owes its name to triosephosphate isomerase (TIM), the ﬁrst en-
zyme discovered to have a (β/α)8-barrel fold. Its structure was solved in 1975 and it is
shown in Figures 1.7a and 1.7b.
(a) (b)
(c)
Figure 1.7: Structure of triosephosphate isomerase
(a) Top view and (b) side view of the triosephosphate isomerase (TIM) structure, solved in 1975 [41]
and deposited on RCSB-PDB under the ID “1TIM”. (c) Topology model of the TIM-barrel fold (from
Ho¨cker et al., 2005 [42]).
The TIM-barrel fold is composed of 8 β-strands forming a closed central β-sheet (β-
barrel), surrounded by 8 α-helices forming an external barrel (α-barrel). The topology
model of TIM-barrels is a 8-fold repetition of the β/α motif (Figure 1.7c). All β-strands
are oriented in the same direction, forming a parallel β-sheet. With the exception of the
TIM-barrel family, all the other β-barrel proteins contain anti-parallel or mixed β-sheets
only [43].
CATH classiﬁcation
The TIM-barrel family is classiﬁed according to the Class, Architecture, Topology and
Homology (CATH) classiﬁcation [44], as 3.20.20: the Alpha Beta Class (3.), the Alpha-
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Beta Barrel Architecture (20.) and the TIM-barrel fold (20). Up to date (January 2019),
37 Superfamilies and 15671 Domains are included in the TIM-barrel family.
The β-barrel structure
Many protein folds containing a β-barrel structure, TIM-barrels included, have been
deeply studied and classiﬁed according to two parameters: the number of strands (n),
and the shear number (S) [45–49]. The shear number is deﬁned as “the change of residue
numbers on a β-strand when a point moves in the left hydrogen bond direction back to
the same β-strand” [45]. Figure 1.8 reports an example of the 3D β-barrel structure of
the TIM-barrel fold and its “unrolled” representation [5].
Figure 1.8: Shear number in β-barrels proteins
Characterization of the β-barrel of the TIM-barrel fold according to the hydrogen bond connection and
the Shear number calculation (from Figueroa et al., 2013 [5]).
The TIM-barrel family is characterized by n=8 and S=8, since 8 “jumps” among
residues are necessary to complete a full turn of the barrel.
The number of strands (n) and the shear number (S) are useful information to char-
acterize β-barrel proteins. When S is positive, the barrel is right-stranded (as in the
TIM-barrel fold). Moreover, when n=S, the side-chains of the β-barrel point alternatively
towards the center of the barrel (pore residues) and towards the α-helices (core residues).
In layer 1 of Figure 1.8, the residues of odd strands (β1, β3, β5 and β7) are pore residues.
They points towards the center of the barrel, while the even strands (β2, β4, β6 and β8)
are core residues and point outside the barrel. The layer 2 has the opposite combination:
odd strands have core residues, even ones pore residues, and so on for the following layers.
This diﬀerence of odd and even strands set the limits for the symmetry of the TIM-barrels,
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which is not a mere repetition of 8 (β/α) motives (8-fold symmetry), but a repetition of
4 (β/α/β/α) motives (4-fold symmetry) [50].
Although the 8 β-strands of the TIM-barrel fold are in general fully connected by H-
bonds, we can ﬁnd examples of proteins that contains “open” β-barrels. One signiﬁcant
example is the methylmalonyl CoA mutase, an enzyme that contains a TIM-barrel fold
among other domains. When the substrate is absent, the β-barrel is split apart in an
“open” conformation, and the active site is accessible to solvent. After binding, the
β-barrel closes around the substrate recovering a fully connected conformation [51].
The α-barrel structure
The α-barrel structure of the TIM barrel fold is less characterized than its β-counterpart.
A single α-helix is exposed to the solvent for 1/3rd of its surface, while the remaining 2/3rd
are involved in hydrophobic interaction with the β-barrel and with the neighboring he-
lices. The hydrophobic core of the TIM-barrel fold is not composed by the residues in
the pore of the TIM-barrel but by the ones situated at the interface of the β-barrel and
the α-barrel (hydrophobic ring) [49]. H-bond interaction among helices are present but,
in contrast with the H-bond network of the β-barrels, they are not necessary. Multiple
examples of missing helices are reported in the literature: the phosphoinositide-speciﬁc
phospholiphases C (PI-PLCs) enzymes lack 2 helices in the prokaryotic homologous (α4
and α5) and a single helix (α5) in the eukaryotic one [52]. The structures of cellobio-
hydrolase II [53] and of E2CD endocellulase [54] are also lacking 2 helices (α7 and α8).
These enzymes present irregularities (distortions and missing elements) in the TIM-barrel
fold to better adapt to the large substrates [52].
The loop region
TIM-barrels contain 15 loops: 8 to connect β-strands with α-helices (called C-term
loops) and 7 for the opposite direction (N-term loops) [43]. C-term loops are usually
longer than N-term loops and can include both additional secondary structures and entire
extra domains [55]. The reason why C-term loops are longer and contain extra-domains
compared to their N-term counterpart is that the active site of TIM-barrel enzymes is
always located at the C-term of the barrel. C-term loops not only form the active site
but they are also extremely important in the substrate recognition and binding. On the
contrary, N-term loops are associated to the stability of the overall structure [56].
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1.2.2 Function
TIM-barrels are involved in 5 out of 7 classes of the Enzyme Commission (E.C.) clas-
siﬁcation for enzymatic activities: 1-oxidoreductase (15% of the TIM-barrel enzymes),
2-transferase (11%), 3-hydrolase (49%), 4-lyase (12%) and 5-isomerase (11%) [57]. The
6-ligase and 7-translocase classes are the only ones in which the fold is not present. How-
ever, not all the TIM-barrels have an enzymatic activity: the narbonin, the concavalin B
and a chitinase-like protein have no enzymatic function [58–60].
The TIM-barrels sub-families can be bound to a single class of enzymatic reactions (i.e.
the racemase family catalyzes only isomerase reactions), while other are spanning among
multiple E.C. classes (i.e. the PP-binding family catalyzes oxidoreductase, transferase,
lyase and isomerase reactions) [57]. There is also an example of a single protein with 2
activities: the N-(5’-phosphoribosyl)-anthranilate isomerase/indole-3-glycerol-phosphate
synthase of E. coli catalyze 2 diﬀerent reactions (isomerase and hydrolase) in the biosyn-
thesis of tryptophan. Indeed the enzyme is composed by two TIM-barrel domains that
do not present signiﬁcant sequence identity [61].
Some of the most eﬃcient enzymes belong to the TIM-barrel family. For example,
the 5’-monophosphate decarboxylase has the largest enhancement rate among any other
enzymes [62], and the triose phosphate isomerase (the original TIM) works at the diﬀusion
rate limit [63].
At biological level, TIM-barrels are involved in the small molecule metabolism (47%),
macromolecule metabolism (25%), energy metabolism (20%), DNA/RNA information
pathways (2%) and ion channel transport (1%) [64].
1.2.3 Evolution
The evolution of the TIM-barrel fold has been extensively discussed during the ’90s.
The ﬁrst theory that has been proposed is that the TIM-barrel fold arose from convergent
evolution to a stable fold. This theory was mainly supported by the observation that the
similarities in sequences, functions and ligands of the known TIM-barrels were too low to
support divergent evolution from a common ancestor [65].
On the other side, evidences to support the divergent evolution theory were three: all
the TIM-barrels has an enzymatic activity (the narbonin was discovered 5 years later), the
active site is always located at the C-term of the protein and similar structural patterns
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are present in diﬀerent structures, including TIM-barrels with diﬀerent functions [65, 66].
Recent evidences suggested that not only the TIM-barrels are the result of a divergent
evolution from a common ancestor, but also that the ancestor was half the size of a modern
TIM-barrel and that the corresponding ancestral gene underwent to duplication, fusion
and evolutionary divergence [49, 67–70].
In 2004, the Sterner group experimentally mimicked the evolution of the TIM-barrel
fold [71]. Starting from the natural proteins HisF and HisA they generate three novel
enzymes by duplication of the C-terminal half of HisF (HisF-CC) and by combination of
the N-terminal half of one protein with the C-terminal half of the other protein (HisAF
and HisFA), shown in Figure 1.9a. Both HisF-CC and HisFA had tendency to aggre-
gate, while HisAF was found stable and monomeric in solution. Improvements in the
packing of HisF-CC led to a stable and monomeric protein (HisF-C*C), supporting the
theory of divergent evolution by duplication of a half-barrel, followed by diversiﬁcation
and eventually recombination, Figure 1.9b.
(a) (b)
Figure 1.9: Evolution of TIM-barrels from half-barrel domains
(a) Structure and topology representations of the natural protein HisF and HisA and their fusion con-
struct; (b) proposed evolution model of natural TIM-barrels (from Hocker et al., 2004 [71]).
Ho¨cker et al. [71] also suggested that the (β/α)4 ancestor of modern TIM-barrels
derived from a ﬂavodoxin-like fold, which is formed by an (β/α)5 domain. Evidences of
sequence identity among HisF and HisA with the ﬂavodoxin-like proteins support this
hypothesis, (Figure 1.9b).
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1.2.4 Folding
TIM-barrel proteins all share homologous 3D structure but display very low sequence
identity. Is their folding driven by the native topology or by their individual amino acid
sequence?
Since the ﬁrst structure was published [41], many studies have been performed to char-
acterize the folding of TIM-barrel proteins, using diﬀerent techniques and approaches:
circular permutation [72], fragmentation [73, 74], chemical-induced unfolding [75–77],
temperature-induced unfolding [78–80] and hydrogen exchange coupled to mass-spectrometry
[81]. Diﬃculties in thermal unfolding studies arose because many TIM-barrel proteins
have irreversible denaturation transitions, usually linked to protein aggregation [82, 83].
However, diﬀerent models of folding pathways have been proposed: from the simple two-
state transition [81, 84] to more complex ones that involve intermediates with multiple
oligomerization states [85, 86]. An exhaustive review about the proposed models of un-
folding was published by Zarate-Perez in 2008 [87].
Intermediates observed in the folding of TIM-barrels are mainly composed by (β/α)
modules. The phosphoribosyl anthranilate isomerase (TrpF), from both yeast and E. coli,
populates a stable intermediate formed by the ﬁrst six (β/α) subunits when tested in vitro
(model 6+2) [73]. Surprisingly, when tested in vivo it is formed by the ﬁrst four subunits
(model 4+4) [70]. Triose-phosphate isomerases (TIMs) from E. coli and rabbit show a
4+4 model, but the homologous enzyme in yeast presents a 3+3+2 folding model [88].
The folding of TIM-barrel proteins can also be mediated by chaperons. In E. coli the
chaperonin GroEL and its cofactor GroES are involved in the folding pathway of more
than 250 proteins (30% to 50% of which contain a TIM-barrel fold) [89, 90]. For example,
folding of dihydrodipicolinate synthase (DapA) from E. coli goes 30 time faster when
associated to the GroEL/ES machinery than with spontaneous folding [91].
1.2.5 Stability
It is diﬃcult to understand which factors are contributing to the stability of TIM-barrel
fold, mainly because the protein sequences are highly variable. Two general approaches
were adopted: site-directed mutagenesis to produce mutants and comparison of TIM-
barrels from diﬀerent environment (psychrophilic, mesophilic and thermophilic).
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In 1998, the group of Wierenga compared the stability of two triose-phosphate iso-
merases, from the psychrophilic Vibrio marinus (vTIM) and from the mesophilic Es-
cherichia coli (eTIM) [82]. The ﬁrst organism has an optimal growth at 15◦C, while
the latter at 37◦C. vTIM and eTIM have 66% of sequence identity, similar kcat values
at their temperature optimum (10◦C and 25◦C respectively) and a temperature of half-
denaturation (Td) of 41
◦C and 54◦C respectively. The group showed how a single mutation
of vTIM (A238S) was increasing the stability of the protein of 5◦C. However, the catalytic
eﬃciency was aﬀected, showing that enhancing the stability can lead to a lack of eﬃciency.
Anyway, this is not always the case. The mutation E65Q of the triose-phosphate
isomerase from Leishmania mexicana (lTIM), increases the stability by 26◦C, converting
a mesophilic protein to a thermophilic one, without losses in the enzymatic activity [92].
Another remarkable example is the mutation of the ﬁrst residue (valine) of the xy-
lanase from Bacillus sp. [93]. This residue is not involved in the formation of secondary
structures. Its mutation in leucine (V1L), increases the overall stability by 5◦C, while
the mutations V1A and V1G decrease it by 2 and 12◦C respectively. The mutations af-
fect in a diﬀerent way the interactions among the N-term and the C-term of the protein,
suggesting that the stability of the TIM-barrel fold can be correlated with the degree of
interaction among its extremities. This theory was demonstrated by Ramakumar group
that showed how increasing non-covalent interactions in the N- and C-term is enhancing
the protein stability, not only in the xylanase (TIM-barrel fold) but also in other protein
folds that have connected N- and C-term [94].
A broader study on the adaptation of the TIM-barrel fold to diﬀerent temperatures
was performed in 1999 by Maes group [95]. They compared 10 diﬀerent TIMs from psy-
chrophilic, mesophilic, thermophilic and hyperthermophilic organisms according to dif-
ferent parameters: a- sequence alignment, b- volumes, c- cavities, d- hydrophobicity, e-
hydrogen bonds, f- salt bridges and g- charge distribution in the helices. Surprisingly, they
did not ﬁnd evidences for correlation between stability and sequence, volumes, cavities or
hydrogen bonding. The psychrophilic and thermophilic TIMs display more salt-bridges
compared to mesophilic TIMs. The hyperthermophilic protein enhanced this trend by
tetramerization: extra salt-bridges are present at the interface between monomers. Ther-
mophilic TIM-barrels, but not psychrophilic and mesophilic ones, are characterized also
by higher hydrophobicity in the protein core. It suggests that folding is mainly driven by
hydrophobic collapse at high temperature [95].
Some of the features and characteristic of the natural TIM-barrel family are important
in the context of de novo design. In the next chapter I will describe the ﬁrst attempts
made in Lie`ge towards the design of artiﬁcial TIM-barrel proteins.
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1.3 The Octarellin story
At the end of the ’90s, the group of Joseph Martial at the University of Lie`ge in
Belgium, started a project dedicated to the de novo design of proteins with a (β/α)8-
barrel fold. This is the base of the present thesis project.
Over the years, six artiﬁcial TIM-barrels (named Octarellins) were designed from
scratch following diﬀerent methods.
Octarellin I [1, 2], II and III [3] were designed in a “manual” way, with a limited use
of computational support. With the advance of computing power and the development of
programs dedicated to the calculation of atomic interactions, the research group switched
from “manual” to “computational” design and designed Octarellin V [4], Octarellin VI
[5] and the present work.
Octarellin V.1 [6] was created through directed evolution of Octarellin V and can be
referred to the result of a “combinatorial” method.
1.3.1 Octarellin I
The design of the ﬁrst artiﬁcial TIM-barrel was published in 1990 by Goraj [1] and
was followed in 1991 by its biophysical characterization [2]. The group aimed to recreate
the TIM-barrel fold by the repetition of 8 structural β/α-units (that gave the name of
Octarellin to the proteins). The repetition unit is composed by a ﬁrst turn, a β-strand,
a second turn and an α-helix. In order to ﬁnd the amino acid sequence for the structural
unit, the group analyzed the sequences and the structures of the three natural TIM-barrels
known at the time: triose phosphate isomerase (TIM) [41], KDPGaldolase [96] and xylose
isomerase [97]. The analysis took into account the length of secondary structure elements
(Figure 1.10a), the residue frequency and the β/α-packing.
Analysis of the amino acid composition led to the design of a 30 aa sequence unit that
was then repeated 8 times to form the (β/α)8-barrel. It is composed by 4 residues for
the ﬁrst turn, 6 for the β-strand, 7 for the second turn and 13 for the α-helix, with the
following residues:
DARS - GLVVYL - GKRPDSG - TARELLRHLVAEG
A ﬁrst plasmid was constructed with the single structural unit, and it was then repli-
cated to obtain 2 to 12 unit repetitions. All the 12 constructs were inserted in E. coli,
and expressed. The expression proﬁle of proteins with 5 to 12 repetition units is shown
in Figure 1.10b. The proteins with 2 to 12 unit repetitions were all produced in inclusion
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bodies. Only the 7-, 8- and 9-fold were extracted from the inclusion bodies by denatura-
tion, refolded by dialysis and characterized by far-UV circular dichroism (CD), infrared
(FTIR), Raman and UV-absorption spectroscopies. Octarellin I was found to consist of
30% of helix- and 40% of strand-content, and a loosely packed 3D structure.
(a) (b)
Figure 1.10: Octarellin I, design and production
(a) Secondary structure lengths in natural TIM-barrels; (b)SDS-PAGE of the artiﬁcial polypep-
tides with 5 to 12 repetition units. Lanes 1-9: inclusion bodies containing the artiﬁcial polypep-
tides (arrows), from 4 to 12 repetition units respectively. Octarellin I is shown in lane 5. Figures
are extracted from Goraj et al., 1990 [1].
1.3.2 Octarellin II and III
The 4-fold symmetry is now commonly associated to the TIM-barrel fold, but was
proposed for the ﬁrst time in 1989 by Lesk [50]. It was not taken in account by the
Martial group until 1995, with the upcoming of the second generation of Octarellins [3].
The design aimed to improve the sequence of Octarellin I, with the help of 5 new natural
TIM-barrel structures [98–102] and the use of a 4-fold symmetry instead the 8-fold one.
Based on the analysis of natural TIM-barrel structures, sequences of the ﬁrst turn, the
beta strand and the second loop were modiﬁed (see Figure 1.11). Octarellin II and III
diﬀer by 20 aa due to symmetry: the second kept a 8-fold repetition symmetry, with
identical strands, while the third makes a distinction between even and odd strands,
introducing the 4-fold symmetry.
Both proteins were produced in inclusion bodies. After refolding, they showed higher
solubility compared to Octarellin I. Biophysical characterization by FTIR, CD and ﬂuo-
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(a)
(b)
Figure 1.11: Octarellin II and III, design and characterization
(a) Evolution of Octarellin I unit peptide (A) to Octarellin II (C) and III (D). The unit sequence was
shorten of 4 residues, one from the β-strands, one from the second turn and two from the helix. (b)
Urea-induced denaturation of Octarellin II and III. Figures are extracted from Houbrechts et al., 1995
[3].
rescence spectroscopies indicated the presence of both helices (30%) and strands (30%)
and weekly packed 3D structures.
Urea-induced denaturation showed a signiﬁcant diﬀerence between Octarellin II and
III, as shown in Figure 1.11b. Octarellin II is partially unfolded at very low concentration
of urea (0.1 M) and fully unfolded at 2-3 M of urea. In contrast, Octarellin III unfolds
according to a sigmoidal cooperative transition that starts ∼2.5 M and ends at ∼4.5 M
urea. There are 20 residues of diﬀerence between Octarellin II and Octarellin III, and all
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of them were designed in β-strand regions. It is interesting to notice how these mutations
positively aﬀect the stability of the protein upon urea-induced unfolding.
1.3.3 Octarellin V
The Octarellin V [4] was the ﬁrst artiﬁcial (β/α)8-barrel protein to be fully designed
with computational assistance. The new generation of Octarellins introduced two diﬀer-
ences with the previous designs. First, the repetition of a structural β/α-unit was no
longer used, and a full polypeptide of 216 residues was designed with no sequence sym-
metry. Second, the design was divided in 2 phases, i.e. the backbone design and the
sequence optimization. This was possible thanks to the creation of specialized programs
for the modelling of peptides and for the calculation of atomic interactions [103–107].
The backbone design was divided in 3 steps: assembly of the 8 β-strands (picture A in
Figure 1.12), assembly of the 8 α-helices (picture B), and connection of α and β elements
with loops (picture C).
Figure 1.12: Octarellin V, backbone and sequence design
(A)Assembly of β-strand elements and (B) α-helix elements; (C) loop connection formation and (D)
sequence optimization. Figures are extracted from Oﬀredi et al., 2003 [4].
Once the full scaﬀold was assembled, the sequence was optimized for the target back-





Octarellin V was produced in inclusion bodies, refolded and characterized by DLS, far-
and near-UV CD, thermal and chemical unfolding and 1H-NMR. The far-UV analysis is
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shown in Figure 1.13a, and GdmCl-induced unfolding is shown in Figure 1.13b. All the
experimental results were encouraging, with the correct secondary structure percentages,
a compact 3D structure and a cooperative thermal unfolding with a melting temperature
(Tm) equal to 65
◦C. However, it was not possible to solve the structure of the protein by
X-Ray crystallography, probably due to its low solubility.
(a) (b)
Figure 1.13: Octarellin V, characterization
(a)Far-UV CD spectrum of Octarellin V and (b) its chemical unfolding in GdmCl by far-UV CD and
ﬂuorescence. Figures are extracted from Oﬀredi et al., 2003 [4].
1.3.4 Octarellin VI
Octarellin VI was designed in 2013 by Figueroa et al. [5], using the Octarellin V
backbone as a starting scaﬀold. Sequence optimization was performed by layers using
the Rosetta software [109]: residues of the hydrophobic ring of the protein (in yellow in
Figure 1.14) were allowed to be changed by hydrophobic residues (M,A,F,L,I,V,W,Y,G
and H) only, while residues of the central pore (in red) and of the surface (in blue) did
not have restrictions for the substitution.





For the ﬁrst time in the Octarellin history, molecular dynamic simulation (MD) in
explicit solvent was performed for 5 nanoseconds with the GROMACS package [110], in
order to verify the stability overtime of the Octarellin VI. Analysis of backbone RMSD vs
time (in Figure 1.15a), RMS ﬂuctuation per residue (in Figure 1.15b), radius of gyration
and secondary structure content were performed.
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Figure 1.14: Octarellin VI, sequence optimization
Layer deﬁnition for the OctarellinVI sequence optimization: hydrophobic core (yellow), central pore (red)
and surface (blue). Figures are extracted from Figueroa et al., 2013 [5].
The protein was expressed in E. coli and produced in inclusion bodies, as for the
previous Octarellins. After refolding, DLS analysis showed the protein to be monomeric,
and far-UV CD indicated a structural content of 34% helices, 18% strands, 19% turns and
29% unordered regions. Near-UV CD spectrum suggested the presence of a stable tertiary
structure. Thermal unfolding showed protein stability up to 70◦C followed by irreversible
denaturation. Chemical unfolding by urea showed a non cooperative transition. However,
as for the previous Octarellins, the poor solubility of Octarellin VI did not allowed the
formation of crystals for structure determination.
(a) (b)
Figure 1.15: Octarellin VI, molecular dynamic simulation
(a) RMSD vs simulation time and (b) RMS ﬂuctuation per residue of the designed model of Octarellin
VI. Figures are extracted from Figueroa et al., 2013 [5].
1.3.5 Octarellin V.1
In 2016 Figueroa et al. [6] returned to Octarellin V in order to improve its solubility
and, hopefully, solve its structure. They used the Green Fluorescent Protein (GFP)
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reporter method developed by Waldo’s group in 1999 [111].
In this method, 20 proteins of Pyrobaculum aerophilum were selected for their diﬀerent
solubility upon expression: from fully soluble proteins to fully unsoluble ones (i.e. inclu-
sion bodies). The proteins were then expressed in fusion with the GFP in E. coli. The
ones that were produced in inclusion bodies showed almost no ﬂuorescence emission, while
fully soluble proteins were highly ﬂuorescent. The researchers demonstrated how the GFP
can be used as solubility reporter, in vivo, since its ﬂuorescence is directly correlated with
the solubility of the fusion protein, (shown in Figure 1.16).
Figure 1.16: Solubility of GFP-fusion products
20 proteins of Pyrobaculum aerophilum are over-expressed in fusion with GFP in E. coli, and their
solubility is directly related to the GFP ﬂuorescence. Details about the proteins are in Waldo et al., 1999
[111].
Figueroa et al. performed directed evolution by using error prone PCR on the gene
of Octarellin V, which was then inserted in a plasmid in fusion with the GFP. They were
able to easily screen in vivo thousands of clones and select the most promising in terms
of solubility (Figure 1.17a, extracted from Figueroa, 2016 [6]). Following 8 rounds of di-
rected evolution, the expression of Octarellin V partially shifted from the inclusion bodies
to the soluble fraction of the cell extract (Figure 1.17b).
The result of the directed evolution is Octarellin V.1, that contains 16 mutations
mainly located at the N- and C-terminal part of the protein (93% of sequence identity).
Biophysical characterization (CD, ﬂuorescence and SAXS among the others) showed no
signiﬁcant diﬀerences at both secondary and tertiary structure levels between Octarellin
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Figure 1.17: Directed evolution of Octarellin V to Octarellin V.1
(a) In vivo ﬂuorescence of Octarellin V in fusion with GFP reporter through 8 cycles of directed evolution
and (b) expression of Octarellin V and V.1 in the total fraction (T), insoluble fraction (I) and soluble
fraction (S) of the crude extract. Figures are extracted from Figueroa et al., 2016 [6].
V and Octarellin V.1.
Octarellin V.1 was then crystallized in the presence of two crystallization helpers: α-
reps (Figure 1.18a) [112, 113] and nanobodies (Figure 1.18b) [114, 115]. α-Reps are based
on natural HEAT repeat proteins, and are composed by α-helices only. From a library
of 1.7 x 109, four diﬀerent α-reps were selected for their interaction with Octarellin V.1.
Nanobodies are single-domain fragments derived from the heavy chain-only antibodies
that are naturally produced by Camelidae. They are formed mainly by β-sheets and have
a molecular mass of 15 kDa. Llama immunization was obtained with 6 injections of 1 mg
of puriﬁed Octarellin V.1 over a period of 6 weeks. A blood sample of 100 mL was obtained
by the immunized llama, and the Peripheral Blood Lymphocytes (PBLs) were isolated.
Following total RNA extraction and cDNA synthesis, the genomic sequences encoding the
nanobodies were obtained. They were used for phage display selection against the puriﬁed
OctarellinV.1. Seven nanobodies were found to stable complexes with the protein. Their
genomic sequence was then identiﬁed.
Both nanobodies and α-reps were produced in E. coli BL21(DE3) and puriﬁed in two
steps: IMAC and size exclusion chromatography.
Crystals were formed with 1 out of the 7 nanobodies and with 1 out of 4 α-reps. The
two helpers were found to bind diﬀerent sites of the protein, and to provide suﬃcient
stabilization for crystallization. In both cases, the obtained structure is not complete,
however they are partially complementary and they agree on the position of all the sec-
ondary structures. Following modelling, the 3D structure of Octarellin V.1 was obtained.




Figure 1.18: Octarellin V.1, model vs structure
(a) Crystal structures of the α-rep and (b) the nanobody that bind Octarellin V.1. (c) Model and (d)
structure of Octarellin V.1, the black arrows indicate the binding site of the crystallization helpers; (e)
comparison of their secondary structure topologies: β-strands (yellow arrows) and α-helices (red bars).
Unexpectedly, the experimental fold resulted to be an αβα-sandwich (Figure 1.18d) in-
stead of the designed TIM-barrel (Figure 1.18c). The nanobody and the α-rep interact
with 3 and 4 helices, respectively, on the same side of the αβα-sandwich (black arrows
in Figure 1.18d). Analysis of the secondary structures (Figure 1.18e) showed that the
position of 7 out of 8 β-strands and 6 out of 8 α-helices in the primary structure of the
protein corresponded to the designed one, but their 3D arrangement resulted to be wrong.
In conclusion, none of the 6 artiﬁcial TIM-barrels designed by the Martial’s group
were fully successful. All of them were produced in inclusion bodies and displayed low
solubility. Resolution of the X-ray structure of Octarellin V.1 showed that the design of
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secondary structure elements was reasonably good, and that troubles arrive with their
arrangement in a 3D structure.
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1.4 Other de novo TIM-barrels
During the ﬁrst 2 years of my PhD, two papers were published on the de novo design
of artiﬁcial TIM-barrels [116, 117]. Both describe the design and the characterization of
the proteins, but the second only reports structural data at high resolution. Diﬀerent
methodologies were used in the designs and a short description of both works is reported
in this chapter.
1.4.1 Symmetrins
In 2015 the group of Rao, Bangalore (India), published a paper [116] on the design of
artiﬁcial and symmetric TIM-barrel proteins called Symmetrins. The design protocol is
diﬀerent in comparison to the one described in this work for the Octarellins. It is reported
in Figure 1.19.
Figure 1.19: Design protocol of Symmetrin proteins
Schematic representation of the design steps for the Symmetrin protein. The picture is taken from
Nagarajan et al., 2015 [116].
Backbone Design
Two ideal βαβ motives of diﬀerent size were selected as a starting point. The two
motives were then integrated to form a single βαβα unit of 56 residues that formed the
single unit repeat of the design. The backbone of the repetition unit is assembled with the
use of βαβ fragments obtained from natural TIM-barrel structures found in the CATH
database [44]. The unit is then repeated 4 times to form a full TIM-barrel, with a total
of 224 residues.
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Sequence Design
The backbone structure is subjected to 16 cycles of design and energy minimization,
performed with the Rosetta software. This protocol is quite standard in the protein design
ﬁeld, and it is used also in the design of the Octarellins. What is diﬀering is the symmetric
restriction that imposes the same amino acid mutations in all the 4-repeated unit of the
Symmetrin protein. 1000 models were created during the sequence design.
Reﬁnement
40 out of the 1000 models are selected based on their lowest Rosetta energy scores and
are subjected to ab-initio folding with Rosetta. This technique is not well performing on
proteins with more than 100 residues, but it is well-suited for symmetric protein that can
be split into smaller sub-units. The 40 models were simulated for ab-initio folding with
a 95 residue sub-unit. The best one was selected for experimental validation and called
Symmetrin-1. Symmetrin-2, -3 and -4 were designed from Symmetry-1 in order to test
diﬀerent kinds of protein stability through mutations in pore residues.
Experimental Validation
Among the 4 Symmetrins, only one is produced in inclusion bodies, while the remaining
three are produced in the soluble fraction. They present an alpha-beta spectrum by
CD spectroscopy, and two of them are monomeric. Surprisingly, the two monomeric
Symmetrins have a Tm of 44
◦C, while the oligomeric one reaches Tm = 63◦C. The 1D-
NMR spectra is well resolved for Symmetrin-1 but it indicates that the protein is in a
molten globule state. No protein structure was published.
1.4.2 sTIM-11
In 2016, the groups of Baker (Seattle, USA) and Ho¨cker (Tubingen, Germany) pub-
lished a paper on the design of another symmetric TIM-barrel, called sTIMs [117]. The
design of the protein is similar to the Symmetrins one described in the previous chap-
ter. The groups succeed in obtaining the structure of one of their models, sTIM-11, and
their design will be used in this work as a positive control during the in silico validation
(Section 2.3.7, page 61).
Backbone Design
For the backbone design, the groups ﬁrst focused on a single βαβα unit. They decided
a ﬁxed length for the β-strands (5 residues) and sampled diﬀerent lengths for N- and
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C-term loops (from 2 to 3 residues) and for the α-helices (from 10 to 14). The best
combination they obtained is a 46 residue repeat unit, that is repeated 4 times to form
the full TIM-barrel model.
Sequence Design
Sequence design is done with 10 cycles of Design and Energy Minimization, the classic
protocol of the Rosetta package. As for the work on the Symmetrin, the group used
restrictions in order to actively design only a fourth of the whole structure, corresponding
to the βαβα unit. Any mutation in the sub-unit is automatically adjusted in the remaining
3 sub-unit of the TIM-barrel.
Reﬁnement
The best 22 models according to the Rosetta energy score are selected for experimental
validation, without any reﬁnement step.
Experimental results
All the 22 proteins are highly expressed in E. coli and puriﬁed. 5 out of them showed
cooperative thermal denaturation and only one was crystallized, sTIM-11. Its structure
resolution is 2 A˚, with an overall Cα-RMSD of 1.28 A˚ and deviations mostly in C-terminal
loops (Figure 1.20). A disulﬁde bridge was designed in sTIM-11 model in order to connect
the ﬁrst and the last units of the TIM-barrels. However, the solved structure shows that
the two cysteines do not form a disulﬁde bond.
Figure 1.20: Comparison of the model and the structure of sTIM11
X-ray crystal structure (in blue) and the designed model (in pink) of sTIM11, top and bottom views.
The picture is taken from Huang et al., 2016 [117].
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Chapter 2
Results and Discussion
2.1 Analysis of natural TIM-barrel proteins
This chapter describes the generation and the analysis of a collection of natural TIM-
barrel structures. Information collected from natural proteins is relevant in both the
design of artiﬁcial TIM-barrels (Chapter 2.2, Protein design, page 45) and their valida-
tion (Chapter 2.3, In silico validation, page 55).
Guidelines for the generation of the collection are two: variability and resolution. As
described in Chapter 1.2, page 11, natural TIM-barrels diﬀers widely in function, 3D
structure and amino acid sequence, and the collection should take into account all the
diﬀerences and should not promote one family over the others (variability). At the same
time the collection should contain only high resolution structures, that are qualitatively
better for analysis, modelling and for a later comparison with artiﬁcial models.
Once the collection is set, its analysis is performed in terms of dimension, energy and
composition. Amino acid full length distributions of the total protein and of individual
strand, helix and loop will deﬁne the geometries for the design of artiﬁcial TIM-barrels
(see Section 2.2.1, Parametric backbone design, page 45). The energy proﬁle and the
amino acid composition will be used as guidelines for the selection of the artiﬁcial models
that will be tested experimentally (see Sections 2.3.1 to 2.3.5, starting at page 55).
2.1.1 Collection of natural TIM-barrels
A simple Google search for “TIM-barrels” lead to the DAtabase of Tim barrel En-
zymes (DATE), a ready-to-use collection of natural TIM-barrel enzymes. The web-site
was created by S. Kumar Singh and M. Madan Babu at the MRC Laboratory of Molec-
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ular Biology in Cambridge (UK) with the aim of providing a quick and comprehensive
information about the TIM-barrel of interest. The database includes 85 TIM-barrel en-
zymes, that are analyzed for composition and residue conformation (Ramachandran plot).
Information as sequence, length, oligomeric status, function and metabolic pathways is
included in the description. There are however two major disadvantages of the website:
only enzymes are included in the list and it was last updated in July 2001. Although it
is a good starting point to ﬁnd natural TIM-barrel structures, it is obviously obsolete.
The 85 enzyme structures were downloaded from the web-site and manually visualized
with Pymol [118]. 52 pdb ﬁles were selected and used as input on PDBeFOLD [119], a
web-service for structural alignment developed in 2003 by E. Krissinel and K. Henrick at
the European Bioinformatic Institute in Cambridge (UK). It can perform 3D structure
comparison between two structures (pairwise) or more (multiple), and it can look for pro-
tein similarity within the whole RCBS-Protein Data Bank archive (RCBS-PDB) [120],
which is exactly what we need in order to ﬁnd more recent structures and improve our
collection of natural TIM-barrels. The 52 structures obtained from DATE were loaded
on the PDBeFOLD web-site for structural alignment against the RCBS-PDB archive and
1623 natural TIM-barrel are obtained as output.
In order to have a non-redundant, high-quality collection, the 1623 structures were
reﬁned with PISCES [121]. This web-service was developed by the Dunbrack’s group in
2003 at the Institute for Cancer Research in Philadelphia (USA) in order to cull proteins
according to their structural resolution and sequence identity. Fasta sequences were up-
loaded on the web-site, and cut-oﬀs of 80% for sequence identity and of 2 A˚ for structure
resolution were set. With the help of PISCES, we obtained 228 high-quality and not-
redundant structures; following visual inspection with Pymol, this number was reduced
to 219.
Both collection, obtained using PDBeFOLD and PISCES and containing 1623 and 219
natural protein respectively, were analyzed for chain length. The PDBeFOLD collection
will not be used for later analysis, and it is shown in Figure 2.1a only to conﬁrm that the
PISCES collection is well representing the whole dataset.
The two distributions are congruous with each other. The length range is between 172
and 1052 aa, with the highest number of representatives in the range of 250-300 aa. In the
collection of 219 natural TIM-barrels (the only one considered from now on), the minimal
length is represented by the structure with pdb code 1VKF, of 172 aa (Figure 2.1b), while
the maximal length correspond to the structure 2FHF with 1052 aa (Figure 2.1c).



































Figure 2.1: Collection of natural TIM-barrels
(a) Length distributions for the collections of 1623 and 219 natural TIM-barrels; (b) the shortest natural
TIM-barrel of the collection, 172 aa (pdb ID: 1VKF) and (c) the longest one, 1052 aa (pdb ID: 2FHF).
More than 60% of the sequence of 2FHF is not involved in the formation of the TIM-
barrel fold: 392 aa are involved in the formation of 3 extra-domains at the N-term of the
protein and 125 aa in the formation of one extra-domain at the C-term of the protein
(highlighted in gray in Figure 2.1c).
Extra-domains are common in almost all the natural TIM-barrels and can be localized
also in the loop regions. Their presence should be taken into account for the analysis of
TIM-barrel features (i.e. the average element length), because they can aﬀect the results.
2.1.2 Length distributions of α-helices
A plot showing the distribution of α-helices according to their length is shown in
Figure 2.2a (the procedure is described in Section 3.1.2, page 169).
In the collection of 219 natural TIM-barrels, the only one considered, there are 3
proteins that lack one out of the eight α-helix that normally form the α-barrel (pdb IDs:
1H4P, 1TZZ and 2ZUV). In the collection, the minimal length for helices is 3 aa and the
maximal is 34 aa. The highest populated lengths are 11 aa and 14-15 aa, showing that the
distribution is not homogeneous. This 3-4 aa diﬀerence can be explained as a full turn of
the helix, in order to keep the overall orientation of the N- and C- termini in direction of
the loops; 1-2 extra aa would cause a misplacement of the N and C- termini in the helix
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Figure 2.2: α-helix length distribution
(a) Length distribution for all the helices of the collection that are involved in the TIM-barrel fold and
(b) single distributions of the helices for each position in the TIM-barrel fold.
and longer loops would be required.
Length distributions at each position of the α-barrel are reported in Figure 2.2b. The
general trend of main helix lengths at 11 aa and 14-15 aa is conserved and these three
lengths together represent 20 to 47% of the whole population. This analysis further
reveals that the 1st and the 5th helices are generally not longer than 17 aa. In contrast,
the 4th and the 8th ones can be made of up to 35 aa. The theory of evolution of the
TIM-barrel fold from two halves, described in Section 1.2.3, page 14, can be reﬂected in
these distributions.
The length distribution of 8th helix is wider than the other helices, and includes one
missing helix, three helices with more than 30 aa and mini-helices of 3-4 aa that are not
present in the other helix distributions.
2.1.3 Length distributions of β-strands
A plot showing the distribution of β-strands according to their length is shown in
Figure 2.3a (the procedure is described in Section 3.1.2, page 169).
Contrary to the α-helices, in the β-strands there are no missing elements. The minimal
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Figure 2.3: β-strand length distribution
(a) Length distribution for all the strands of the collection that are involved in the TIM-barrel fold and
(b) single distributions of the strands for each position in the TIM-barrel fold.
length is 3 aa and the maximal one is 14 aa. The highest populated lengths are 5 and 6
aa, representing together more than 50% of the population.
Figure 2.3b shows the length distributions for each individual β-strand of the β-barrel.
The general behavior with the main length at 5-6 aa is conserved but odd strands show
a maximum at ≥6 aa while the even ones have it at ≤6 aa. This trend can be explained
taking into account the structural diﬀerences in the even and odd β-strands of the TIM-
barrels, as reported in Section 1.2.1, page 11.
2.1.4 Length distributions of loops
In this work loops are considered as the connectivity unit between α-helices and β-
strands involved in the TIM-barrel fold and they can include extra element of secondary
structures.
Two kinds of loops are present in the TIM-barrel fold: from β-strand to α-helix
(hereafter called C-term loop, because it is at the C-terminus of the β-strand), and from
α-helix to β-strand (N-term loop). The ﬁrst is mainly involved in function (i.e. active site),
while the latter is important for the structure and stability of the protein, as discussed in
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Section 1.2.1, page 11.
Plots showing the distributions of C-term and N-term loops according to their length
are shown in Figs. 2.4b and 2.4a respectively. Their equivalent subgroups for position in
the TIM-barrel are shown in Figs. 2.4d and 2.4c.
The minimal loop length is 1 aa and the maximal is 120 aa for C-term loops and
130 aa for N-term loops. The majority of the N-term loops is less than 10 aa long, and
the outlier of 130 residues is exceptional and includes an entire extra-domain (pdb ID:
1ZFJA). The C-term loops are usually less than 50 aa long. This diﬀerence is typical in
TIM-barrels: as described in Section 1.2.1, page 11, C-terminal loops are usually longer
and involved in the function of the natural protein (i.e. enzymatic activity), while the
N-term loops are shorter and important for structural stability.
In the N-term group, around 70% of the loops have a length of 1-3 aa, and this trend
is strictly conserved at each of the seven possible positions in the barrel. On the contrary,
the C-term group does not show conserved trends.
2.1.5 Rosetta total energy of natural TIM-barrels
Figure 2.5: Energy minimization
The structure of the natural protein 1A53 be-
fore (blue) and after (green) energy minimiza-
tion.
Energy minimization (also called relax) of
the 219 natural TIM-barrel proteins down-
loaded from RCBS-PDB was done with the Re-
lax package of Rosetta [38] in order to remove
bias and constraints present in the crystal struc-
ture (details in Section 3.1.3, page 170). The
total energy score is calculated by Rosetta in
terms of Rosetta Energy Units (REU), that are
not related to the physical energy units kcal/-
mol or kJ/mol and rely on an arbitrary scale.
As shown in Figure 2.5 with the nat-
ural protein 1A53 before (blue) and af-
ter (green) energy minimization, there are
no relevant changes in the protein struc-
ture after relaxation. Only highly ﬂexi-
ble regions (i.e. loops) can result slightly
aﬀected, with a small deviation of the
main-chain compared to the original struc-
ture.
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Figure 2.4: Loop length distribution
(a and b ) Length distributions for N-term and C-term loops respectively; (c and d) their corresponding
plots for individual position in the TIM-barrel fold. For graphical clearness, all graphs are showing only
the ﬁrst 20 aa in the scale. Full distributions are showed in Annex 6.3, page 240.
The total energy score for each natural TIM-barrel is calculated and plotted against
the protein length (Figure 2.6a). There is a linear correlation between energy and protein
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dimension: the bigger the protein the more negative is the score value.
Dividing the energy value by the amino acid length gives the average energy per
residue for the collection of natural TIM-barrels, which is between -2.05 and -1.60 REU
per residue (Figure 2.6b). Values bigger than -1.6 REU represent structures with poor
stability, and this value will be used as cut-oﬀ value in the selection of the designed
proteins. It is not clear whether it is possible to get values lower than -2.05 REU per
residue and obtain super-stable variants, or if it represents a minimum limit. Thus, the
range -2.05 to -1.60 REU per residue will be useful later on for the next step of design



























































































































































Figure 2.6: Energy minimization on natural TIM-barrels
(a) Energy score versus protein length for each structure of the collection of natural TIM-barrels and (b)
distribution plot of the per-residue energy.
2.1.6 Rosetta β-sheet energy of natural TIM-barrels
Analysis of the Rosetta energy score of the β-barrel is an important tool in the com-
parison of natural and artiﬁcial TIM-barrels. In nature, the eight strands form a single
sheet that is closed on itself (forming the β-ring). If H-bonds are missing between the
strands, the overall stability of the structure decreases. In particular, the H-bonds be-
tween the ﬁrst and the last strands function as a zip that keeps the overall structure in a
“closed” conformation (Figure 2.7a).
As described in Section 2.1.5, page 38 for the total energy, the energy value due to
H-bonding between the backbone atoms in the β-strands was calculated following energy
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minimization (referred as β-energy from now on). The number of residues of the β-strand













































































































































Figure 2.7: β-energy of natural TIM-barrels
(a) β-barrel detail of the natural protein 1A53 with H-bonds highlighted, (b) β-energy score versus
total β-length for each structure of the collection of natural TIM-barrels and (c) distribution plot of the
per-residue β-energy.
The ratio of β-score versus length gives the average β-energy per residue for natural
TIM-barrels, and it is shown in Figure 2.7c. The overall range in our collection is between
-0.5 and -1.0 REU, with peaks at -0.6 and -0.65 REU. This range will be useful for the
design and validation of artiﬁcial TIM-barrels.
2.1.7 Analysis of amino acid composition
The relative amount of each natural amino acid in the 219 TIM-barrel sequences was
calculated. For example, the protein 1VKF (the smallest protein of the collection with 172
aa, shown in Figure 2.1b), contains 11% of valine, 10% of isoleucine, 9% of alanine, leucine
and lysine, 8% of glutamic acid and glycine, 5% of aspartic acid, 4% of phenylalanine,
arginine and serine, 3% of proline and threonine, 2% of methionine and asparagine, 1%
of histidine, glutamine, thryptophan and tyrosine and no cysteine (see Section 3.1.4,
page 171 for details).
Amino acid distributions across all the natural TIM-barrels are shown in Figure 2.8
and the ranges are reported in Table 2.1.
Out of the 219 sequences, 26 do not contain cysteines and 13 do not contain trypto-
phans. On the contrary, alanines, valines, leucines, and glycines are always found with
a minimum of 3% of sequence coverage each. Valines and leucines are the predominant
residues in β-strands [122] and it is intuitive their relevance in the TIM-barrel structure,
but alanines and glycines are unexpected.



































































Figure 2.8: Amino acid composition of natural TIM-barrels
In each boxplot the black line inside the green bar is the median, the green bar represent 50%
of the population and the upper and lower whiskers represent 25% of the population each.
IDs Min % Max % IDs Min % Max %
Alanine 3.4 23.3 Leucine 3.3 20.1
Arginine 0.7 10.2 Lysine 0.5 12.1
Asparagine 0.0 12.4 Methionine 0.0 5.4
Aspartic acid 1.0 10.2 Phenilalanine 0.9 7.1
Cysteine 0.0 3.3 Proline 1.3 8.5
Glutammine 0.0 7.2 Serine 0.8 12.2
Glutamic acid 1.3 12.4 Threonine 1.5 10.6
Glycine 3.8 12.6 Tryptophan 0.0 5.9
Histidine 0.0 5.3 Tyrosine 0.4 8.5
Isoleucine 0.4 14.0 Valine 3.1 14.4
Table 2.1: Composition ranges in natural TIM-barrels
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2.1.8 Analysis of amino acid properties
The distribution of amino acid in the collection of natural TIM-barrels is an useful
information but it is not fully comprehensive. For a functional protein (i.e. enzymatic
activity), the residues of the active site are highly conserved and their substitution is
harmful in the majority of the cases [92]. On the contrary, outside the active site, se-
quences are less conserved and most residues can be substituted with others that have
similar properties, such as size or charge [93]. For example a lysine can be exchanged
with an arginine without changing the overall charge, and they can be consider equiv-
alent. This trend is highly reﬂected in the TIM-barrel family, that have extremely low
sequence identities (down to 15%) despite their common fold (see Chapter 1.2).
In order to detect hidden patterns due to equivalent residues, amino acids were or-
ganized in seven groups according to their properties: polar (D,E,H,K,S,N,Q,R,T,C),
charged (D,E,K,R), positive charged (K,R), negative charged (D,E), small (A,C,G,S), apo-
lar (W,Y,P,V,P,L,I,A,G,M) and aromatic (W,Y,F) (see Section 3.1.4 for details, page 171).
The collection of 219 natural TIM-barrel was tested for each category composition and

























































Figure 2.9: Composition by amino acid property of natural TIM-barrels
In each boxplot the black line inside the green bar is the median, the green bar represent 50%
of the population and the upper and lower whiskers represent 25% of the population each.
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The majority of the proteins in the collection have around 55% of apolar and 45% of
polar residues. There is 24% of charged residues, with a slight excess of negatively (13%)
versus positively (11%) charged ones. The aromatics represent around 8% of the total
composition and the small residues 20%. This analysis will be used in the screening of
artiﬁcial TIM-barrels, descibed in Section 2.3.5, page 58.
IDs Min % Max % IDs Min % Max %
Polar 32.5 51.8 Negative Charged 6.0 19.4
Apolar 48.2 67.5 Small 14.9 34.5
Charged 11.8 35.4 Aromatic 3.3 19.0
Positive Charged 3.1 17.3
Table 2.2: Amino acid property ranges in natural TIM-barrels
2.2. PROTEIN DESIGN 45
2.2 Protein design
This chapter describes the design from scratch of artiﬁcial TIM-barrel structures and
sequences. Four steps are needed for the creation of more than 4000 backbone scaﬀolds. 28
out of them are chosen for sequence optimization in 10 cycles of design and minimization
leading to the creation of more than 8000 ﬁnal models and sequences.
2.2.1 Parametric backbone design
De novo design of scaﬀolds for artiﬁcial TIM-barrels was done with the BundleGrid-
Sampler package of Rosetta [38]. This program allows to design from scratch any sec-
ondary structure around a central bundle axis and is well suited for proteins that have
circular symmetry, like TIM-barrels or helical bundles. Description of software, parame-
ters and options is reported in Section 3.2.1, page 173.
The scaﬀold was designed by assembling 16 individual peptide fragments, 8 β-strands
arranged in an internal β-barrel and 8 α-helices arranged in an external α-barrel, with
a total length of 240 aa, all alanines (Figures 2.10a and 2.10b). Secondary structure
elements are highly ideal: all residues belonging to the helices have exactly the same
φ and ψ angles (-65◦,-41◦), whereas all residues belonging to strands have few diﬀerent
couples of angles: the φ values are between -131◦ and -143◦ and the ψ ones between 128◦
and 140◦ (Figure 2.10c). This small variation in dihedral angles is caused by the tilting
of β-strands around the central axis.
(a) (b) (c)
Figure 2.10: Parametric Design with BundleGridSampler package of Rosetta
(a) Front and (b) top view of the designed scaﬀold to mimic the TIM-barrel fold and (c) its Ramachandran
Plot.
Due to the small size of alanine residues, no interactions are formed between the
diﬀerent secondary structure elements, and the Rosetta energy score is +14440.363 REU,
which is outrageously high for a protein of this size (-450 REU was calculated from the
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per residue distribution in Section 2.1.5, page 38). A more realistic energy score will
be obtained following the next steps of design, i.e. alanine substitution in Section 2.2.2,
page 46, loop closure in Section 2.2.3, page 48, and energy minimization in Section 2.2.4,
page 49.
2.2.2 Alanine substitution
The substitution of alanine in the parametric structure (described in Section 2.2.1,
page 45) is a necessary step in the creation of de novo scaﬀolds. Loop closure and
energy minimization of the alanine scaﬀold will cause deformations of the whole structure
because the programs are set to ﬁll empty spaces in the core of a protein. The void
space between α-helices and β-strands in the parametric scaﬀold is ﬁlled through the
substitution of the small alanines with bigger residues, which side-chains form interactions
between fragments, leading to increase in the stability of the structure before loop closure
and energy minimization.
Alanine substitution was done with the Design package of Rosetta in 4 steps, one for
each layer (i.e. core, boundaries, surface and loops, see Figure 2.11) in the structure. The
attempt of substitution of all the alanines in one step resulted in a low variation at the
sequence level, with just a few diﬀerent combinations compared to the thousands possible.
Parameters, options and instructions for substitution used are described in Section 3.2.2,
page 174.
Figure 2.11: Protein layers
Top view and side view of the parametric structure by layers: the core in blue, the boundary in orange,
the surface in red and the loop in green. All the 240 residues are attributed to one of the layers.
The ﬁrst step of alanine substitution targeted all the amino acids that are involved in
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the interface between α-helices and β-strands of the TIM-barrel (the hydrophobic ring),
and those that point to the central axis of the barrel (in blue in Figure 2.11). The β-
strand residues that points to the central axis were limited to be changed only to valine,
isoleucine or leucine in order to keep the strand conformation, while those forming the
hydrophobic ring are allowed to be changed in any apolar amino acid in order to increase
sequence variety and to optimize the stability and the compactness of the structure.
200 outputs were produced and 129 out of them are non-redundant sequences ( 65%).
The energy score improved by 3050 REU from the initial score of +14440 REU, with the
worst model out of the 200 scoring +11388 REU and the best +11279. The ﬁrst 8 best
scoring models are selected for the next step.
The second step targeted 40 amino acids localized at the interface between the hy-
drophobic core and the hydrophilic surface of the protein (in orange in Figure 2.11). These
boundary amino acids were allowed to be changed to both polar and apolar residues with
the exception of alanine, proline, glycine and cysteine. 400 models were obtained as out-
put, with no duplicates. The energy score improved by 10 REU from the previous step,
resulting in range of +11289 and +11268 REU. The ﬁrst 3 best scoring models for each
initial input (a total of 24) were selected for the next step.
The third step targeted 40 amino acids that were exposed to the solvent on the protein
surface (in red in Figure 2.11). They were allowed to be changed to any polar residues
except glycine and cysteine. 1200 models were obtained (50 for each of the 24 inputs).
Two sequences out of the 1200 resulted to be identical and one duplicate was discarded.
The energy score improved by 13 REU, resulting in a range of values between +11254
and +11266 REU. 50 best scoring models were selected for the next step.
The fourth step targeted 64 amino acids that form the loop connections between sec-
ondary structure elements (in green in Figure 2.11). They were allowed to be changed
to any residue with the exception of tryptophan, tyrosine, phenylalanine, glycine, cys-
teine and lysine. 4000 models were obtained and 32 out of them were discarded because
duplicates. The resulting backbones structures are 3968.
The energy value increase from the previous step of 300 REU, resulting in a range
of values between +11493 and +11586 REU. This is due to the fact that new residues
partially overlap and cause repulsion between atoms, which gives an unfavorable con-
tribution to the overall energy score. So far, neither the backbone nor the side-chains
of the protein are been adjusted in order to form interactions (H-bonds, salt bridges or
hydrophobic interactions) that will give a more favorable contribution to the score. The
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following energy minimization step will remove these bias, but ﬁrst the loops have to be
connected to form a continuous polypeptide chain.
2.2.3 Loop closure
Loop closure to connect the 16 individual peptide fragments in a single chain was
performed for each of the 3968 models with the Loopmodel package of Modeller [123].
15 loops have to be created, 8 to connect β-strands to α-helices and 7 for the opposite
direction. In all cases two residues of the β-strand and three of the α-helix were used to
form the ﬁnal loop (see details in Section 3.2.3, page 176).
Figures 2.12a and 2.12b show in green the residues that are involved before (a) and
after (b) the loop formation step. There is no addition of amino acids and the rest of the
fragments are not distorted, as shown in Figure 2.12c.
The Ramachandran plot (Figure 2.12d) of the single polypeptide is more dispersed
compared to the one of the parametric scaﬀold (Figure 2.10c), but the majority of the
residues of strands and helices are still displayed at the original coordinates because, so
far, only the loop region was subjected to energy minimization, while the central body is
still not relaxed. The energy score reﬂects this partial minimization, values improved of
5000 REU ranging from 6852 to 9273 REU, but it is still not close to expected scores.
(a)
(b) (c) (d)
Figure 2.12: Loop Closure
(a) Example of a single loop before and (b) after the closure of the loop; (c) comparison of the whole
model before (green) and after (blue) the closure and (d) Ramachandran plot of one of the scaﬀolds.
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2.2.4 Energy minimization
Energy minimization (or relax) is an important step in protein modelling, especially for
structures designed from scratch. Bias such as overlapping atoms or empty spaces in the
models can be easily removed during the relaxation process, promoting the formation of
interactions like H-bonds, salt bridges and Van der Waals clusters. Energy minimization

















Figure 2.13: Energy Minimization
(a) Energy distribution of the 3968 models and (b) comparison between one model before (green) and
after (blue) the relaxation process and (c) its Ramachandran plot.
Following energy minimization, all the models improved their Rosetta energy score by
7000 REU, reaching negative values in the range of -125 to -290 REU. Their distribution
is shown in Figure 2.13a. The values are similar to those of small natural proteins, but
remain above to those expected for a protein of 240 aa (in the range of -384 to -492
REU, as mentioned in Section 2.1.5, page 38). The score will be further improved by the
sequence design step in Section 2.2.6, page 52.
The minimization process adjusts both the side-chain and the backbone atoms, and
some of the conformational adjustments are visible in the main-chain (Figure 2.13b). The
Ramachandran plot after minimization is more natural-like, with dispersed φ and ψ angles
in α- and β-regions (Figure 2.13c).
2.2.5 Backbone selection
The design of backbone structures that mimic the TIM-barrel-fold was performed with
the programs Rosetta and Modeller and resulted in the creation of ∼4000 diﬀerent scaf-
folds. Selection is necessary to ﬁnd the best models for the following step of sequence
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design. The selection was made according to structural features only (i.e. sequence infor-
mation is not taken into account), in order to ﬁnd models with the most stable α-helix
and β-strand content.
The scoring function of Rosetta was used to rank the models on the basis of main-chain
H-bonds values, for α-helices and β-strands individually. Bonds due to side-chain/side-
chain or side-chain/main-chain interactions were not taken in account and the models
were ranked according to the stability of their secondary structure elements only. For ex-
ample, a model with an α-score of -35 REU contains more H-bonds in its helices compared
to a model with score -15 REU, leading to a higher stability in the secondary structure
elements.
The distribution of the α-backbone energy scores is shown in Figure 2.14, while the






























Figure 2.14: Backbone energy scores
(a) Contribution to the energy score of the secondary structures for the 3968 scaﬀold for the helix (red)
and (b) for the strand (yellow).
From the initial 3968 structures, the best 10% were selected according to their α-helix
score. Of those 396, the best 10% were selected according to the β-strand rank. 11 out
of the 39 best models were discarded because of their high sequence similarity, and the
28 remaining are shown in Figure 2.15. Although the overall shape is the same, in each
model there are small diﬀerences that are due to the energy minimization step associated
to diﬀerent amino acid sequences. Diﬀerences are quite obvious at the level of the β-ring:
some are perfectly spherical, others are more ovoid and others ones have a more triangular
shape.
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Figure 2.15: 28 selected backbone structures
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2.2.6 Sequence design
The 28 selected backbone structures were subjected to 10 cycles of sequence design
and energy minimization, using Rosetta. For a full description of the methods see Sec-
tions 3.2.5 and 6.5.7. In Figures 2.16 are reported the RMSD versus Total score for each
of the designed sequences for cycle 1 (a), cycles 2-4 (b), cycles 5-7 (c) and cycles 8-10 (d).
(a)





















































































Figure 2.16: RMSD vs Energy in the sequence design cycles
(a) Initial 28 backbone structures (black) and output models (orange) of the ﬁrst cycle of sequence design.
(b) Input (orange) and output models (blue) for the 2nd to 4th cycles. (c) Input (blue) and output models
(red) for the 5nd to 7th cycles. (d) Input (red) and output models (green) for the 8nd to 10th cycles.
Gray circles are the models of the previous steps of design.
The 28 initial structures are used for comparison to calculate the RMSD of the de-
signed models, and they are represented in Figure 2.16a as black circles, with RMSD
equals to 0, and in Figure 2.17 as gray bars. Their energy range is between -199 and -284
REU, with the most populated value at -250 REU.
The ﬁrst cycle targeted 96 aa belonging to the hydrophobic core of the fold in order to
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improve the packing of the structure and increase the overall stability. The resulting 2800
outputs are represented in orange circles (Figure 2.16a) and bars (Figure 2.17), and show
an improvement in the total energy, with a range between -357 and -241 REU and the
more populated value at -310 REU. The RMSD is acceptable in the majority of the models
with a minimum of 0.57 A˚ of Cα -deviation, due mainly to the side-chain substitution
and backbone rearrangement. There are few outliers with RMSD above 4 A˚, up to a














Figure 2.17: Total energy proﬁles of the sequence design
Total energy for the initial 28 backbone structures (gray) and for the output models sequence design: 1st
cycle in orange, 2nd to 4th cycles in blue, 5nd to 7th cycles in red and 8nd to 10th cycles in green.
The 2nd to 4th cycles targeted all the 240 aa of the artiﬁcial TIM-barrels, with restric-
tions that depended on the layer of the protein, apolar residues for the core, polar for the
surface and all for boundary and loops. The 1060 outputs are shown as blue circles in
Figure 2.16b and blue bars in Figure 2.17. The RMSD range from 0.57 to 3.27 A˚. The
total energy improved in the majority of the models on average by ∼120 REU, but in few
cases the total energy is worst than the score of the 28 not-optimized initial structures.
The energy score range from -151 to -461 REU and the most populated value is at -400
REU.
For the majority of the models, the theoretic energy range per residue (see Sec-
tion 2.1.5) is reached: for a protein of 240 residues the total energy should be between
-492 and -384 REU.
The 5th to 7th cycles targeted all the 240 residues as described in the previous cycle.
The 1070 outputs are shown as red circles in Figure 2.16c and red bars in Figure 2.17.
The RMSD is in the range of 1.15-2.55 A˚. The total energy values slightly improved of
54 CHAPTER 2. RESULTS AND DISCUSSION
∼20 REU, ranging from -483 to -232 REU and the most populated value is -440 REU,
showing that the major improvements in the packing are been reached in cycles 2nd to
4th. Now on the sequence design cycles will have as objective to increase the sequences
variability.
The 8th to 10th cycles targeted all the 240 aa and there are no restrictions: any residue
can change in any other, in order to mimic natural TIM-barrel in which, for example,
polar residues are found in the internal β-ring (see Section 1.2, page 11). The 3217 out-
puts are shown as green circles in Figure 2.16c and green bars in Figure 2.17. The RMSD
range from 1.31 to 2.86 A˚. The total energy values slightly improved of ∼20 REU, with
a overall range of -277 to -502 REU, with the most populated value at -465 REU.
In Table 2.3 are reported all the steps of sequence design based on the initial family,
with the number of selected inputs and of not-redundant outputs.
1st cycle 2-3-4th cycles 5-6-7th cycles 8-9-10th cycles
Family Inputs Outputs Inputs Outputs Inputs Outputs Inputs Outputs
1 1 100 4 40 4 40 2 69
2 1 100 4 40 4 40 3 130
3 1 100 4 40 4 40 2 134
4 1 100 3 30 2 20 2 83
5 1 100 4 40 3 30 4 141
6 1 100 4 40 2 20 2 65
7 1 100 4 40 3 30 1 65
8 1 100 4 40 3 30 1 56
9 1 100 4 40 4 40 4 113
10 1 100 3 30 3 30 4 142
11 1 100 4 40 2 20 2 76
12 1 100 4 40 4 40 2 88
13 1 100 4 40 3 30 2 79
14 1 100 4 40 4 40 4 126
15 1 100 4 40 3 30 1 58
16 1 100 4 40 3 30 3 134
17 1 100 4 40 3 30 3 139
18 1 100 3 30 3 30 4 140
19 1 100 3 30 4 40 3 140
20 1 100 4 40 3 30 3 101
21 1 100 4 40 3 30 3 134
22 1 100 4 40 3 30 4 129
23 1 100 4 40 3 30 3 142
24 1 100 4 40 4 40 4 134
25 1 100 4 40 2 20 3 151
26 1 100 4 40 2 20 4 145
27 1 100 3 30 4 40 3 138
28 1 100 3 40 3 40 4 146
Total 28 2800 106 1060 88 880 80 3198
Table 2.3: Resume of the sequence design
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2.3 In silico validation
This chapter describes six methods used to select 10 models for experimental valida-
tion. The selection criteria are ﬁrst tested on our collection of 219 natural TIM-barrels
(see Section 2.1.1, page 33) in order to extract cut-oﬀ values for the selection of artiﬁ-
cial TIM-barrels. Selection methods include the comparison of energy values, amino acid
compositions, secondary structure predictions and molecular dynamics simulations. The
10 models chosen for experimental validation are shown and described at the end of the
chapter.
2.3.1 Models selection
The previous chapter describes the creation of 7949 artiﬁcial and non-redundant se-
quences modeled on the TIM-barrel fold (Section 2.2.6, page 52). The 2800 outputs of
the ﬁrst cycle of sequence design (in orange in Figure 2.17), are not considered for exper-
imental validation since their energy score is lower than -387 REU (the minimum energy
score described in Section 2.1.5 for a protein of 240 aa, page 38). The remaining 5149
models, distributed among the 28 Families, are all included. The 28 Families are not
equally represented, with a minimum number of 125 representatives for Family 06 and a
maximum of 217 for Family 28 (see Table 2.4 in Section 2.3.8 for details, page 68).
2.3.2 Analysis of the total energy
The ﬁrst step in the in silico validation is the analysis of the energy score. Energy
values were calculated for each of the 5149 selected models with the Rosetta method used
for natural TIM-barrel (see Section 3.1.3, page 170). The total energy score is directly
correlated with protein length, as seen in Section 2.1.5, page 38, and a direct comparison
of total energy values between artiﬁcial models and natural proteins can be misleading
because of the length factor: natural proteins have diﬀerent lengths while all the models
are made up of 240 residues. The per-residue energy value is better suited for this analysis.
The range of per-residue energy for natural TIM-barrels is between -2.02 and -1.61
REU, with a peak centered at -1.8 REU (in yellow in Figure 2.18). The distribution of
the artiﬁcial models is shown in blue, and their per-residue energy ranges from -2.09 to
-0.63 REU (not shown in the picture). The peak is centered at -1.9 REU, showing that
the majority of them have a lower per-residue energy than the natural proteins (and so
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a higher per-residue stability). 112 models have values lower than the natural maximum
of -2.09, and they are in theory more stable than natural proteins. Because there is
no information about drawbacks in highly stable proteins, these models are kept in the
validation process. On the contrary, models that have higher values than -1.61 REU are
considered less stable. In order to be more strict in the selection of good variants, the
cut-oﬀ limit is set at -1.7 REU, and 358 models are discarded. The remaining sequences




















Figure 2.18: Per-residue energy scores of artiﬁcial TIM-barrels
Distributions of the per-residue energy scores for the 5149 artiﬁcial TIM-barrels (blue) and for the 219
natural ones (yellow).
2.3.3 Analysis of the β-energy
The second step in the in silico validation is the analysis of the energy score of the
β-barrel, that takes in consideration only the H-bonds in the backbone structure of the
β-strands. β-energy values were calculated for each of the 4791 remaining models with
the method used for natural TIM-barrel (see Section 3.1.3, page 170).
The number of residues in β-strands versus the β-energy for both natural (yellow)
and artiﬁcial (blue) TIM-barrels is shown in Figure 2.19a, and the per-residue β-energy
distributions are in Figure 2.19b. For natural TIM-barrels the per-residue range of β-
energies is between -0.96 and -0.49 REU, and for artiﬁcial ones it is between -0.77 and
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-0.44 REU. The data show that on average artiﬁcial TIM-barrels have higher energies
(and lower stability) in their β-strands compared to natural ones. This is in contrast with
the total energy distribution shown in Section 2.3.2, page 55, in which the per-residue























































































































































































































































































































































































































































Figure 2.19: Per-residue β-energy scores of artiﬁcial TIM-barrels
(a) Strand residues versus total β-energy for the 5149 artiﬁcial TIM-barrels (blue) and for the 219 natural
ones (yellow), and (b) their per-residue β-energy distributions.
The results suggest that the H-bond network in the β-barrels is generally larger in
natural TIM-barrels, but the H-bond network in α-helices or among side-chains is more
extended in the artiﬁcial group, leading to a higher score in the total per-residue energy.
Despite that, almost all the models are included in the range of natural TIM-barrels,
with only 67 outliers. As for the total energy selection, in order to be more restrictive,
the cut-oﬀ value was set to -0.55 REU and a total of 1084 models are discarded. The
remaining models for the next step of validation are 3707 (see Table 2.4 in Section 2.3.8
for details, page 68).
2.3.4 Analysis of amino acid composition
The third step in the in silico validation is the analysis of the amino acid composition.
The 20 natural amino acids were counted in each of the 3707 models and their percentage
was compared with the ranges that were obtained for natural TIM-barrels (Section 2.1.7,
page 41). If all the amino acid counts are in the range, the model passes to the next step.
If one or more of them is outside the range the model is discarded. Technical details for
the method are described in Section 3.1.4, page 171, and the ranges of natural TIM-barrels
are shown in Table 2.1 in Section 2.1.7, page 42.
This selection step discarded 2882 models, and the remaining ones are 825 (details are
reported in Table 2.4 in Section 2.3.8, page 67).
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The number of cysteines is out of range in all the discarded models, reaching up to
7.9% of sequence coverage instead of a maximum of 2.8%. This excess is a problem of
the Rosetta software, that favors the cysteine due to its size and to its capacity to form
H-bonds, but does not consider its reactivity and its danger in living cells.
The second residue out of range in 66% of the discarded models is the valine, under-
represented in all the cases with values lower than the minimal 3.1% of sequence coverage
that is found in natural TIM-barrels.
The third residue out of range in 31% of the discarded models is the phenylalanine,
overrepresented in all the cases with values higher than the maximal 6.6%. In the analysis
of natural TIM-barrels this residue type is absent in 13 out of 219 structures, suggesting
that it is not required for the TIM-barrel fold.
Methionines and glycines are both out of range in 18% of the discarded structures,
mainly for overrepresentation. Lysines are overrepresented in 7% of the cases, and all the
remaining residue types are out of range in less than 2% of the models, with the exception
of alanines, asparagines, isoleucines and prolines that are in the correct range in all the
tested models.
2.3.5 Analysis of amino acid properties
The fourth step in the in silico validation is the analysis of the artiﬁcial TIM-barrel
composition on the basis of amino acid properties. As described in Section 2.1.8, page 43,
amino acids can be grouped according to their basic properties, such as size or charge, and
seven groups were selected and tested on natural TIM-barrels: polar, charged, positive,
negative, small, apolar and aromatic amino acids (see Section 3.1.4 and Section 2.1.8 for
details, page 171).
The same analysis was performed on the 825 remaining artiﬁcial models and 2 of them
were discarded because out of range compared to natural TIM-barrels.
The discarded models belong to Family 25 and in both cases the apolar residues content
is out of the maximum limit (67.5%). Details are reported in Table 2.4 in Section 2.3.8,
page 68.
2.3.6 Secondary structure prediction
The ﬁfth step in the in silico validation is the secondary structure prediction, in order
to discard the sequences that are less-likely to fold into the correct secondary structure
elements.
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There are nowadays many software and web-services that can predict secondary struc-
tures starting from the amino acid sequences. They can be divided in two classes: the
ones that use only the amino acid propensity and statistics of natural proteins for the
prediction, and those that include also evolutionary information. In this second case,
the target sequence is used on the one side for the propensity analysis and the statistic,
and on the other side to ﬁnd homologous sequences that have already been characterized
for their secondary structure content. Results of the evolutionary predictors are highly
eﬃcient and the errors are minimal for natural proteins. However, the analysis of artiﬁ-
cial models with this kind of predictors is aﬀected since they lack of known homologous
proteins.
Software that do not use evolutionary information are more prone to errors in the
prediction of the secondary structure for natural proteins, but they are not aﬀected by ar-
tiﬁcial sequences. For this reason, the screening of the artiﬁcial TIM-barrels is done with
both kind of prediction software: SSpro [124], that is based on evolutionary information,
and JPred4 [125] that is not.
In order to estimate the error of the predictions, fasta sequences of natural TIM-barrels
were analyzed with both software, and the results were compared with the DSSP analysis
of the corresponding pdb structures (see Section 3.3.1, page 179). All the residues with
mismatching conformation are considered errors. The analysis of the error range in nat-
ural TIM-barrels will be useful to establish cut-oﬀ values for the prediction error, that is
then used to screen the remaining 823 artiﬁcial sequences. A model is considered valid if
it pass the cut-oﬀ value in both SSpro and JPred4 predictions.
The error distribution of the natural TIM-barrel sequences with SSpro and JPred4 are
shown in Figures 2.20a and 2.20b, respectively.
The error distributions of the two software are diﬀerent: SSpro has a range between
0 and 28% of mismatching residues, with more than 90% of correct predictions in the
majority of the proteins. The error range of JPred4 is between 8 and 37%, and the
majority of the proteins have around 75% of correct predictions. This diﬀerence between
SSpro and JPred4 shows the importance of evolutionary information in the quality of the
prediction.
The cut-oﬀ value chosen for the SSpro predictor is 28%, its maximum value for natural
TIM-barrels. The lack of evolutionary information in the analysis of artiﬁcial TIM-barrels
will increase the error rate of the prediction, and a more restrictive cut-oﬀ value can be
harmful, discarding potential good sequences. On the contrary, JPred4 is not inﬂuenced
by artiﬁcial sequences and the chosen cut-oﬀ value is 25%, in order to be more restrictive
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in the selection.
The results of the analysis of the artiﬁcial TIM-barrel structures are shown in Fig-
ure 2.21a for SSpro and in Figure 2.21b for JPred4. The SSpro predictions for the artiﬁcial
sequences have a minimum of 10% and a maximum of 42% of mismatching residues. In
comparison with the range 0-28% of the natural proteins, the importance of evolutionary
information is evident. For the majority of the models, the error range in the artiﬁcial
TIM-barrels prediction by JPred4 is comparable to the natural one; only 9 out of them
have more than 37% of error.
The cut-oﬀ values chosen for SSpro and JPred4 after the analysis of natural TIM-
barrels are 28% and 25% respectively. The models that have higher values than the































Figure 2.20: Secondary structure prediction of natural TIM-barrels
(a) Error distributions in the secondary structure prediction calculated for natural TIM-barrels with

































Figure 2.21: Secondary structure prediction of artiﬁcial TIM-barrels
(a) Error distributions in the secondary structure prediction calculated for artiﬁcial TIM-barrels with
SSpro and (b) Jpred4.
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remaining sequences. Details for each Family are reported in Table 2.4 in Section 2.3.8,
page 68.
2.3.7 Molecular dynamics
In the ﬁelds of molecular biology and biochemistry, molecular dynamic (MD) is widely
used to simulate the stability overtime of given macromolecules (proteins, DNA, RNA and
lipids), their structural, conformational and functional characteristics, their interactions
with solvent, ligands or other macromolecules and, in the case of proteins, their folding.
MD simulates atom motion of a system according to the Newton’s second law: F =
ma, in which F is the force, m the mass and a the acceleration. Because the force is
correlated to the potential energy and the acceleration to the velocity, it is possible to
calculate and simulate the trajectories that each atom of the system takes in a deﬁned
period of time.
The full-atom MD simulation of a protein is very accurate but it is slow due to the
high number of atoms that are simulated. For example, a protein of 250 amino acids
contains around 4000 atoms. A simulation of 50 ns requires 25000000 steps. This means
that the number of trajectories that are calculated is 4000 atoms x 25000000 steps = 1011
trajectories. From the trajectories and the protein structure then we can obtain the 3D
coordinates, the energies, the RMSD and so on. All these features however have a cost in
term of calculation time: MD simulations are extremely accurate but very slow.
Moreover, in this example we did not mention that MD simulations can be done in
explicit-solvent conditions. In this kind of simulations, water molecules (and optionally
buﬀer, salt, detergent) are added around the protein to form a shell and both are sim-
ulated together. The simulation becomes more realistic because proteins are usually in
solution, and more accurate since the eﬀect of the solvent on the protein is taken into
account. The advantages are enormous, however the simulation takes longer due to the
presence of around 8000-9000 extra particles in the system. A 50 ns simulation for a pro-
tein of 250 aa in explicit solvent conditions (a total of 10000-11000 atoms), takes 5 days
using the cluster VEGA of the Belgian Consortium des E´quipements de Calcul Intensif
(CECI), funded by the Fonds de la Recherche Scientiﬁque de Belgique (F.R.S.-FNRS)
under Grant No. 2.5020.11.
Because of MD is time-consuming, it is not possible to test all the remaining 598
models. One model of each of the 28 Families was chosen as representative in order to
obtain information on their stability and quality of the design. None of the models of
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Family 11 passed the secondary structure prediction step, and the MD simulation was
done on the best model of the previous step to evaluate its overall behavior. Family 11
will not be considered for experimental validation.
Additionally, four control proteins were chosen for the comparison with the artiﬁcial
sequences: three are the positive ones and the remaining is the negative one. Among the
positive control there are two natural TIM-barrel (1K77 and 4AAJ, of 260 and 200 aa, re-
spectively), and sTIM-11, the artiﬁcial four-fold symmetrical TIM-barrel of 184 residues
described in Section 1.4.2, page 30. The artiﬁcial OctaV (designed as TIM-barrel and
folded in an αβα-sandwich, see details Section 1.3.3, page 22, and 1.3.5, page 24), is the
negative control.
The 32 structures were simulated for 50 ns in explicit solvent with the GROMACS
package [110], using the force-ﬁeld is AMBER99SB [126] and the water-type is TIP3P
[127]. AMBER99SB is one of the most common force-ﬁeld for the simulation of soluble
globular proteins. Moreover, it resulted the best one (among 10) in replicating the dy-
namic results obtained by NMR experiments for two globular proteins, ubiquitine and
gb3 domain of protein G [128]. The choice of force-ﬁeld and water-type was made based
on the Details on the preparation of the structures, addition of water and ions, energy
minimization and equilibration are described in Section 3.3.2, page 180.
The dynamics of 50 ns are shown in Figure 2.22a in green for the positive controls
(1K77, 4AAJ and sTIM-11) and in red for the negative control (OctaV). RMSD distribu-
tions are shown in Figures 2.22b with the same color code.
The natural TIM-barrel 4AAJ (light green) is the most stable protein among the 4,
with a RMSD distribution between 0.0765 and 0.1347 nm and the peak centered at 0.10
nm. 1K77 (dark green) has a RMSD distribution between 0.0828 and 0.1522 nm and
the peak centered at 0.13 nm. Both proteins can be considered stable and in a rigid
conformation. The artiﬁcial sTIM-11 (lime-green) is less stable over time compared to
the two natural TIM-barrel, with a RMSD distribution between 0.0627 and 0.1883 nm
and a peak centered at 0.17 nm, but there are not signiﬁcant RMSD jumps during the
course of the simulation.
The artiﬁcial model of OctaV (red) behaves diﬀerently from the positive controls.
Already in the ﬁrst nanoseconds, the RMSD jumps to values higher than 0.3 nm and
the distribution ranges from 0.0939 to 0.4983 nm, with the peak centered at 0.42 nm.
The model of the OctaV is known to be wrong, and the MD simulation is obviously able
to predict it here. Note that it is not possible to follow conformational changes in 50
ns of simulation because theese take place on a µs timescale of. Drastic structural re-
arrangements in the ﬁrst nanoseconds of the simulation could be an indication of the low
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quality of the tested models.
The RMSD vs Time and the RMSD distributions plots of the simulations of the 28
representatives are shown in Figures 2.23 to 2.50.
None of the tested models behave as well as the positive controls, but all of them perform
better than OctaV, the negative control. The best Families are 06, 12, 16 and 26, with
sharp distributions and the average RMSD lower than 0.2 nm. Distributions that are
wider or that present multiple peaks are in general less preferable than single sharp peaks,
because they reveal alternative protein conformations. One extreme example is Family
28, which shows a little shoulder below 0.2 nm, a peak centered at 0.22 nm and a second
peak at 0.32 nm (Figure 2.50).
After analysis of the 28 simulations, 14 Families are discarded:
1. Families 19, 20, 27 and 03 are the worst behaving, with respectively 73.2%, 68.3%,
55.6%, 50.6% of RMSD values higher than 0.3 nm.
2. Families 01, 02, 14, 15, 18, 21 and 28 display multiple wider peaks in the region of
0.2 to 0.3 nm of RMSD, suggesting that they are having small re-arrangements and
that they are not stable.
3. Families 10, 22 and 24 present a plateau before the peak that indicates a slow but















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.22: Molecular dynamics of the control group
(a) RMSD vs Time and (b) RMSD distributions for the controls 1K77 (dark green), 4AAJ (light green),
sTIM-11 (lime-green) and OctaV (red).
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Figure 2.23: MD Family 01





















































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.24: MD Family 02



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.25: MD Family 03


















































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.26: MD Family 04




















































































































































































































































































































































































































































































































































































































































































































































































Figure 2.27: MD Family 05




























































































































































































































































































































































































































































































































































































































Figure 2.28: MD Family 06























































































































































































































































































































































































































































































































































































































































































Figure 2.29: MD Family 07














































































































































































































































































































































































































































































































































































































































































































































































Figure 2.30: MD Family 08
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Figure 2.31: MD Family 09
















































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.32: MD Family 10





































































































































































































































































































































































































































































































































































































































































































































Figure 2.33: MD Family 11



















































































































































































































































































































































































































































































































































































































































































Figure 2.34: MD Family 12














































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.35: MD Family 13


































































































































































































































































































































































































































































































































































































































































































































































Figure 2.36: MD Family 14







































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.37: MD Family 15





























































































































































































































































































































































































































































































































































































































































Figure 2.38: MD Family 16































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.39: MD Family 17















































































































































































































































































































































































































































































































































































































































































































































Figure 2.40: MD Family 18
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Figure 2.41: MD Family 19
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.42: MD Family 20























































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.43: MD Family 21



















































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.44: MD Family 22






















































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.45: MD Family 23







































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.46: MD Family 24































































































































































































































































































































































































































































































































































































































































































Figure 2.47: MD Family 25







































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.48: MD Family 26
















































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.49: MD Family 27























































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.50: MD Family 28
2.3. IN SILICO VALIDATION 67
The number of remaining models for experimental validation is 355, and 14 Families
out of 27 have been discarded. Details are reported in Table 2.4 in Section 2.3.8, page 68.
2.3.8 Summary of the in silico validation
A total of 5149 models, distributed among 28 Families, were selected. Each model was
tested in comparison to our collection of natural TIM-barrels (described in Section 2.1.1),
to identify the best models for experimental validation. The 6 steps of the in silico
validation were:
1. Analysis of the total energy (Section 2.3.2, page 55)
2. Analysis of the β-energies (Section 2.3.3, page 56)
3. Analysis of amino acid composition (Section 2.3.4, page 57)
4. Analysis of amino acid properties (Section 2.3.5, page 58)
5. Secondary structure prediction (Section 2.3.6, page 58)
6. Molecular dynamic simulation (Section 2.3.7, page 61)
Table 2.4 summarizes the 6 validation steps for the 28 Families and give the number
of successful models following each step.
The ﬁrst step removed 331 models, with a minimum of 4.1% representatives in Family
28 and a maximum of 21.6% in Family 06. The second step reduced of 83% the population
of Family 11, but it had no eﬀect on Family 20 and 21. The discarded models at this
step are 1084. The third step was the more eﬃcient, with a minimum of 34.8% (Family
07) and a maximum of 99.5% (Family 28) of discarded models, a total of 2851. The forth
step was the less eﬃcient with just two models discarded, both belonging to Family 25.
The ﬁfth step removed 181 models. All the models of Families 22, 23 and 28 passed the
secondary structure prediction test, whereas Family 11 was completely discarded. The
sixth step excluded 14 Families and a total of 287 models.
More than 90% of the initial models were discarded after the six steps of in silico
validation, leaving 355 sequences available for experimental validation.
68 CHAPTER 2. RESULTS AND DISCUSSION
Family Models Step 1 Step 2 Step 3 Step 4 Step 5 Step 6
01 149 127 81 6 6 5 0
02 210 196 195 36 36 32 0
03 214 210 174 36 36 32 0
04 133 123 107 14 14 9 9
05 211 202 161 32 32 20 20
06 125 98 55 4 4 3 3
07 135 117 89 58 58 40 40
08 126 104 61 8 8 7 7
09 193 176 64 4 4 3 3
10 202 197 139 18 18 16 0
11 136 124 21 2 2 0 0
12 168 160 126 18 18 13 13
13 149 136 132 36 36 31 31
14 206 192 191 55 55 10 0
15 128 115 53 2 2 1 0
16 204 188 112 52 52 35 35
17 209 206 109 42 42 34 34
18 200 182 153 36 36 24 0
19 210 198 193 33 33 28 0
20 171 169 169 22 22 20 0
21 204 186 186 30 30 19 0
22 199 181 48 5 5 5 0
23 212 207 204 44 44 44 44
24 214 200 181 13 13 7 0
25 211 200 172 87 85 71 71
26 205 199 137 78 78 45 45
27 208 190 187 53 53 27 0
28 217 208 207 1 1 1 0
Total 5149 4791 3707 825 823 598 355
Table 2.4: Summary of in silico validation
2.3.9 Model selection for experimental validation
Among the 355 models, 10 are selected for experimental validation from 10 diﬀerent
Families out of the remaining 13. The models are named OctaVII 01 to OctaVII 10 and
they are described herefter.
OctaVII 01
The model is chosen among the 40 sequences that belong to Family 07 according to
its Rosetta energy score (-473.823 REU), the best one in the group. Its β-energy per
residue equals to -0.573 REU and its secondary structure prediction errors are 22.82%
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The presence of aromatic residues is important for the experimental validation, and Oc-
taVII 01 contains 9 tryptophans and 5 tyrosines. 3 cysteines are present in the structure
and none of them is supposed to form a disulﬁde bridge.
Sequence alignment against the non-redundant protein database, performed with the
program BLAST (see Section 3.3.3, page 181), produced 2 outputs: the ﬁrst is a tran-
scriptional regulator of the WhiB family [Arthrobacter ] that has 36% of sequence identity
in 29% of sequence coverage (around 25 residues out of 70) and the second is a sensory
transduction histidine kinase [Paenibacillus alvei ] that has 41% of identity in 18% of cov-
erage (around 17 residues out of 43). Because sequence identities of the full protein are
lower than 25% (respectively 10.4% and 7%), the sequence can be considered not related
to natural sequences.
OctaVII 02
The second model is chosen among the 7 sequences that belong to Family 08 according
to its Rosetta energy score (-464.922 REU), the best one in the group. Its β-energy per
residue equals to -0.575 REU, slightly better than OctaVII 01, and its secondary structure
prediction errors are 14.52% with JPred4 and 20.74% with SSpro, considerably low for




OctaVII 02 contains 1 tryptophan, 5 tyrosines and 4 cysteines (none of them forming a
disulﬁde bridge).
BLAST produced 2 outputs: an hypothetical protein BDEG 25319 [Batrachochytrium
dendrobatidis ], that has 43% of identity in 19% of sequence coverage (around 20 residues
out of 45) and the chaperonin GroEL [Methanosarcina mazei ], that has 42% of identity
in 23% of coverage (around 23 residues out of 55). Because sequence identities of the full
protein are lower than 25% (respectively 8.3% and 9.6%), the sequence can be considered
not related to natural sequences.
OctaVII 03
The third model is chosen among the 35 sequences that belong to Family 16 according
to its Rosetta energy score (-499.38 REU), the best one in the group. Its β-energy per
residue equals to -0.592 REU, better than the previous ones, and its secondary structure
prediction errors are 20.33% with JPred4 and 21.16% with SSpro. It is also one of the
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OctaVII 03 contains 6 tryptophan, 6 tyrosines and 5 cysteines (none of them forming a
disulﬁde bridge).
BLAST produced 2 outputs: a diguanylate cyclase [Marinobacter persicus ] that has
44% of identity in 15% of sequence coverage (around 15 residues out of 36) and an hy-
pothetical protein MYCFIDRAFT 41956, partial [Pseudocercospora ﬁjiensis CIRAD86 ]
that has 28% of identity in 68% of coverage (around 45 residues out of 163). Because
sequence identities of the full protein are lower than 25%, (respectively 6.5% and 18.7%),
the sequence can be considered not related to natural sequences.
OctaVII 04
The fourth model is chosen among the 44 sequences that belong to Family 23 according
to its Rosetta energy score (-478.016 REU), the best one in the group. Its β-energy per
residue equals to -0.634 REU, better than the previous ones, and its secondary structure





OctaVII 04 contains 7 tryptophan, 2 tyrosines and 6 cysteines (none of them forming a
disulﬁde bridge).
BLAST produced 1 output: a quinone-dependent dihydroorotate dehydrogenase [Le-
gionella moravica] that has 31% of identity in 47% of sequence coverage (around 37
residues out of 112). Because sequence identity of the full protein is lower than 25%,
(15.4%), the sequence can be considered not related to natural sequences.
OctaVII 05
The ﬁfth model is chosen among the 45 sequences that belong to Family 26 according
to its Rosetta energy score (-488.990 REU), the best one in the group. Its β-energy per
residue equals to -0.586 REU and its secondary structure prediction errors are 18.25% with
JPred4 and 22.40% with SSpro. It is also one of the best models according to molecular
dynamics (Family 26). Its amino acid sequence is the following:




OctaVII 05 contains 5 tryptophan, 7 tyrosines and 3 cysteines (none of them forming a
disulﬁde bridge).
BLAST produced 1 output: a LacI family transcriptional regulator [Celeribacter baek-
donensis ] that has 51% of identity in 14% of sequence coverage (around 15 residues out of
33). Because sequence identity of the full protein is lower than 25%, (6.5%), the sequence
can be considered not related to natural sequences.
OctaVII 06
The sixth model is chosen among the 3 sequences that belong to Family 06 according to
its Rosetta energy score (-492.517 REU), the best one in the group. The model contains
2 cysteines in 2 diﬀerent loop regions that are mutated to serines with Rosetta (see
Section 3.3.4, page 182), with a new score of -496.148 REU. Its β-energy per residue equals
to -0.522 REU and its secondary structure prediction errors are 18.67% with JPred4 and
21.16% with SSpro.
It is also one of the best models according to molecular dynamics (Family 06). Its




OctaVII 06 contains 7 tryptophan and 3 tyrosines.
BLAST produced “No signiﬁcant similarity found”. The sequence can be considered
not related to natural sequences.
OctaVII 07
The seventh model is chosen among the 13 sequences that belong to Family 12 accord-
ing to its Rosetta energy score (-486.863 REU), the best one in the group. The model
contains 6 cysteines in the loop region that are mutated to serines with Rosetta (see Sec-
tion 3.3.4, page 182), without changes in the total score. Its β-energy per residue equals
to -0.619 REU and its secondary structure prediction errors are 16.18% with JPred4 and
19.08% with SSpro.
It is also one of the best models according to molecular dynamics (Family 06). Its
amino acid sequence is the following:




OctaVII 07 contains 8 tryptophan and 3 tyrosines.
BLAST produced 1 output: a hypothetical protein [Endozoicomonas acroporae] that
has 33% of identity in 36% of sequence coverage (around 28 residues out of 86). Because
sequence identity of the full protein is lower than 25%, (1.6%), the sequence can be
considered not related to natural sequences.
OctaVII 08
The eighth model is chosen among the 31 sequences that belong to Family 13 according
to its Rosetta energy score (-482.207 REU), the best one in the group. The model contains
6 cysteines in the loop region that are mutated to serines with Rosetta (see Section 3.3.4,
page 182), with a new score of -478.687 REU. Its β-energy per residue equals to -0.606
REU and its secondary structure prediction errors are 21.57% with JPred4 and 24.89%




OctaVII 08 contains 3 tryptophan and 8 tyrosines.
BLAST produced 1 output: a adenosine deaminase [Streptomyces kasugaensis ] that
has 49% of identity in 22% of sequence coverage (around 26 residues out of 53). Because
sequence identity of the full protein is lower than 25%, (10.8%), the sequence can be
considered not related to natural sequences.
OctaVII 09
The ninth model is chosen among the 9 sequences that belong to Family 04 according
to its Rosetta energy score (-490.861 REU), the best one in the group. The model contains
5 cysteines in the loop region that are mutated to serines with Rosetta (see Section 3.3.4,
page 182), with a new score of -486.798 REU. Its β-energy per residue equals to -0.630
REU and its secondary structure prediction errors are 19.91% with JPred4 and 22.40%
with SSpro.
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OctaVII 09 contains 3 tryptophan and 5 tyrosines. BLAST produced 1 output: a
hypothetical protein [Vitiosangium] that has 22% of identity in 52% of sequence coverage
(around 27 residues out of 124). Because sequence identity of the full protein is lower
than 25%, (11.2%), the sequence can be considered not related to natural sequences.
OctaVII 10
The tenth model is chosen among the 20 sequences that belong to Family 05 according
to its Rosetta energy score (-484.991 REU), the best one in the group. The model contains
6 cysteines in the loop region that are mutated to serines with Rosetta (see Section 3.3.4,
page 182), with a new score of -483.617 REU. Its β-energy per residue equals to -0.576
REU and its secondary structure prediction errors are 18.67% with JPred4 and 24.48%
with SSpro.




OctaVII 10 contains 6 tryptophans and 3 tyrosines.
BLAST produced 1 output: a hypothetical protein [Vitiosangium] that has 22% of
identity in 52% of sequence coverage (around 27 residues out of 124). Because sequence
identity of the full protein is lower than 25%, (11.2%), the sequence can be considered
not related to natural sequences.
A summary of the characteristics of 10 models chosen for experimental validation is
presented in Table 2.5, and their 3D structures is shown in Figure 2.51.
Energy (REU) β-energy (REU) JPred4 SSpro Trp Tyr Phe Cys Max ID
OctaVII 01 -473.823 -0.573 22.82 % 24.48 % 9 5 14 3 10.4 %
OctaVII 02 -464.922 -0.575 14.52 % 20.74 % 1 5 11 4 9.6 %
OctaVII 03 -499.38 -0.592 20.33 % 21.16 % 6 6 12 5 18.7 %
OctaVII 04 -478.016 -0.634 18.25 % 17.24 % 7 2 12 6 15.4 %
OctaVII 05 -488.99 -0.586 18.25 % 22.40 % 5 7 11 3 6.5 %
OctaVII 06 -496.148 -0.522 18.67 % 21.16 % 7 3 14 0 0.0 %
OctaVII 07 -486.863 -0.619 16.18 % 19.08 % 8 3 10 0 11.6 %
OctaVII 08 -478.687 -0.606 21.57 % 24.89 % 3 8 12 0 10.8 %
OctaVII 09 -486.798 -0.630 19.91 % 22.40 % 3 5 14 0 12.2 %
OctaVII 10 -483.617 -0.576 18.67 % 24.48 % 6 3 14 0 11.2 %
Table 2.5: Models for experimental validation





Figure 2.51: Selected OctaVIIs for experimental validation
(a) Models of OctaVII 01, (b) OctaVII 02, (c) OctaVII 03, (d) OctaVII 04, (e) OctaVII 05, (f) Oc-
taVII 06, (g) OctaVII 07, (h) OctaVII 08, (i) OctaVII 09 and (j) OctaVII 10.
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2.4 Experimental Validation
The experimental validation of the OctaVII proteins is described in this chapter. In
addition to the 10 selected variants, 5 mutants have been produced and characterized.
The ﬁrst mutant, OctaVII 02 Y57Q, has been designed in our laboratory in order to
solve a complication during the experimental validation of OctaVII 02 (see Section 2.4.2,
page 83). The next three mutants, OctaVII 04 NoCys, OctaVII 04 WS and OctaVII 05
NoCys, have been designed following a collaboration with Dr. Wim Vranken at the Vrije
Universiteit Brussel (VUB), Belgium. The goal of the collaboration was to ﬁnd the best
amino acid substitutions to improve the design according to the software developed in
Vranken’s lab (described in Section 2.4.6, page 99). The last mutant, OctaVII 09 WS, is
the result of a collaboration with Dr. Jens Meiler at the Vanderbilt University, USA. Since
software for protein modelling, including Rosetta, are constantly updated and improved,
it was interesting to verify if the new version of the software could improve the OctaVII 09
design.
In the following sections we describe and discuss each of the 15 proteins individually.
Some experiments have been conducted in parallel on several proteins, however, and
there are cross-references and shared results. Moreover, the proteins are not produced
and characterized at the same time: OctaVII 01 and OctaVII 02 are the ﬁrst ones tested
(June 2016) while OctaVII 09 WS is the last one (June 2018, at the really end of my
PhD). For this reason the characterization of the last proteins is more poor compared to
the ﬁrst ones. The time-line in Figure 2.52 shows the dates when the genes were obtained
after synthesis.
Figure 2.52: Time-line for experimental validation
The time-line shows the moment in which the genes for the diﬀerent OctaVII proteins have been received
at our lab. The representation was made for this thesis by Ruth Kellner.
Comparison among the OctaVIIs will be discussed in a recapitulation chapter at the
end of the 15 individual sections.
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2.4.1 OctaVII 01
OctaVII 01 is a 249 aa artiﬁcial protein that was chosen for experimental validation
on the basis of its high Rosetta energy score among the models of Family 07 (details are
given in Section 2.3.9, page 68). The gene was synthesized and inserted in the pET28a
vector by the company IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet was resuspended in 40 µL of ﬁltered mQ water and, after concentration
measurement with Nanovue, a stock reserve was prepared with a ﬁnal concentration of 50
ng/µL. Transformation of 50 µL of competent E. coli DG1 competent cells was done with
50 ng of OctaVII 01 DNA in order to replicate the plasmid for sequencing. The protocols
for transformation, culture production, plasmid extraction and preparation of samples for
sequencing are described in Sections 4.3.1, 4.3.2, 4.3.3 and 4.3.4, respectively, starting at
page 193. Sequencing results conﬁrmed the correct sequence of the OctaVII 01 gene (see
Annex 6.4, page 241). The veriﬁed plasmids were used for a transformation in both E.
coli BL21 (DE3) cells, to produce the protein, and DG1 cells to create as stock at -20◦C.
Expression Trials
After transformation of BL21(DE3) competent cells with the OctaVII 01 plasmid, two
colonies were selected from the plate and grown for 6 hours at 37◦C. An aliquot was taken
for the non induced (NI) sample, and 1 mM of IPTG was added to the rest of the culture.
Aliquots were taken at 2 and 4 hours after induction (2h and 4h). SDS-PAGE analysis of
the crude extract is shown in Figure 2.53.
Figure 2.53: First expression trial of OctaVII 01
SDS-PAGE of the total extract for 2 diﬀerent clones of OctaVII 01. Both clones have been induced at
37◦C with IPTG 1 mM for 0, 2 and 4 hours (NI, 2h and 4h, respectively). The red arrow indicates the
expected molecular mass for OctaVII 01 (27 kDa).
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The theoretic molecular mass of OctaVII 01 is 28.3 kDa, however there are not signif-
icant bands in the induced samples, nor at that size nor in the rest of the gel.
A second trial for protein expression was done with a new colony of transformants.
Induction was performed at 37◦C with 1 mM IPTG for 0 (NI), 1, 2, 3, 4 hours and
overnight (ON). For each condition, SDS-PAGE gels were prepared in order to show the
protein expression in the total, soluble (S) and insoluble (I) fractions (Figure 2.54). As
in the previous case, no evidence of expression is visible on the gel for any fraction.
(a) (b)
Figure 2.54: Second expression trial of OctaVII 01
(a) SDS-PAGE of the total fraction for 6 diﬀerent conditions of induction at 37◦C with IPTG 1 mM: 0,
1, 2, 3, 4 hours and overnight (NI, 1h, 2h, 3h, 4h and ON, respectively). (b) SDS-PAGE of the same
samples after separation of the soluble fraction (S) and the insoluble fraction (I). The red arrows indicate
the expected molecular mass for OctaVII 01 (27 kDa).
Puriﬁcation
A third experiment to conﬁrm that OctaVII 01 is not expressed in the cell is performed
through puriﬁcation on IMAC column. The principle at the basis of the experiment is
that if OctaVII 01 is produced at minimal level (not visible in the SDS-PAGE), a large
production (1 L) and puriﬁcation might concentrate the protein enough to make it visible
on SDS-PAGE.
The induction was done at 37◦C for 4h, and cells were disrupted with 3 cycles of French
Press. The soluble fraction was separated from the insoluble one through centrifugation
and both fractions were loaded on a 5 mL HisTrap HP column. The puriﬁcation proﬁles
and the SDS-PAGE gels are shown in Figure 2.55. OctaVII 01 does not seem to be
expressed, nor in the soluble fraction nor in the insoluble one, conﬁrming the previous
results.
Western blot
In order to detect a basal expression of the protein, a forth trial of expression was done
following induction at 18◦C using diﬀerent concentrations of IPTG: 0, 10, 20, 50 and 100
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Figure 2.55: Puriﬁcation of OctaVII 01
(a) Elution proﬁles of OctaVII 01 from the soluble fraction and (b) from the insoluble fraction. The blue
line is the absorbance at 280 nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5
M) and the red line is the concentration of the denaturant buﬀer (urea 8 M). Black squares represent
the fractions that are shown in (c), SDS-PAGE of the puriﬁcations from the soluble (lanes 1-8) and the
insoluble fractions (lanes 9-13). Line 1,9 the input samples; 2,10 the ﬂow-throughs; 3-8 and 11-13, the
elution peaks.
µM. The experiment was done in parallel with both OctaVII 01 and OctaVII 02, and the
analysis was done with both SDS-PAGE (Figure 2.56a) and Western-Blot analysis using
anti-HisTag antibodies (Figure 2.56b).
(a) (b)
Figure 2.56: Third expression trial of OctaVII 01
(a) SDS-PAGE of the total fraction for 5 diﬀerent concentrations of IPTG for both OctaVII 01 (lanes 1-5)
and OctaVII 02 (lanes 6-10). Lines 1,6, non-induced; 2,7, IPTG 10 µM; 3,8, IPTG 20 µM; 4,9, IPTG
50 µM and 5,10, IPTG 100 µM. The red arrow indicates the expected molecular mass for OctaVII 01
(27 kDa). (b) Western Blot of the same samples after 10 minutes of ﬁlm exposition, using anti HisTag
antybodies.
The SDS-PAGE gel with the expression of both OctaVII 01 and OctaVII 02 does not
show signiﬁcant bands for both proteins. However, as shown in Figure 2.56b, the antibody
anti-HisTag recognizes both the tagged markers and the OctaVII 02 (its discussion will
be done in the next chapter). Despite the long time of exposition there are no bands
in the lanes of OctaVII 01. This experiment is a clear indication that the protein is not
expressed in the cell, not even at basal level. One hypothesis that can explain the lack
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of the protein in the crude extract of the cell culture is that the protein may be toxic for
the cells even at low concentrations. In order to inquire this hypothesis, we analyzed the
growth rate of the cells bearing the OctaVII 01 plasmid in comparison with cells bearing
the OctaVII 02 plasmid.
Growth rate
A new transformation was done for both OctaVII 01 and OctaVII 02 in BL21(DE3)
cells. Visual inspection of the agar plates revealed that colonies bearing the OctaVII 01
plasmid were smaller than those with the OctaVII 02 plasmid, suggesting that the protein
may alter the metabolism of the cell.
For each protein, 2 colonies were selected and grown overnight in fresh LB-Kan
medium. In the morning, cells were inoculated in fresh medium. To normalize the number
of starting cells in each culture, the 4 pre-cultures were diluted to reach Abs600=0.6 and
the same volume was then injected in the fresh media. Their growth was monitored each


































































































































Figure 2.57: Growth rates for OctaVII 01 and OctaVII 02
(a) Time vs absorbance at 600 nm of 2 clones of OctaVII 01 (green) and 2 clones of OctaVII 02 (blue).
Bacterial cells are grown in the same condition at 37◦C, without induction. (b) Time vs absorbance at
600 nm for the same 4 clones (independent preparation) after induction with IPTG 1 mM.
The clones of OctaVII 01 have a longer lag-phase compared to the one of OctaVII 02
(around the double of time). The log-phase has the same rate for both proteins, but
the deceleration phase for OctaVII 01 start around Abs600=1.0, while OctaVII 02 one
starts at Abs600=1.5. After almost 24 hours, the absorbance of OctaVII 01 did not reach
values over 1.7. This experimental data supports the hypothesis that OctaVII 01 may be
partially toxic and may slow down the natural metabolism of the cell. The results were
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obtained without induction of the expression of the protein, but the pET28a vector is
known to be “leaky” and to allow a basal production of the target protein.
In order to verify what happens following induction, the same 4 clones were grown up
in independent cultures to reach Abs600=0.6, and were then induced with IPTG 1 mM.
The absorbance of the induced samples was measured every hour and the result is shown
in Figure 2.57b. The clones for OctaVII 02 have identical growth rates during induction,
reaching Abs600=2 in just 4 hours. The growth of the clones of OctaVII 01 is initially
very moderated, and than vary depending on the clone: one is not growing at all during
the 4h induction (expected behavior when proteins are toxic), but the other restarted to
grow after around 2 hours, and reached Abs600=1.5 in the remaining 2 hours.
Despite diﬀerent trials, it was not possible to express the protein. The OctaVII 01 is
discarded from further experimental validation.
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2.4.2 OctaVII 02
OctaVII 02 has 250 residues and it is the best representative of Family 08 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
and inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 02 was manipulated for sequencing and storage as de-
scribed for OctaVII 01 in Section 2.4.1. The results of the sequencing conﬁrmed the
correct sequence of the gene (see Annex 6.4, page 241), that was then used for a trans-
formation in BL21 (DE3) cells for expression trials.
Expression Trials
Following transformation of E. coli BL21(DE3) competent cells with the OctaVII 02
plasmid, two colonies were selected from the plate and grown for 6 hours at 37◦C. An
aliquot was taken for the non induced (NI) sample, and 1 mM of IPTG was added to the
rest of the culture. Aliquots were taken at 1, 2, 3, 4 and ∼15 hours after induction (1h, 2h,
3h, 4h and ON). SDS-PAGE analysis of the total, soluble (S) and insoluble (I) fractions
is shown in Figure 2.58. It is clear that the protein is over-expressed and already visible
on the gel 1 hour after the induction, and its production increases over-time. Analysis
of the soluble (S) and insoluble (I) fractions of the crude extract shows that the protein
is produced mainly in inclusion bodies (Figure 2.58b). The theoretic molecular mass of
the protein is 27.5 kDa, but the bands appear at 20 kDa. It is not clear if the protein
is degraded inside the cells to a lower molecular mass species after synthesis, or if it is
produced directly at the wrong size. A western blot analysis was performed to answer
that question.
Western blot
The western blot analysis shown in Figure 2.59 is the same as described for OctaVII 01
in Section 2.4.1, page 79. OctaVII 02 is not visible in the SDS-PAGE gel (Figure 2.59a),
but it is clearly present in the western blot (Figure 2.59b), showing that it is expressed
at low concentration of IPTG (0 to 100 µM) and low temperature (18◦C). The molecular
mass of the protein is 15 kDa and does not correspond to the theoretic one of 27.5 kDa.
This truncation is surely located at the N-terminal of the protein because the 6x HisTag
recognized by the antibody is at the C-terminal.
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(a) (b)
Figure 2.58: Expression trial of OctaVII 02
(a) SDS-PAGE of the total fraction for 6 diﬀerent conditions of induction of OctaVII 02 at 37◦C with
IPTG 1 mM: 0, 1, 2, 3, 4 hours and overnight (NI, 1h, 2h, 3h, 4h and ON, respectively). (b) SDS-PAGE
of the same samples after separation of the soluble fraction (S) and the insoluble fraction (I).
The western blot also shows that the protein is not present as a single band but with
at least two main populations at similar size, and few minor bands at lower molecular
mass (very likely, degradation products).
(a) (b)
Figure 2.59: Western blot of OctaVII 02
(a) SDS-PAGE of the total fraction for 5 diﬀerent concentrations of IPTG for both OctaVII 01 (lanes
1-5) and OctaVII 02 (lanes 6-10). Lines 1,6, non-induced; 2,7, IPTG 10 µM; 3,8, IPTG 20 µM; 4,9,
IPTG 50 µM and 5,10, IPTG 100 µM. (b) Western Blot of the same samples after 10 minutes of ﬁlm
exposition.
Puriﬁcation of the soluble fraction
Despite of the truncation and the double band of OctaVII 02, we decided to produce
the protein. The cells of 1 L cultures were disrupted and the soluble fraction was separated
from the insoluble one by centrifugation. Figure 2.60b shows the diﬀerence between
the crude extract (total fraction obtained after cell disruption) and the soluble fraction
(sample obtained after centrifugation of the crude extract). The band of OctaVII 02 is
predominant in the crude extract (lane 1), while it is barely noticeable among the other
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cellular proteins in the soluble fraction (lane 2).
After ﬁltration on 0.22 µm ﬁlters, the soluble fraction of the crude extract was loaded
on an HisTrap HP column for puriﬁcation. The elution proﬁle is shown in Figure 2.60a,
and its analysis on SDS-PAGE is shown in Figure 2.60b in lanes 4 to 9.
(a)



































































Figure 2.60: Puriﬁcation of OctaVII 02, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 02: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. Lane 1 the crude extract; 2 the input sample;
3 the ﬂow-through; 4-9 the elution peak.
Most proteins of the crude extract did not interact with the column and were eluted
in the ﬂow-through (lane 3). Some contaminants are eluted in the ﬁrst fractions following
initiation of the imidazole gradient (lane 4), suggesting that their interaction with the Ni2+
matrix is weak and probably due to a single exposed histidine. Lines 5 to 9 present a
band at 20 kDa that might correspond to OctaVII 02, but contaminant bands are present
at higher and lower molecular mass, especially in lane 5. The molecular mass of 15 kDa
that was shown in the western blot may just be an artifact due to the membrane transfer,
but, despite the low quality of the gel resolution, it seems that two or more bands are
overlapping at 20 kDa.
Puriﬁcation of the insoluble fraction
The insoluble fraction of the crude extract of the 1 L culture was washed a couple of
times prior to denaturation. The refolding of the protein was done in parallel with its
puriﬁcation: the unfolded protein in 8 M urea (see Section 4.7.4, page 202) was loaded
in the HisTrap HP column and its 6x HisTag bounds tightly to the Ni2+ matrix. The
concentration of urea was then progressively decreased with a gradient from 8 to 0 M
(red line in Figure 2.61a). Under this condition, the protein can possibly refold and equi-
librate in the standard buﬀer prior to elution with an imidazole buﬀer. This technique is
called on-column refolding and is an eﬃcient method to simultaneously refold and purify
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proteins.
Inclusion bodies of OctaVII 02 were resuspended in a buﬀer with urea 8 M and left
stirring overnight at room temperature. In the morning the solution of unfolded soluble
proteins was centrifuged and ﬁltered on 0.22 µm ﬁlters. Figure 2.61b, (lanes 1 and 2
shows no signiﬁcant diﬀerence between the resuspended pellet and the ﬁltrated solution.
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Figure 2.61: Puriﬁcation of OctaVII 02, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 02: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration
of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b),
the SDS-PAGE gel. Lane 1 the resuspended pellet; 2 the input sample; 3 the ﬂow-through; 4-14 the
elution peak.
The unfolded OctaVII 02 was then loaded on the HisTrap HP column, refolded and
eluted. The majority of the contaminants does not bind to the column and they are
eluted in the ﬂow-through (lane 3 in the SDS-PAGE gel). The refolding process (between
50 and 140 mL of the elution volume) does not aﬀect the binding of the HisTag to the
resin, as indicated by the low absorbance signal at 280 nm (blue line in Figure 2.61a).
The elution of the protein starts at 150 mM of imidazole and present a sharp peak. The
high absorbance signal after the elution peak is due to the increasing concentration of
imidazole, that absorbs at 280 nm. The fractions on gels (lanes 4 to 14) shows that
OctaVII 02 is the predominant band, although minor contaminants are visible at both
higher and lower molecular masses. The next step in the analysis of OctaVII 02 is the
evaluation of its oligomeric state through size exclusion chromatography.
Size Exclusion, Superdex75
The fractions containing the refolded OctaVII 02 were pooled in one sample that was
centrifuged and ﬁltered on 0.22 µm ﬁlters. The protein concentration dropped from 0.75
mg/mL to 0.25 mg/mL during this manipulation, suggesting that the refolded protein
may not be fully soluble. However there are not diﬀerences in the intensity of the bands
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on the gel before and after the ﬁltration (lanes 1 and 2, respectively, in Figure 2.62b). This
change in the concentration is probably bound to a decrease of imidazole in the solution
due to precipitation. Pure imidazole does not absorbs at 280 nm, however impurities in
the reagent may cause absorption. Indeed, the absorbance of the imidazole solution used
during elution corresponds to 0.8 in Figure 2.61a. In order to avoid absorbance at 280
nm due to the impurities, only highly pure imidazole will be used for the puriﬁcation of
the following OctaVIIs.
The protein sample was loaded on a preparative Superdex-75 column for a size ex-
clusion chromatography (see Table 4.13, page 206), and its elution proﬁle is shown in
Figure 2.62a. Two main peaks are visible according to absorbance measurements at 280
nm: the ﬁrst one is centered at 50 mL and the second one at 140 mL. Fractions corre-
sponding to both peaks were taken for SDS-PAGE analysis, shown in Figure 2.62b, lanes
3 to 11. The second peak (lanes 7-11) does not present protein bands, and thus the signal
at 280 nm may be due to the imidazole molecules that absorbs in that range. The ﬁrst
peak presents the protein band and also contaminant species of low molecular mass, sug-
gesting that the protein is interacting with them. The ﬁrst elution peak corresponds to
the void volume of the column, suggesting a molecular mass above 100 kDa. It is not clear
if this high molecular mass is caused by interaction of OctaVII 02 with the contaminant
in solution or with itself.
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Figure 2.62: Puriﬁcation of OctaVII 02, size exclusion
(a) Size exclusion elution proﬁle of the pool of the refolded OctaVII 02: the blue line is the absorbance at
280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the pool of the refolded OctaVII 02; 2 the input sample; 3-6 the ﬁrst
elution peak; 7-11 the second elution peak.
So far OctaVII 02 is well expressed in inclusion bodies, it is truncated, not very soluble
and apparently present in diﬀerent isoforms and oligomerization states. The protein itself
does not worth further characterization, but a last attempt we can do is to recover the
full size of the protein.
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N-sequencing
The sample with the refolded OctaVII 02 was used for N-sequencing (see Section 4.6.6
for the method description, page 200). The resulting sequence at the N-terminal of
OctaVII 02 is SxGGM, that corresponds to the sequence SCGGM located at about 60
residues from the expected N-terminus. The truncation covers the ﬁrst βαβα unit and
the theoretic molecular mass of the truncated form correspond to 20.9 kDa, that is in
good agreement with the bands on the gels at ∼20 kDa.
The reasons at the basis of the truncation in OctaVII 02 are not clear, and after
sequencing of the plasmid we could exclude errors in the DNA sequence of the gene.
Two other possibilities have been considered: 1- an error during the production of the
protein, in which the translation machinery missed the ﬁrst starting codon, ATG, but
recognized another one downstream the sequence, or 2- a post-translational cleavage due
to endogenous proteases.
We could exclude the ﬁrst hypothesis because the truncated version of OctaVII 02 does
not begin with a methionine, and the closest one is 23 residues upstream the truncation
region. It is very unlikely that the truncation of the protein is due to an error during the
translation of the protein.
The second hypothesis was assessed through analysis of the sequence cleavage sites.
Two predictors for protein cleavage were used: PeptideCutter [129] and PROSPER [130].
The ﬁrst predictor found 2 proteases that cut the protein between Y59 and S60, the ﬁrst
residue of OctaVII 02: chymotrypsin-like proteases (that cleave the C-term of F, W, Y,
M and L residues), and Proteinase K (that cleaves the C-term of aromatic residues). The
second program predicted a cleavage by a serine proteases.
Ehrmann group at the University of Duisburg-Essen has a public web-site that resume
all the proteases of E. coli :
https://www.uni-due.de/zmb/members/ehrmann/e-coli-proteases/.
Among all the proteases, the ATP-dependent Clp proteolytic subunit may be respon-
sible for the truncation of OctaVII 02: it is localized in the cytoplasm of E. coli cells,
it has a chymotrypsin-like activity (cleavage after F, W, Y, M and L residues) and it
plays a major role in the degradation of misfolded protein (like the OctaVII 02 before
compartmentalization in inclusion bodies).
In order to understand if the reason of the truncation is a cleavage by endogenous
proteases of E. coli, and if it is possible to recover the full length of the protein, we
decided to produce a variant of OctaVII 02 in which the recognition site of the putative
protease (Y59) is mutated to a glutamine (OctaVII 02 Y59Q).
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2.4.3 OctaVII 02 Y59Q
Site-directed mutagenesis and sequencing
The single point mutation in the gene of OctaVII 02 was done by PCR with the kit
QuickChange II XL Site-Directed Mutagenesis from Agilent Technologies. The sequence
of the two primers, Y57Q forward and Y57Q reverse, for the mutagenesis are reported in
Section 4.1.3, page 184.
Transformation of DG1 competent cells and plasmid replication were done in order to
verify by sequencing the presence of the correct mutation. 4 out of 5 clones contained the
good sequence which was used for stock preparation and protein expression.
Expression Trials
After transformation of E. coli BL21(DE3) competent cells with both OctaVII 02 wild-
type and OctaVII 02 Y59Q, two cultures were prepared to verify the protein size of the
Y59Q mutant. The SDS-PAGE gel is shown in Figure 2.63a, and it clearly shows that the
single point mutation does not prevent the putative cleavage observed with OctaVII 02.
Both OctaVII 02 and OctaVII 02 Y59Q are discarded from further characterization be-
cause they lack 60 out of 250 residues (Figure 2.63b).
(a) (b)
Figure 2.63: Expression trial of OctaVII 02 Y59Q
(a) SDS-PAGE of the total (T), soluble (S) and insoluble (I) fractions of OctaVII 02 (WT) and OctaVII 02
Y59Q. (b) Models of the theoretic full-length protein (top) and of its truncated version (bottom).
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2.4.4 OctaVII 03
OctaVII 03 has 250 residues and it is the best representative of Family 16 according
to the Rosetta energy score (details in Section 2.3.9, page 68). It is also the best rep-
resentative of all the models according to molecular dynamics (details in Section 3.3.2,
page 180). The gene was synthesized and inserted in the pET28a plasmid by IDT, that
shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 03 was manipulated for sequencing and storage as de-
scribed for OctaVII 01 in Section 2.4.1. The results of the sequencing conﬁrmed the
correct sequence of the OctaVII 03 gene (see Annex 6.4, page 241), that was then used
for a transformation in BL21 (DE3) cells for expression trials.
Expression Trials
After transformation, a colony was selected from the plate to grow for 8 hours at 37◦C.
An aliquot was taken for the non induced (NI) sample, and 1 mM of IPTG was added to
the rest of the culture for an overnight induction at 37◦C. The overnight sample was used
for analysis of the total (T), the soluble (S) and the insoluble (I) fractions. SDS-PAGE
analysis for the 4 conditions (NI, T, S and I) is shown in Figure 2.64. The protein is
over-expressed and mainly produced in inclusion bodies. The theoretic molecular mass
of the protein is 28.1 kDa, but the bands appears at 23 kDa, suggesting that OctaVII 03
might also be truncated. Since our eﬀorts to recover the full length of OctaVII 02 did not
brought signiﬁcant results (see Section 2.4.3, page 89), OctaVII 03 is discarded without
further analysis.
Figure 2.64: Expression trial of OctaVII 03
SDS-PAGE of OctaVII 03 after induction with 1 mM IPTG overnight. From left to right: the non-induced
sample (NI), the total fraction (T), the soluble fraction (S) and the insoluble fraction (I).
92 CHAPTER 2. RESULTS AND DISCUSSION
2.4. EXPERIMENTAL VALIDATION 93
2.4.5 OctaVII 04
OctaVII 04 has 250 residues and it is the best representative of Family 23 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
and inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 04 was manipulated for sequencing and storage as de-
scribed for OctaVII 01 in Section 2.4.1, page 77. The results of the sequencing conﬁrmed
the correct sequence of the OctaVII 04 gene (see Annex 6.4, page 241), that was then
used for a transformation in BL21 (DE3) cells for expression trials.
Expression Trials
After transformation of E. coli BL21(DE3) competent cells with the OctaVII 04 plas-
mid, a colony was selected from the plate to grow for 8 hours at 37◦C. An aliquot was
taken for the non induced (NI) sample, and 1 mM of IPTG was added to the rest of the
culture for an overnight induction at 37◦C. SDS-PAGE analysis of the total (T), soluble
(S), and insoluble (I) fractions is shown in Figure 2.65. It is clear that the protein is
over-expressed and mainly produced in inclusion bodies. The theoretic molecular mass
of the protein is 27.9 kDa, and the bands appear at the expected position in the gel.
Expression trials were performed also at 18◦C overnight with the same results (data not
shown).
Figure 2.65: Expression trial of OctaVII 04
SDS-PAGE of OctaVII 03 (already analyzed in Section 2.4.4, page 91) and OctaVII 04, after induction
with 1 mM IPTG overnight. From left to right: the non-induced sample (NI), the total fraction (T), the
soluble fraction (S) and the insoluble fraction (I).
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Puriﬁcation of the soluble fraction
Cells of 1 L culture with overnight induction at 37◦C were disrupted. Soluble and
insoluble fractions were separated by centrifugation. After ﬁltration on 0.22 µm ﬁlters,
the soluble fraction of the crude extract was loaded on an HisTrap HP column for pu-
riﬁcation. The elution proﬁle is shown in Figure 2.66a, and its analysis on SDS-PAGE is
shown in Figure 2.66b in lanes 2 to 9.
Almost all the proteins of the sample do not interact with the column and are eluted
in the ﬂow-through (lane 2). Some contaminants at high molecular mass are eluted with
imidazole 75 mM in the ﬁrst fractions (lanes 3 and 4). Lanes 5 to 9 correspond to a band
at 28 kDa that might represent the OctaVII 04.
As for the puriﬁcation of the soluble fraction of OctaVII 02, the overall amount of
OctaVII 04 is extremely low for an over-expression. Its presence in the soluble fraction
may be due other factors rather than spontaneous folding in the cytoplasm of the cells.
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Figure 2.66: Puriﬁcation of OctaVII 04, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 04: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2 the
ﬂow-through; 3-4 the ﬁrst elution peak at imidazole 75 mM; 5-9 the second elution peak.
Puriﬁcation of the insoluble fraction
The insoluble fraction of the crude extract of the 1 L culture was washed a couple of
times prior to denaturation. As for OctaVII 02, the refolding of the protein was performed
in parallel with its puriﬁcation. The unfolded OctaVII 04 in 8 M urea was loaded on the
HisTrap HP column, refolded and eluted (Figure 2.67a). In the input solution OctaVII 04
is the predominant band, however few contaminants are visible in the SDS-PAGE (lane 1
in Figure 2.67b). The contaminants and part of OctaVII 04 are eluted in the ﬂow-through
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(lanes 2-4). The presence of OctaVII 04 in the ﬂow-through is due to simple saturation
of the column.
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Figure 2.67: Puriﬁcation of OctaVII 04, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 04: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration
of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b),
the SDS-PAGE gel. In lane 1 there is the input sample; 2-4 the ﬂow-through; 5-8 the elution peak.
The refolding process (between 100 and 150 mL of the elution volume) does not aﬀect
the binding of the protein to the matrix because there are no changes in the absorbance
at 280 nm (blue line in Figure 2.67a). The elution of the protein starts at 250 mM of
imidazole and present a sharp peak. The fractions on gels (lanes 5 to 8) shows that
OctaVII 04 is the predominant band and that it is of high purity (> 95%).
Desalting
In order to remove the imidazole from the protein sample and prevent any precipi-
tation, a desalting chromatography was done just after the elution of the refolded Oc-
taVII 04. The fractions containing the protein were pooled together, the sample was
centrifuged, ﬁltered on 0.22 µm ﬁlters and loaded onto the desalting column. The elution
proﬁle is shown in Figure 2.68a.
The peak of elution of the protein (from 50 to 100 mL in the elution volume) is well
separated from the peak in conductivity (110 to 160 mL), due to the imidazole. The SDS-
PAGE in Figure 2.68b shows the presence of few contaminants at 45 kDa, but OctaVII 04
is always the predominant band.
Biophysical characterization
The fractions containing OctaVII 04 were pooled together and centrifuged at 20000
rpm for 20 mins. The sample was ﬁltered on 0.22 µm ﬁlters and an absorption spectrum
was recorded (Figure 2.69a).
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Figure 2.68: Puriﬁcation of OctaVII 04, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 04: the blue line is the absorbance
at 280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-7 the elution peak.
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Abs280 = 0.229, [C] = 0.154 mg/mL
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 λmax = 338 nm
Figure 2.69: Biophysical characterization of OctaVII 04
(a) Absorption spectrum of the pool of OctaVII 04 after desalting. Abs280 is used to calculate the protein
concentration. (b) CD spectrum of the protein (top) and high-tension (bottom); the dotted line indicates
the baseline at [Θ]=0. (c) Emission ﬂuorescence spectrum of the protein. The dotted line at 354 nm
indicates the expected maximum for unfolded proteins.
The Abs260/Abs280 ratio is 0.82 and indicates that there is no signiﬁcant contamination
by nucleic acids; the shoulder at 290 nm is typical of tryptophan and the Abs280 is 0.23.
The concentration of the protein was calculated with the Equation 4.3, and equals to 0.154
mg/mL. The molar extinction coeﬃcient (εm) is reported in Table 4.16 in the method
section 4.8.1, page 209.
The sample was then diluted to 0.1 mg/mL and 0.01 mg/mL for analysis by circular
dichroism (CD) and ﬂuorescence, respectively. Reliable CD signal could be measured
down to 195.6 nm before saturation of the photo-multiplicator. The CD spectrum shows
the presence of α-helices, with minima around 222 and 208 nm. The analysis of the
spectrum by CDpro, using the program CDSSTR, is compared with the DSSP analysis
obtained from the model structure of OctaVII 04. Both are shown in Table 2.6.
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% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 34.9 17.4 19.5 27.9
DSSP 47.9 18.7 16.6 16.6
Table 2.6: Secondary structures content, OctaVII 04
The percentages of β-strands and turns obtained from the experimental data are in
good agreement with the model ones, 18% each. However, the α-helix content is decreased
of 13% compared to the model.
Analysis of the tertiary structure was done by ﬂuorescence and is reported in Fig-
ure 2.69c. The maximum in intensity is at 338 nm and indicates that the aromatic
residues are not exposed to the solvent. The protein have a compact 3D structure, but it
is not clear if it is well-packed or in a molten globule state.
The protein was subjected to ﬁltration steps in order to reach a concentration > 2
mg/mL. Unfortunately, the majority of the protein precipitated after just few cycles. It
was not possible to reach a concentration greater than 0.2 mg/mL in any trial done with
OctaVII 04.
Size Exclusion, Superdex75
A new sample of the refolded OctaVII 04 was loaded on a Superdex-75 column in
order to inquire its oligomerization state. The sample was less pure than the previous
one: contaminant bands are visible on SDS-PAGE gel at 66 kDa and 23 kDa (lane 1 in
Figure 2.70b).
(a)
























































Figure 2.70: Puriﬁcation of OctaVII 04, size exclusion
(a) Size exclusion elution proﬁle of the pool of the refolded OctaVII 04: the blue line is the absorbance at
280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-5 the ﬁrst elution peak; 6-7 the second elution
peak.
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The elution proﬁle of OctaVII 04 is shown in Figure 2.70a, in which a main peak with
multiples shoulders is visible. The peak is centered at 7.9 mL, corresponding to the void
volume of the column. This result suggests that the majority of the protein is in a higher
oligomerization state than 75 kDa, as for OctaVII 02. The SDS-PAGE gel shows that a
proteins at 66 kDa and the OctaVII 04 co-elute in the main peak (lanes 2 and 3). One of
the shoulders is centered at 10 mL, corresponding to 60 kDa. In this fraction the protein
can be in a dimeric form, but the SDS-PAGE gel shows that OctaVII 04 is co-eluting
with the protein at 23 kDa.
It is not clear if OctaVII 04 is interacting with the contaminant bands in solution,
or if it is forming homo-oligomers on its own. The presence of 6 free cysteines in the
sequence of OctaVII 04 may be a reason for its high oligomerization state. It can possibly
be related also to the low solubility of the protein in solution. We decided to discard
OctaVII 04 from further analysis and to create a mutant without cysteins in order to
obtain a monomeric form.
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2.4.6 OctaVII 04 NoCys
OctaVII 04 NoCys is a mutant of OctaVII 04 that does not contain cysteine. The
substitution of the 6 original cysteines was done in collaboration with the laboratory of
Dr. Wim Vranken at the Vrije Universiteit Brussel (VUB), Belgium. He and his group
developed a methodology based on the Hidden Markov model (named HMM) that is able
to score a protein starting from its sequence and to suggest beneﬁcial mutations that
may improve the score. Rosetta does the same, but it requires a starting 3D structure.
HMM was trained on databases of natural proteins that furnish statistical results, that
were then used for the analysis of the protein sequence. The HMM methodology is very
promising, because it can be used with all the proteins, natural or artiﬁcial, that do not
have a solved structure. In this collaboration, all the work related to the HMM software
is done by Gabriele Orlando, a PhD student in Vranken’s Lab.
The OctaVII 04 sequence was analyzed with HMM, that suggested the beneﬁcial mu-
tations for the substitution of the 6 cysteines: three of them have one single option of
mutation (C61I, C89L and C210A), while the remaining three has two options each (C34
T or V, C65 S or V and C214 T or M). All the possible combinations are 8. We tested each
of them with both HMM (that uses as input the amino acid sequence) and Rosetta (that
uses as input a 3D model structure). The preparation of the 8 models is described in Sec-
tion 3.3.4. The scores of HMM and Rosetta are reported in Table 2.7. Their normalized
values (against OctaVII 04) are plotted in Figure 2.71.
Name Mutations HMM score Rosetta score
OctaVII 04 C34, C61, C65, C89, C210, C214 27.62 -478.016
Mutant 1 C34V, C61I, C65S, C89L, C210A, C214T 26.01 -479.136
Mutant 2 C34V, C61I, C65S, C89L, C210A, C214M 27.82 -476.161
Mutant 3 C34V, C61I, C65V, C89L, C210A, C214T 29.47 -472.391
Mutant 4 C34V, C61I, C65V, C89L, C210A, C214M 30.02 -473.415
Mutant 5 C34T, C61I, C65S, C89L, C210A, C214T 29.67 -474.525
Mutant 6 C34T, C61I, C65S, C89L, C210A, C214M 28.22 -477.103
Mutant 7 C34T, C61I, C65V, C89L, C210A, C214T 29.94 -474.011
Mutant 8 C34T, C61I, C65V, C89L, C210A, C214M 30.65 -470.749
Table 2.7: Design of OctaVII 04 NoCys
The HMM scores are all improving compared to the score of OctaVII 04 with the
exception of Mutant 1. The Rosetta scores behaves in the opposite way: the best Rosetta
score is of Mutant 1. Compared to OctaVII 04 it is the only one with a lower score, while
the other 7 variants has an higher total energy (so, a lower stability). Mutant 8 has 7.2
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Figure 2.71: Cysteines substitution of OctaVII 04
Normalized scores for the 8 mutants of OctaVII 04 according to HMM (blue) and Rosetta (green) scores.
The numbers 1 to 8 on the x-axis represent the 8 mutants and 0 is the original OctaVII 04.
REU of diﬀerence compared to the original, but this diﬀerence is not signiﬁcant (1.5% of
the total energy).
We chose Mutant 8 among the 8 variants, that has the best score according to HMM.
It is renamed OctaVII 04 NoCys and it has 250 residues. The gene was synthesized and
inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 04 NoCys was manipulated for sequencing and storage
as described for OctaVII 01 in Section 2.4.1, page 77. The results of the sequencing
conﬁrmed the correct sequence of the OctaVII 04 NoCys gene (see Annex 6.4, page 241),
that was then used for a transformation in E. coli BL21 (DE3) cells for expression trials.
Expression Trials
Expression trials of OctaVII 04 NoCys were performed with IPTG 1 mM in two con-
ditions: overnight at 18◦C and 4 hours at 37◦C. In both cases the protein was highly
produced and represents the major band in the total fraction (lines 1 in Figure 2.72).
The protein was mainly produced in inclusion bodies (insoluble fraction), but the gel sug-
gests that a small amount might be present also in the soluble fraction. For this reason,
we tried to purify the protein from the soluble fraction with the HisTrap HP column.
Puriﬁcation of the soluble fraction
The protein was produced in 1 L of cell culture with 4 hours of induction at 37◦C.
The crude extract was obtained after 3 cycles of disruption and it is shown in 2 diﬀerent
concentrations in Figure 2.73b (lanes 1 and 2). The soluble fraction was separated from
the pellet via centrifugation and ﬁltered on 0.22 µm ﬁlters. The input sample (lane 3)
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(a) (b)
Figure 2.72: Expression trials of OctaVII 04 NoCys, soluble fraction
(a) Expression trials of OctaVII 04 NoCys at 18◦C overnight: lane 1 total, 2 insoluble and 3 soluble
fractions. (b) Expression trials of OctaVII 04 NoCys at 37◦C for 4 hours: lane 1 total, 2 soluble and 3
insoluble fractions.
was loaded on the HisTrap HP column, and the protein was puriﬁed as described in
Section 4.7.3, page 201. The chromatogram of the puriﬁcation is shown in Figure 2.73a.
The elution peak is visible at 75 mM of imidazole. This concentration is too low for the
6x HisTag, that normally eluates at 300 mM of imidazole. The peak is composed by
contaminants, as shown in the SDS-PAGE in lanes 8 to 12, and OctaVII 04 NoCys is not
produced in the soluble fraction. This result may suggest that the small elution peak that
was obtained after puriﬁcation of the soluble fraction is not due to spontaneous folding.
(a)


































































Figure 2.73: Puriﬁcation of OctaVII 04 NoCys, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 04 NoCys: the blue line is the absorbance at 280
nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares
represent the fractions that are shown in (b), the SDS-PAGE gel. Lanes 1-2, the crude extract, 4 µL
and 1 µL, respectively; 3 the input sample; 4-7 the ﬂow-through; 8-12 the elution peak.
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Puriﬁcation of the insoluble fraction
The insoluble fraction (pellet) produced in 1 L of cell culture was washed and re-
suspended at room temperature overnight in a buﬀer containing urea 8 M. The solution
was centrifuged at 20000 rpm for 20 min and the supernatant was ﬁltered on 0.22 µm
ﬁlters. This input sample was loaded on the HisTrap HP column for puriﬁcation and
refolding (described in Section 4.7.4, page 202) and it is shown in Figure 2.74b in lane
1. OctaVII 04 NoCys is the predominant protein, but contaminants are visible at higher
molecular mass. OctaVII 04 NoCys is present in the ﬂow-through (lanes 2 to 5), sug-
gesting that the column reached saturation. There are two elution peaks: the ﬁrst one is
between 200 and 300 mM of imidazole, which is the optimal concentration for the elution
of HisTagged proteins, and the second is at 500 mM of imidazole. It is not clear why part
of the protein elutes at higher concentration of imidazole. The puriﬁcation was repeated
4 times with the same results. The second peak is more concentrated than the ﬁrst one,
and it contains more contaminants compared to the ﬁrst one (in particular the band at
33 kDa that is not visible in the ﬁrst peak). However, OctaVII 04 NoCys is always the
main band. The two peaks are individually pooled and manipulated for comparison.
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Figure 2.74: Puriﬁcation of OctaVII 04 NoCys, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 04 NoCys: the blue line is the absorbance at
280 nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the
concentration of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are
shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-5 the ﬂow-through; 6-11 the
ﬁrst elution peak and 12-13 the second elution peak.
Desalting
For each of the two elution peaks of the refolded OctaVII 04 NoCys, a pool was created
(Pool 1 and Pool 2, respectively). Both were centrifuged and ﬁltered prior to loading onto
the desalting column. The elution proﬁle is shown only for Pool 1 (Figure 2.75a), but the
SDS-PAGE gel shows the elution fractions for both samples.
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Figure 2.75: Puriﬁcation of OctaVII 04 NoCys, desalting
(a) Elution proﬁle of the desalting of Pool 1 of the refolded OctaVII 04: the blue line is the absorbance at
280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample of Pool 2 and 2-8 its elution peak; lane 9 the input
sample of Pool 1 and 10-14 its elution peak.
Biophysical characterization
After desalting, Pool 1 and Pool 2 were centrifuged in order to remove possible aggre-
gates. Absorbance spectra were recorded in order to quantify the protein and they are
shown in Figure 2.76.
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Abs280 = 0.229, [C] = 0.154 mg/mL
Abs280 = 0.514, [C] = 0.346 mg/mL
Abs280 = 0.302, [C] = 0.204 mg/mL
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Abs280 = 0.180, [C] = 0.121 mg/mL
Abs280 = 1.225, [C] = 0.825 mg/mL
Abs280 = 0.219, [C] = 0.147 mg/mL
Figure 2.76: Concentration trials of OctaVII 04 NoCys
(a) Absorption spectrum of Pool 1 of OctaVII 04 NoCys after desalting (blue), after concentration (green)
and after centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b)
The same analysis for Pool 2 of OctaVII 04 NoCys.
Pool 1 appears to have aggregates in solution, because the signal above 310 nm is not
zero (blue line in Figure 2.76a). After 2 steps of concentration by ultraﬁltration (green
line), the aggregates are visible in solution, and a centrifugation step at high speed is
necessary to remove them. The solution is then ﬁltered and the protein concentration
resulted 0.2 mg/mL (red line). This concentration is similar to the one obtained for
OctaVII 04. Pool 2 does not seem to have aggregates after desalting (blue line in Fig-
ure 2.76b), anyway they show up after 4 cycles of concentration by ultraﬁltration (green
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line). Centrifugation at high speed and ﬁltration removed the aggregates, but also the
majority of the protein from the solution, and the ﬁnal concentration of the sample is
0.15 mg/mL.
The concentrations of Pool 1 and Pool 2 of OctaVII 04 NoCys are low, but enough to
perform far-UV circular dichroism and ﬂuorescence measurements.
Figure 2.77a shows the CD spectra of Pool 1 and Pool 2 of OctaVII 04 NoCys. Both
show a signiﬁcative fraction of α-helical secondary structures, as indicated by the two
minima at 222 nm and 208 nm. The spectre are, however, not identical. The analysis
of the 2 datasets with CDpro, using the program CDSSTR, conﬁrmed the presence of
diﬀerences between the two pools (Table 2.8).
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 λmax = 335 nm
Figure 2.77: Biophysical characterization of OctaVII 04 NoCys
(a) CD spectra of Pool 1 in blue and Pool 2 in green of OctaVII 04 NoCys (top) and high-tension
(bottom); the dotted line indicates the baseline at [Θ]=0. (b) Emission ﬂuorescence spectrum of Pool 1
of OctaVII 04 NoCys; the dotted line at 354 nm indicates the theoretic maximum for unfolded proteins.
Pool 1 contains 33.7% of helix, while Pool 2 only 22.3%. However, the strand content
is lower in Pool 1 (18.3%) and higher in Pool 2 (26.8%). These results may suggest that
there are two populations of OctaVII 04 NoCys. This might be due to the refolding on-
column, however we did not inquire deeper the situation: both population do not reach
the expected content of helix predicted by DSSP (47%). The content of the strands is
however in good agreement between Pool 1 and DSSP, around 18.5%. Only Pool 1 was
so used to analysis of the tertiary structure by ﬂuorescence, as shown in Figure 2.77b.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) Pool 1 33.7 18.3 19.0 28.6
CDpro (CDSSTR) Pool 2 22.3 26.8 21.6 29.0
DSSP 47.9 18.7 16.6 16.6
Table 2.8: Secondary structures content, OctaVII 04 NoCys
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The maximum intensity is centered at 335 nm, suggesting that the aromatic residues
are localized in the core of the protein and that they are not exposed to the solvent.
Attempts to concentrate the protein for near-UV CD analysis (up to 2 mg/mL) led to
protein precipitation. The maximum concentration that was reached without evidences
of aggregates was 0.35 mg/mL. Because of its poor solubility and its tendency to form
aggregates, OctaVII 04 NoCys is discarded from further analysis.
106 CHAPTER 2. RESULTS AND DISCUSSION
2.4. EXPERIMENTAL VALIDATION 107
2.4.7 OctaVII 04 WS
OctaVII 04 WS (Weak Spots) is a mutant of OctaVII 04 NoCys, designed in collab-
oration with the laboratory of Wim Vranken at the Vrije Universiteit Brussel (VUB),
in Belgium. The goal of the collaboration was to improve the sequence of OctaVII 04
NoCys to fold in a TIM-barrel with the use of HMM methodology. However, the method-
ology needed to be adapted in order to recognize the TIM-barrel fold among unknown
sequences. To do so, the software was trained with a database of TIM-barrel proteins
only (described in section HMM training). This new methodology (named HMM-TIM)
was then used to analyze the OctaVII 04 NoCys sequence and discriminate the amino
acids that are less favorable to form a TIM-barrel fold. Once these “weak spots” were
deﬁned, HMM-TIM was used to predict suitable amino acid substitutions (see section
HMM-TIM predictions). As mentioned for the cysteine substitution of OctaVII 04,
all the computational work bound to the HMM training and the HMM-TIM predictions
was done by Gabriele Orlando, a PhD student in Vranken’s Lab.
HMM training
In order to train the HMM mothodology to recognize the TIM-barrel fold among un-
known sequences, a structure-based multiple sequence alignment (MSA) of 100 known
TIM-barrels was generated based on information from the Protein Data Bank. Then, ev-
ery amino acid was encoded with a set of features that describes their physical-chemical
behavior. 16 features with less then 0.4 of pairwise Pearson’s correlation coeﬃcient were
selected from the Aaindex (www.genome.jp/aaindex). To this, the DynaMine predicted
backbone dynamics were added, resulting in a total of 17 features (reported in An-
nex 6.6). With this information, Vranken’s Lab built a logistic proﬁle Hidden Markov
Model (lHMM) based on the MSA information (named HMM-TIM) and trained it to
distinguish TIM-barrel sequences from other folds.
In order to evaluate the prediction capability of HMM-TIM, Vranken’s Lab performed
three blind tests with datasets of random folds, including the TIM-barrel one. The
datasets were prepared in order to contain representatives for all kinds of proteins: only-α,
only-β and α-β-proteins. Particular attention was paid to include in each dataset repre-
sentatives for the α-β-α sandwich and the Rossmann-like folds which have very similar
secondary structure content as the TIM-barrel fold. They then used the trained software,
to discriminate between TIM-barrels and other folds in the blind datasets. The results
were analyzed with the area under the ROC curve (AUC) method, shown in Figure 2.78.
They ranged from 92 to 96%, indicating that the biophysical characteristics enabled a
good separation between TIM barrel-forming and non-TIM barrel forming sequences.
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Figure 2.78: HMM-TIM blind test
Analysis of one blind test of HMM-TIM according to the area under the ROC curve method. This plot
is used to evaluate the capability of the machine learning program to discriminate among true positive
and false positive predictions. The dashed diagonal line indicates random predictions, while the blue line
indicates the HMM-TIM predictions. Since the blue curve is in the upper left-hand corner, the software
has a low rate of false positive predictions and an high-rate of true positive predictions. This means that
the predictions of the software are very accurate.
HMM-TIM Predictions
Following the training and the blind test, HMM-TIM was used to predict which amino
acid in OctaVII 04 NoCys sequence was less favorable to form a TIM-barrel fold. Results
are shown in Figure 2.79.
Figure 2.79: Analysis of the sequence of OctaVII 04 NoCys
Blue dots HMM-TIM score for each residue in the OctaVII 04 NoCys sequence. Red and yellow bars
representations of the secondary structures of the protein: helices in red and strands in yellow. Green
and purple circles cluster of 3 and 4 consecutive residues, respectively, that are less-likely to fold in a
TIM-barrel structure.
The x-axis corresponds to the amino acid sequence of OctaVII 04 NoCys, whereas the
score of the software is given on the y-axis. Values close to 0 indicate that the residues are
very-likely to fold in a TIM-barrel, while values that are lower than -0.8 are less likely to
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form a TIM-barrel. A schematic representation of the helices (red) and strands (yellow)
of the protein is reported in full colors at the bottom of the graph and in soft colors at
the level of the cut-oﬀ value (-0.8). 49 out of 240 residues have a lower score than -0.8.
Among them, 22 were selected since they form clusters of consecutive “bad” residues, or
weak spots. Green and purple circles indicate the 6 clusters of 3 consecutive residues and
the single cluster of 4 residues, respectively.
Following the analysis of the OctaVII 04 NoCys sequence, HMM-TIM was then used to
ﬁnd the best amino acid substitution for each of the 22 mutations. Two out of 22 residues
have only one suggested amino acid, while the remaining 20 have 2 suggested residues. All
the possible combinations are 220 (more than 1 million of possibilities) and it is not possible
to compute them all at once. To simplify the computations, each cluster is modeled
independently (52 models) and the best combinations of mutations are then combined
in the ﬁnal sequence. All the suggested mutations are reported by cluster in Table 2.9
together with the scores obtained with both the HMM-TIM software and Rosetta. In
general, the mutations are considered “synonymous”: the residues are substituted with
other amino acids with the same properties (dimension, charge, polarity). For instance,
leucine 8 is exchanged with an isoleucine or a valine, that share the same dimension and
hydrophobicity; tyrosine 97 is exchanged with the aromatic residues phenylalanine and
tryptophan; glycine 185 is exchanged with the small residues alanine and serine. “Non-
synonymous” examples are asparagine 91, that is exchanged in one case with a bigger and
charged residue, lysine, and in the second case with a small and uncharged glycine, and
glutamic acid 226 that is changed in one case in a positive charged residue, arginine, and
in the other case with a neutral glutamine.
Name Mutations HMM-TIM score Rosetta score
OctaVII 04 NoCys 31.50 -470.74
Cl1 1 L8V, Q9D, G10N 31.77 -464.97
Cl1 2 L8V, Q9D, G10S 32.11 -464.77
Cl1 3 L8V, Q9N, G10N 32.26 -461.38
Cl1 4 L8V, Q9N, G10S 32.56 -467.31
Cl1 5 L8I, Q9D, G10N 31.60 -464.90
Cl1 6 L8I, Q9D, G10S 31.82 -464.90
Cl1 7 L8I, Q9N, G10N 32.02 -466.14
Cl1 8 L8I, Q9N, G10S 32.24 -466.42
Cl2 1 K88E, L89I, D90N, N91K 30.54 -464.28
Cl2 2 K88E, L89I, D90N, N91G 31.37 -463.43
Cl2 3 K88E, L89I, D90E, N91K 31.09 -457.85
Cl2 4 K88E, L89I, D90E, N91G 31.71 -462.77
Cl2 5 K88N, L89I, D90N, N91K 30.49 -464.13
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Name Mutations HMM-TIM score Rosetta score
Cl2 6 K88N, L89I, D90N, N91G 31.37 -463.88
Cl2 7 K88N, L89I, D90E, N91K 30.66 -463.18
Cl2 8 K88N, L89I, D90E, N91G 31.41 -461.59
Cl3 1 L96I, Y97W, S98E 32.80 -461.49
Cl3 2 L96I, Y97W, S98N 33.30 -461.35
Cl3 3 L96I, Y97F, S98E 34.15 -467.45
Cl3 4 L96I, Y97F, S98N 34.62 -467.53
Cl3 5 L96V, Y97W, S98E 32.17 -461.03
Cl3 6 L96V, Y97W, S98N 32.67 -461.25
Cl3 7 L96V, Y97F, S98E 33.93 -463.91
Cl3 8 L96V, Y97F, S98N 34.40 -464.75
Cl4 1 T122S, L123M, I124V 31.15 -465.90
Cl4 2 T122S, L123M, I124L 31.37 -466.56
Cl4 3 T122S, L123V, I124V 29.62 -466.33
Cl4 4 T122S, L123V, I124L 29.86 -470.23
Cl5 1 T156A, G157S, I158V 32.25 -463.36
Cl5 2 T156A, G157S, I158F 32.62 -461.50
Cl5 3 T156A, G157N, I158V 31.78 -461.82
Cl5 4 T156A, G157N, I158F 32.20 -460.54
Cl5 5 T156V, G157S, I158V 33.28 -465.65
Cl5 6 T156V, G157S, I158F 33.57 -461.66
Cl5 7 T156V, G157N, I158V 32.95 -451.29
Cl5 8 T156V, G157N, I158F 33.25 -457.11
Cl6 1 W184Y, G185S, V186L 31.01 -468.28
Cl6 2 W184Y, G185S, V186I 31.43 -469.42
Cl6 3 W184Y, G185A, V186L 30.70 -459.06
Cl6 4 W184Y, G185A, V186I 31.11 -471.95
Cl6 5 W184F, G185S, V186L 31.04 -467.83
Cl6 6 W184F, G185S, V186I 31.46 -468.17
Cl6 7 W184F, G185A, V186L 30.80 -467.07
Cl6 8 W184F, G185A, V186I 31.20 -471.75
Cl7 1 M225I, E226R, K227R 33.13 -467.35
Cl7 2 M225I, E226R, K227E 33.20 -466.70
Cl7 3 M225I, E226Q, K227R 32.96 -467.86
Cl7 4 M225I, E226Q, K227E 32.97 -469.00
Cl7 5 M225V, E226R, K227R 32.53 -467.45
Cl7 6 M225V, E226R, K227E 32.61 -467.00
Cl7 7 M225V, E226Q, K227R 32.38 -470.08
Cl7 8 M225V, E226Q, K227E 32.33 -470.58
Table 2.9: Mutations in the clusters of OctaVII 04 NoCys
The result of the mutations in Clusters 1, 3, 5 and 7 is always positive according to
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HMM-TIM. The best combinations are: Cl1 4 (L8I, Q9N, G10S), Cl3 4 (L96I, Y97F,
S98N), Cl5 6 (T156V, G157S, I158F) and Cl7 4 (M225I, E226Q, K227E).
Clusters 2, 4 and 6 on the contrary have all the combinations with a lower score
compared to OctaVII 04 NoCys, with the exception of Cl2 4 (K88E, L89I, D90E, N91G).
The results according to Rosetta score are all higher than OctaVII 04 NoCys (and so less
favorable), with the exception of Cl6 4 and Cl6 8. The higher change in the overall energy
is of 4.1% with Cl5 7.
The best combination of mutations for each cluster is then combined with the others in
one model, OctaVII 04 WS (Weak Spots). The 22 mutations are: L8V, Q9N, G10S, K88E,
L89I, D90E, N91G, L96I, Y97F, S98N, T122S, L123V, I124V, T156V, G157S, I158F,
W184F, G185S, V186I, M225I, E226R and K227E. The Rosetta score of OctaVII 04 WS
drop from -470.75 to -435.34 REU. Its gene was synthesized and inserted in the pET28a
plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 04 WS was manipulated for sequencing and storage as
described for OctaVII 01 in Section 2.4.1, page 77. The results of the sequencing conﬁrmed
the correct sequence of the OctaVII 04 WS gene (see Annex 6.4, page 241), that was then
used for a transformation in E. coli BL21 (DE3) cells for expression trials.
Expression Trials
Expression trials for OctaVII 04 WS were performed in two conditions: overnight
induction at 18◦C (data not shown) and 4 hours induction at 37◦C (Figure 2.80a). Al-
though the SDS-PAGE gel was clearly underloaded, a band is present at 27 kDa for both
clones (lanes 1 and 2). A small culture of both OctaVII 04 NoCys and OctaVII 04 WS
was prepared in order to compare the crude extracts, shown in Figure 2.80b. In both
cases, the protein is not visible in the soluble fraction (S). Experiments on OctaVII 04
NoCys already conﬁrmed the absence of the protein in the soluble fraction, but this was
not conﬁrmed yet for OctaVII 04 WS (next section). A predominant band at the correct
size is visible for both proteins in the insoluble fraction (I), which contains also many
contaminants at various molecular masses. Despite two washing of the inclusion bodies
(w1 and w2), the pellet remained highly contaminated.
Puriﬁcation of the soluble fraction
In order to verify the presence of OctaVII 04 WS in the soluble fraction, 1 L of cell
culture was produced and disrupted (the crude extract is shown in lane 1 of Figure 2.81b).
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(a) (b)
Figure 2.80: Expression trials of OctaVII 04 WS
(a) Expression trials of two clones of OctaVII 04WS at 37◦C for 4 hours; (b) Crude extracts of OctaVII 04
NoCys (left) and OctaVII 04 WS (right): S is the soluble fraction, I the insoluble one and w1 and w2
are the washing steps.
The sample was centrifuged and the supernatant ﬁltered and loaded on the HisTrap HP
column (the input sample is shown in lane 2). The majority of the proteins was eluted
in the ﬂow-through, as visible in the chromatogram (Figure 2.81a) and in lanes 3 and 4
of the SDS-PAGE gel. A peak of elution appears at 50 mM of imidazole, that is a low
concentration for the elution of an HisTagged protein (250 mM imidazole). As shown
on gel in lanes 5 to 7, the peak of elution is composed almost entirely by contaminants
at high molecular mass, and OctaVII 04 WS does not seem to be present in the soluble
fraction of the crude extract.
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Figure 2.81: Puriﬁcation of OctaVII 04 WS, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 04 WS: the blue line is the absorbance at 280 nm,
the green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the crude extract; 2 the input
sample; 3-4 the ﬂow-through; 5-7 the elution peak.
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Puriﬁcation of the insoluble fraction
The pellet obtained from the culture of 1 L was washed twice in order to decrease
the amount of contaminants. It was then resuspended overnight at room temperature in
a buﬀer containing urea 8 M. The sample was then centrifuged, ﬁltered and loaded on
HisTrap HP columns for the refolding and the puriﬁcation. The input sample is shown in
lane 1 of Figure 2.82b. OctaVII 04 WS is the predominant band, but contaminants are
present at high and low molecular masses. The chromatogram is shown in Figure 2.82a,
many contaminant protein are eluted in the ﬂow-through (lanes 2 to 5 in the SDS-PAGE).
The refolding of the protein from 60 mL to 160 mL does not cause elution of the proteins
since there is no signal at 280 nm. The elution of the protein started at around 250
mM of imidazole, which was the expected concentration for the dissociation of the 6x
HisTag from the matrix of the column. The elution peak is shown in lanes 6 to 13 of the
SDS-PAGE gel and the presence of contaminant is visible in lane 8.
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Figure 2.82: Puriﬁcation of OctaVII 04 WS, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 04 WS: the blue line is the absorbance at 280 nm,
the green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration
of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b),
the SDS-PAGE gel. In lane 1 there is the input sample; 2-5 the ﬂow-through; 6-13 the elution peak.
Desalting
The fractions collected during the elution of OctaVII 04 WS after the refolding on
column were pooled together and centrifuged at 20000 rpm in order to remove possible
aggregates. The supernatant was ﬁltered and loaded on a desalting column in order to
remove the imidazole from the protein sample. The input sample is shown in Figure 2.83b
in lane 1. The chromatogram of the puriﬁcation is shown in Figure 2.83a, where the
separation of the protein (blue line) and the imidazole (brown line) is visible. The SDS-
PAGE in Figure 2.83b shows that OctAVII 04 WS is predominant, anyway there are
contaminants at ∼48 kDa.
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Figure 2.83: Puriﬁcation of OctaVII 04 WS, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 04 WS: the blue line is the
absorbance at 280 nm and the brown line is the conductivity. (b) SDS-PAGE of the desalting: lane 1 is
the input sample, 2-6 the elution peak.
Biophysical characterization
The fractions containing OctaVII 04 WS after desalting were pooled together, cen-
trifuged in order to remove possible aggregates and analyzed by absorbance spectrometry
(line blue in Figure 2.84a). The sample was then concentrated by ultraﬁltration (green
line) and centrifuged at high speed and ﬁltered (red line). The values at Abs280 are used
to calculate protein concentration, that is 0.73 mg/mL, a much higher value compared to
the concentrations of OctaVII 04 and OctaVII 04 NoCys.
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Abs280 = 0.461, [C] = 0.373 mg/mL
Abs280 = 1.300, [C] = 1.053 mg/mL
Abs280 = 0.908, [C] = 0.735 mg/mL
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λmax = 336 nm
Figure 2.84: Biophysical characterization of OctaVII 04 WS
(a) Absorption spectrum of OctaVII 04 WS after desalting (blue), after concentration (green) and after
centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b) CD spectra
of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at [Θ]=0. (c)
Emission ﬂuorescence spectrum of OctaVII 04 WS; the dotted line at 354 nm indicates the theoretic
maximum for unfolded proteins.
The sample was used for analysis by far-UV circular dichroism and ﬂuorescence mea-
surements (Figure 2.84). The CD signal presents minima at 222 nm and 208 nm, as
expected for a protein with high helical content. Analysis of the spectrum by CDpro,
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using the program CDSSTR, indicates that the sample contains 34.4% of helix and 30.3%
of strands. These results are not in agreement with the DSSP analysis of the model,
that it is supposed to contain 48% of helix and 20% of strands. However, the content
of helix in OctaVII 04 WS is similar to the one of OctaVII 04 NoCys (33.7%). On the
contrary, the content of strands and of unstructured regions are 15% higher and 15%
lower, respectively, in the mutant compared to the wild-type. These results suggests that
in OctaVII 04 WS, part of the unstructured regions of OctaVII 04 NoCys folds mainly in
β-strands, passing from 13.3% to 30.3%.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 34.4 30.3 16.0 13.1
DSSP 48.3 20.4 15.4 15.8
Table 2.10: Secondary structures content, OctaVII 04 WS
Analysis of the tertiary structure of OctaVII 04 WS (see Figure 2.84c), showed a
maximum in intensity centered at 336 nm, suggesting that the protein is folded and that
the aromatics are not exposed to the solvent.
As for the previous OctaVIIs, OctaVII 04 WS was concentrated by ultraﬁltration in
order to perform near-UV CD analysis. However, the protein precipitated at a concen-
tration lower than 1 mg/mL. Also OctaVII 04 WS is discarded for its low solubility.
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2.4.8 OctaVII 05
OctaVII 05 has 249 residues and it is the best representative of Family 26 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
and inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 05 was manipulated for sequencing and storage as de-
scribed for OctaVII 01 in Section 2.4.1, page 77. The results of the sequencing conﬁrmed
the correct sequence of the OctaVII 05 gene (see Annex 6.4, page 241), that was then
used for a transformation in E. coli BL21 (DE3) cells for expression trials.
Expression Trials
Expression trials of OctaVII 05 were done in two conditions: overnight induction at
18◦C and 4 hours induction at 37◦C (Figure 2.85). The SDS-PAGE gel shows the total
(T), the insoluble (I) and the soluble (S) fractions of the crude extract after sonication.
OctaVII 05 is visible in the total fraction and in the pellet of the condition at 37◦C,
but not in the condition at 18◦C. Multiple trials were done with diﬀerent clones and
transformations, but the protein was never expressed at lower temperature. The reasons
of this particular phenomenon were not further inquired and large volume production of
OctaVII 05 cultures was performed at 37◦C only.
Figure 2.85: Expression trials of OctaVII 05
(a) Expression trials of OctaVII 05 with overnight induction at 18◦C (left) and at 37◦C for 4 hours (right);
for each condition the total (T), the soluble (S) and the insoluble (I) fractions of the crude extract are
reported.
Puriﬁcation of the soluble fraction
The soluble fraction of the crude extract of 1 L cell culture of OctaVII 05 was ﬁltered
and loaded on HisTrap HP column for puriﬁcation. The input sample is shown in lane
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1 of Figure 2.86b. A small band is visible at ∼27 kDa, the theoretic molecular mass of
OctaVII 05. The chromatogram of the puriﬁcation is shown in Figure 2.86a. The majority
of the proteins elutes in the ﬂow-through, but two peaks are visible during the imidazole
gradient: a ﬁrst and higher one at 75 mM of imidazole and a second and smaller one at
the beginning of the gradient from 15% of imidazole to 100%. Fractions of both peaks
were loaded on SDS-PAGE gels and are shown in lanes 4 to 6 and 7 to 8, respectively.
The ﬁrst peak is mainly composed of contaminants at higher and lower molecular mass,
but a quite intense band is visible at the correct size for OctaVII 05. The second peak
contains mainly OctaVII 05, but some contaminants are still present.
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Figure 2.86: Puriﬁcation of OctaVII 05, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 05: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-3 the
ﬂow-through 4-6 a ﬁrst elution peak at imidazole 75 mM; 7-9 a second elution peak.
Puriﬁcation of the insoluble fraction
The pellet of the crude extract obtained from 1 L of cell culture was washed twice
prior to resuspension in the buﬀer urea 8 M. The resuspension of the inclusion bodies in a
buﬀer containing urea 8 M was performed at room temperature overnight and the sample
is then centrifuged and ﬁltered. The refolding and the puriﬁcation of the protein is done
with an HisTrap HP column and the chromatogram is shown in Figure 2.87a. Part of the
protein was eluted in the ﬂow-through (lanes 1-3 in Figure 2.87b), suggesting that the
column reached saturation. The protein was not eluted during the refolding step (60 to
110 mL of elution volume), but during the imidazole gradient at a concentration of ∼ 300
mM. The protein resulted highly pure in the SDS-PAGE gel (lanes 4 to 9).
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Figure 2.87: Puriﬁcation of OctaVII 05, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 05: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration
of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b),
the SDS-PAGE gel. In lanes 1-3 there is the ﬂow-through and in lanes 4-9 the elution peak.
Desalting
The fractions containing OctaVII 05 after puriﬁcation of the soluble fraction were
pooled together and termed Pool Sol, lane 1 in Figure 2.88c, and the ones obtained by
refolding of the inclusion bodies were pooled together and termed Pool Insol, lane 1 of
Figure 2.88b. Both samples were centrifuged and ﬁltered (lanes 2). The samples were
loaded on the desalting column for removal of imidazole and the chromatogram relative
to this step is shown for Pool Insol only, in Figure 2.88a. Lanes 3 to 9 in both SDS-PAGE
gels show the fractions obtained in the elution peaks.
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Figure 2.88: Puriﬁcation of OctaVII 05, desalting
(a) Elution proﬁle of the desalting of the pool of OctaVII 05 Pool Insol : the blue line is the absorbance at
280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), its SDS-PAGE gel. (c), SDS-PAGE of the desalting of Pool Sol. For both samples, lanes 1 are
the input samples before centrifugation; 2 the inputs after centrifugation and ﬁltration; 3-9 the elution
peaks.
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Biophysical characterization
After desalting, the fractions were pooled together in Pool Insol and in Pool Sol, lanes
1 and 6, respectively, in Figure 2.89a). Pool Insol showed signs of degradation: two
bands are visible at around 27 kDa and 25 kDa. The time interval between the desalting
(Figure 2.88b) and the SDS-PAGE (Figure 2.89a) was of three days only, suggesting
that the protein is prone to degradation. Both samples were concentrated by 3 steps of
ultraﬁltration (lanes 7-9 and 2-4, respectively), and centrifuged at high speed in order to
remove aggregates. They were then diluted at 0.1 mg/mL and 0.01 mg/mL for CD and
ﬂuorescence analysis, respectively.
CD spectra for both OctaVII 05 Pool Sol and Pool Insol are shown in Figure 2.89b.
The data-points collected when the high-tension is higher than 600 V are discarded.
OctaVII 05 Pool Sol results to have signal at 222 nm of around -15000 mdeg cm2 mol−1,
which is quite unlikely. It is possible that the high number of contaminants in the sample
(lane 9 in Figure 2.89a), may aﬀect the calculation of the concentration of the protein, and
thus aﬀect the calculation for the residue molar ellipticity. However, both samples show
the typical signal for helices at 222 nm. The spectra are not reaching wavelengths lower
than 205 nm and it is not possible to calculate the percentages of secondary structures.
The samples are probably contaminated by low amounts of DTT or imidazole that disturb
the CD analysis.
(a) (b)
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 λmax = 337 nm
 λmax = 338 nm
Figure 2.89: Biophysical characterization of OctaVII 05
(a) Concentration steps for Pool Insol and Pool Sol of OctaVII 05: lanes 1,6 the pool after desalting;
2,7, ﬁrst step of concentration by ultraﬁltration; 3,8, second step; 4,9, third step and 5, sample after
centrifugation and ﬁltration. (b) CD spectra of the two protein samples (top) and high-tension (bottom);
the dotted line indicates the baseline at [Θ]=0. (c) Emission ﬂuorescence spectra of the protein samples.
The dotted line at 354 nm indicates the theoretic maximum for unfolded proteins.
Analysis of the tertiary structure of both samples was done by ﬂuorescence (Fig-
ure 2.89c). The two spectra are very similar, with just a small diﬀerence in the maximum
intensity that is higher in the soluble OctaVII 05. Again this diﬀerence may just be caused
by an error in the quantiﬁcation of the protein due to the presence of many contaminants.
2.4. EXPERIMENTAL VALIDATION 121
The two λmax are centered at 337 and 338 nm, respectively, indicating that the aromatic
residues of the proteins are not exposed to the solvent.
Disulﬁde interactions
The presence of OctaVII 05 in the soluble fraction of the cell extract is really promising,
but we do not know if the protein spontaneously folds in low percentages in the cytoplasm
or if there are other reasons that can explain this behavior. OctaVII 05 bears 3 free
cysteines and a possible explanation for its presence in the soluble fraction may be the
formation of disulﬁde bonds with soluble proteins of the cell. In order to verify if the
protein is covalently bound to soluble proteins we performed a simple test on both the
OctaVII 05 obtained from the soluble fraction (Pool Sol) and the refolded one (Pool
Insol). The puriﬁed proteins were centrifuged at high speed in order to precipitate possible
aggregates. The supernatant was separated from the pellet, which was then resuspended
in the same volume. For each pool of OctaVII 05, three samples were taken for SDS-
PAGE analysis: the ﬁrst, from the supernatant, was treated with a loading buﬀer that
does not contain β-mercaptoethanol (lanes 1 in Figure 2.90). The other two were taken
from the supernatant and from the resuspended pellet and were treated with the reducing
agent (lanes 2 and 3, respectively).
Figure 2.90: Disulﬁde bonds
Analysis of disuﬁde bond formation for the Pool Sol and the Pool Insol of OctaVII 05. Lanes 1 the su-
pernatant without β-mercaptoethanol, 2 the supernatant with β-mercaptoethanol and 3 the resuspended
pellet with β-mercaptoethanol.
From the SDS-PAGE it is clear that both pools of OctaVII 05 are in a higher oligomer-
ization state due to disulﬁde bonds since the samples without β-mercaptoethanol are not
even entering into the gel (dark band at the beginning of the well in lanes 1). The same
sample with the reducing agent clearly shows the presence of the protein at the correct
molecular mass. In the case of the soluble OctaVII 05 also all the contaminant are visible
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in lane 2. This experiment seems to conﬁrm that the presence of OctaVII 05 in the sol-
uble fraction of the crude extract is due to covalent binding with soluble protein. These
proteins seems also to prevent the precipitation of OctaVII 05 since its amount in the
resuspended pellet (lane 3) is much lower in comparison to the refolded OctaVII 05.
In normal conditions of growth, the cytoplasm should be in a constant reduced state
thanks to the thioredoxin and the glutaredoxin systems, that use NADPH as source of re-
ducing power [131]. However, the production of OctaVII 05 is a stressful condition for the
cell: ﬁrst, the cell is forced by external induction to overproduce the protein (which is not
even useful for the cellular metabolism!). This over-expression is so intense that usually
after just one hour of induction the target protein is the main band on the SDS-PAGE.
Second, OctaVII 05 has 3 free cysteines that have to be reduced during the over-expression
and perhaps synthesized in response to the over-expression. Third, the protein is actively
segregated in inclusion bodies just after translation. The energetic resources of the cell
may drastically diminish during the induction, and it may be that the NADPH levels in
the cytoplasm are too low to avoid the formation of disulﬁde bonds between OctaVII 05
and endogenous proteins. Moreover, this covalent interaction between proteins seems to
be inaccessible to reducing agents such as DDT, freshly added in all the buﬀers for protein
extraction and puriﬁcation.
Free cysteines are present in the ﬁrst 5 OctaVIIs, from OctaVII 01 to OctaVII 05. Oc-
taVII 01 and OctaVII 03 did not show this behavior because the ﬁrst was never expressed
and the second was discarded prior to puriﬁcation. OctaVII 02 is puriﬁed in high amount
from the soluble fraction (Figure 2.60), and, in a much lower amount, OctaVII 04 also is
puriﬁed from the soluble fraction (Figure 2.66). These results suggest that OctaVII 02
and OctaVII 04 may share the same phenomena found in OctaVII 05, however we did
not tested it. To exclude the hypothesis of spontaneous folding of OctaVII 05 in the
soluble fraction of the protein, and possibly avoid aggregation due to disulﬁde formation,
we created a mutant without cysteins of OctaVII 05, called OctaVII 05 NoCys.
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2.4.9 OctaVII 05 NoCys
OctaVII 05 NoCys is the mutant of OctaVII 05 that contains no cysteines. As for
the couple OctaVII 04 and OctaVII 04 NoCys, the choice of residues to replace the 3
original cysteines of OctaVII 05 was done in collaboration with the laboratory of Dr.
Wim Vranken at the VUB. The HMM methodology, (described in Section 2.4.6, page 99),
suggested one mutation for C40 (threonine), and two possible mutations for C126 (serine
or alanine), and C184 (threonine or valine). As for OctaVII 04, we created the four
possible combinations and we tested each of them with both HMM (that uses the amino
acid sequence as input) and Rosetta (that uses a 3D model structure as input). The
preparation of the 4 models is described in Section 3.3.4, page 182. The scores of HMM
and Rosetta are reported in Table 2.11 and the normalized values (against OctaVII 04)
are plotted in Figure 2.91.
Name Mutations HMM score Rosetta score
OctaVII 05 C40T, C126, C184 31.33 -488.99
Mutant 1 C40T, C126S, C184T 31.02 -488.31
Mutant 2 C40T, C126S, C184V 31.85 -486.68
Mutant 3 C40T, C126A, C184T 31.04 -487.92
Mutant 4 C40T, C126A, C184V 31.89 -489.64


































Figure 2.91: Cysteines substitution of OctaVII 05
Normalized scores for the 4 mutants of OctaVII 05 according to HMM (blue) and Rosetta (green) scores.
The numbers 1 to 4 on the x-axis represent the 4 mutants and 0 is the original OctaVII 05.
The scores of OctaVII 05 improved in 2 combinations out of the 4 (Mutant 2 and
Mutant 4) according to HMM, and in 1 out of 4 (Mutant 4) according to Rosetta. Among
the 4 variants, we chosed Mutant 4, that has the best score according to both software.
It is renamed OctaVII 05 NoCys and it has 250 residues. The gene was synthesized and
inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
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Sequencing
The DNA pellet of OctaVII 05 NoCys was manipulated for sequencing and storage
as described for OctaVII 01 in Section 2.4.1, page 77. The results of the sequencing
conﬁrmed the correct sequence of the OctaVII 05 NoCys gene (see Annex 6.4, page 241),
that was then used for a transformation in E. coli BL21 (DE3) cells for expression trials.
Expression Trials
Expression trials for OctaVII 05 NoCys were done in two conditions: induction at 37◦C
for 4 hours and at 18◦C overnight. As for OctaVII 05, the protein was highly expressed
at 37◦C (lane 1 in Figure 2.92), but not at 18◦C (lane 4). The protein was produced in
inclusion bodies (lane 3), but it is not clear if a small amount is present in the soluble
fraction. As for the other OctaVIIs, we searched for the target protein in the soluble
fraction.
Figure 2.92: Expression trials of OctaVII 05 NoCys
Expression trials of OctaVII 05 NoCys at 37◦C with 4 hours induction (left) and at 18◦C overnight
(right). Lanes 1,4 show the total fraction of the crude extract, 2,5 the soluble one and 3,6 the insoluble
one.
Puriﬁcation of the soluble fraction
OctaVII 05 NoCys was produced in 1 L of cell culture. After cell disruption the crude
extract was centrifuged in order to separate the surnatant (soluble fraction) from the in-
clusion bodies (insoluble fraction), and ﬁltered. The input sample (lane 1 in Figure 2.93b)
was loaded on HisTrap HP columns for puriﬁcation. Its chromatogram is reported in Fig-
ure 2.93a. The majority of the proteins are not binding the column and are eluted in the
ﬂow-through (lanes 2-3). The elution peak is eluted at ∼100 mM of imidazole, which is a
low concentration for the dissociation of the 6x HisTag (250 mM). The peak is composed
by contaminants at all molecular masses as shown in lanes 4-6 of the SDS-PAGE gel.
OctaVII 05 NoCys is not present in the elution peak.
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Figure 2.93: Puriﬁcation of OctaVII 05 NoCys, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 05 NoCys: the blue line is the absorbance at 280
nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares
represent the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample;
2-3 the ﬂow-through and 4-6 the eluction peak.
Puriﬁcation of the insoluble fraction
The pellet (inclusion bodies) obtained from 1 L of cell culture was washed twice and
dissolved in urea 8 M at room temperature overnight. The solution was centrifuged,
ﬁltered and loaded on HisTrap HP column for refolding and puriﬁcation (chromatogram
in Figure 2.94a).
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Figure 2.94: Puriﬁcation of OctaVII 05 NoCys, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 05 NoCys: the blue line is the absorbance at
280 nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the
concentration of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that
are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-4 the ﬂow-through; 5 a
post-refolding fraction 6-14 the elution peaks.
The input sample is shown in lane 1 of Figure 2.94b: OctaVII 05 NoCys is the main
band on the gel, but contaminants are present especially at high molecular mass. The
majority of them is eluted in the ﬂow-through (lanes 2-3), together with part of the
protein, suggesting that the column reached saturation. The refolding of the protein (60
to 160 mL) did not cause dissociation of the HisTag from the matrix, and its elution
126 CHAPTER 2. RESULTS AND DISCUSSION
presents 2 peaks: a sharp one at 150 mM of imidazole that is composed by contaminants
(lane 6 on the SDS-PAGE gel), and a second and wider peak (lanes 7 to 14). The SDS-
PAGE for the elution shows two bands, one at the size of OctaVII 05 NoCys and the
second at higher molecular mass. This is presumably still OctaVII 05 NoCys due to its
high concentration. Also OctaVII 05 shows a double band after refolding and desalting,
but it is not clear why it happens.
Desalting
The pool of the refolded OctaVII 05 NoCys was centrifuged and ﬁltered prior to load-
ing on the desalting column. The chromatogram of the puriﬁcation is shown in Fig-
ure 2.95a. After the puriﬁcation the fractions containing OctaVII 05 NoCys were pooled
together (lane 1 in Figure 2.95b) and concentrated through 4 steps of ultraﬁltration with
Amicon ﬁlters. Each step was done by centrifugation at 4000 rpm for 5 minutes and they
are shown in lanes 2-5 in the SDS-PAGE gel. After the third step of concentration, the
sample was centrifuged at 14000 rpm for 20 minutes in order to remove the aggregates
that were visible in the sample (lane 4) . The supernatant was then concentrated a last
time and ﬁltered on 0.22 µm ﬁlters. The double band of OctaVII 05 NoCys is still visible
through all the steps of concentration.
(a)













































Figure 2.95: Puriﬁcation of OctaVII 05 NoCys, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 05 NoCys: the blue line is the
absorbance at 280 nm and the brown line is the conductivity; (b), the SDS-PAGE gel of the concentration
steps of the protein. Lane 1 the pool after desalting; 2 ﬁrst concentration step; 3 second step; 4 third
step followed by centrifugation and 5 forth step of concentration followed by ﬁltration.
Biophysical characterization
The outcome of the concentration steps described in the previous section are shown
in Figure 2.96a: the blue line is the pool after desalting, the green line the third step of
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concentration by ultraﬁltration (lane 4 in the SDS-PAGE) and the red line the pool after
centrifugation at high speed and ﬁltration. The ﬁnal concentration is 0.3 mg/mL.
(a)






















Abs280 = 0.137, [C] = 0.101 mg/mL
Abs280 = 0.598, [C] = 0.442 mg/mL
Abs280 = 0.416, [C] = 0.307 mg/mL
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Figure 2.96: Biophysical characterization of OctaVII 05 NoCys
(a) Absorption spectrum of OctaVII 04 WS5 NoCys after desalting (blue), after concentration (green)
and after centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b)
CD spectra of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at
[Θ]=0.
The analysis by CD is shown in Figure 2.96b, where the typical signal of the helix is
present with minima at 222 nm and 208 nm. The analysis of the spectrum by CDpro,
using the program CDSSTR, indicates a content of 40% helix and 17% strands, which is
more in agreement with the DSSP analysis compared to the other OctaVIIs: 48% helix
and 19% strands. These results, however, should be carefully taken into account since the
sample present a double band of proteins.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 39.6 17.2 17.6 25.2
DSSP 47.9 18.7 17.0 17.5
Table 2.12: Secondary structures content, OctaVII 05 NoCys
The attempts to concentrate the protein for near-UV CD analysis however were not
successful. As for the previous OctaVIIs, the protein did not reach 1 mg/mL of concen-
tration without the formation of aggregates that were visible by eye. The low solubility
and the presence of a double band after refolding are the reason why OctaVII 05 NoCys
is discarded from further analysis.
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2.4.10 OctaVII 06
OctaVII 06 has 250 residues and it is the best representative of Family 06 according
to the Rosetta energy score (details in Section 2.3.9, page 68). It is also one of the best
model according to molecular dynamics. The gene was synthesized by IDT, that shipped
it as dry pellet.
Sequencing
The DNA pellet of OctaVII 06 (gBlock®), was digested with the restriction enzymes
NcoI and XhoI in parallel with an empty pET28a vector (see Section 4.2.2, page 190).
After puriﬁcation of both DNA (Section 4.2.3, page 191), the gene was inserted in the
vector by ligation with the T4 ligase (Section 4.2.5, page 191). The plasmid was used
for transformation in E. coli DG1 competent cells for sequencing. The results of the
sequencing conﬁrmed the correct sequence of the OctaVII 06 gene in 1 out of 4 clones.
The plasmid bearing the good sequence was then used for a transformation in E. coli
BL21 (DE3) cells for expression trials and in DG1 competent cell for stock preparation.
Expression Trials
Expression trials for OctaVII 06 were done in two conditions: induction with IPTG 1
mM at 37◦C for 4 hours (Figure 2.97a) and at 18◦C overnight (Figure 2.97b).
(a) (b)
Figure 2.97: Expression trials of OctaVII 06
(a) Expression trials of OctaVII 04 NoCys (already discussed in Section 2.4.6) and of OctaVII 06 at 37◦C
for 4 hours and (b), at 18◦C overnight: lanes 1 total fraction, 2 insoluble fraction and 3 soluble fraction.
In both cases the protein is highly expressed in inclusion bodies (lanes 2). The low
quality of the gel does not allow us to understand if part of the protein is present in the
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soluble fraction. So, as for the previous OctaVIIs, we tried to purify the protein from a
bigger volume of culture.
Puriﬁcation of the soluble fraction
OctaVII 06 was produced in 1 L of culture with overnight induction at 18◦C. The
crude extract obtained after disruption (lane 1 in Figure 2.98b) was centrifuged, ﬁltered
and loaded on the HisTrap HP column. The chromatogram of the puriﬁcation is shown
in Figure 2.98a and the SDS-PAGE in Figure 2.98b. The majority of the proteins are
eluted in the ﬂow-through (lanes 3 to 5) and the remaining one that bound the column
are eluted at low concentration of imidazole. As shown in the SDS-PAGE, the elution
peak is composed only by contaminants, and OctaVII 06 is not produced in the soluble
fraction.
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Figure 2.98: Puriﬁcation of OctaVII 06, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 06: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the crude extract; 2 the input
sample; 3-5 the ﬂow-through; 6-7 the elution peak.
Puriﬁcation of the insoluble fraction
The pellet of 1 L culture was washed twice and resuspended in buﬀer with urea 8 M in
order to dissolve the inclusion bodies. The solution was stirred overnight at room temper-
ature, and centrifuged the day after. Diﬀerently from the other OctaVIIs, the inclusion
bodies of OctaVII 06 did not completely dissolve in urea and a signiﬁcant amount of pel-
let was present after centrifugation. The sample in urea before and after centrifugation
is shown in lanes 1 and 2, respectively, in Figure 2.99b. The supernatant was anyway
ﬁltered and loaded on the HisTrap HP column but only few contaminants were eluted
(Figure 2.99a). The increase in absorbance during the refolding step is due to the buﬀer
exchange. It is present in all the puriﬁcation from the insoluble fraction, but here is more
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noticeable because the absorbance scale is short (from 0 mAU to 300 mAU). The denat-
uration of the inclusion bodies in urea 8 M was tried twice, and we obtained the same
negative results. A last trial to dissolve the pellet was done with a buﬀer containing 6
M guanidinium chloride (GdmCl) as denaturing agent instead of urea and it was possible
to purify a small amount of protein. The chromatogram of the puriﬁcation of the sample
in GdmCl is shown in Figure 2.99c. Since the GdmCl and the SDS-PAGE technique are
incompatible, the gel of the second puriﬁcation is not shown.
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Figure 2.99: Puriﬁcation of OctaVII 06, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 06 dissolved in a buﬀer with urea 8 M: the blue
line is the absorbance at 280 nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5
M), the red line is the concentration of the denaturing buﬀer (Urea 8 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-4 the
ﬂow-through; 5-6 the elution peak. (c) Elution proﬁles of the insoluble fraction of OctaVII 06 dissolved
in a buﬀer with GdnCl 6 M.
Desalting
The fractions collected after the puriﬁcation of the OctaVII 06 in GdmCl were pooled
together and centrifuged in order to remove possible aggregates. The sample was then
ﬁltered (lane 1 in Figure 2.100b) and loaded on the desalting column to remove the
imidazole. The elution peak is shown in the chromatogram (Figure 2.100a) and in lanes
2 to 7 of the SDS-PAGE gel.
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Figure 2.100: Puriﬁcation of OctaVII 06, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 06: the blue line is the absorbance
at 280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-7 the elution peak.
Biophysical characterization
The fractions containing the refolded OctaVII 06 were pooled together and centrifuged
in order to remove possible aggregates. The sample was used to measure by absorbance the
protein concentration, which is extremely low: 0.036 mg/mL (blue line in Figure 2.101a). 8
steps of concentration by ultraﬁltration were done until precipitates were visible in solution
(green line). The sample was centrifuged at high speed and ﬁltered (red line). The ﬁnal
concentration was 0.2 mg/mL, enough for analysis by far-UV circular dichroism. The
CD signal is shown in Figure 2.101b, and presents the usual curve for proteins containing
helices.
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Abs280 = 0.055, [C] = 0.036 mg/mL
Abs280 = 0.487, [C] = 0.322 mg/mL
Abs280 = 0.311, [C] = 0.206 mg/mL
(b)















































Figure 2.101: Biophysical characterization of OctaVII 06
(a) Absorption spectrum of OctaVII 06 after desalting (blue), after concentration (green) and after
centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b) CD spectra
of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at [Θ]=0.
The analysis by CDpro, using the program CDSSTR, is shown in Table 2.13, and as
for the previous OctaVIIs there is not an agreement in the content of secondary structures
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between the experimental protein and its model. Although the strand content is similar
(20.8% and 17.5%, respectively), the helix one is diﬀerent of about 10% (37.8% and
48.3%).
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 37.8 20.8 15.7 25.4
DSSP 48.3 17.5 15.0 19.7
Table 2.13: Secondary structures content, OctaVII 06
The protein is also poorly soluble because attempts to reach higher concentration
ended with its precipitation. For these results, also OctaVII 06 is discarded from further
characterization.
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2.4.11 OctaVII 07
OctaVII 07 has 250 residues and it is the best representative of Family 12 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 07 (gBlock®), was manipulated for digestion, ligation,
transformation and sequencing as described for OctaVII 06 in Section 2.4.10, page 129.
The results of the sequencing conﬁrmed the correct sequence of the OctaVII 07 gene in 1
clone out of 9. The plasmid bearing the good sequence was then used for a transformation
in E. coli BL21 (DE3) cells for expression trials and in DG1 competent cell for stock
preparation.
Expression Trials
Expression trials for OctaVII 07 were done in two conditions: induction for 4h at 37◦C
(Figure 2.102) and overnight induction at 18◦C (data not shown). In both cases there is
over-expression of the protein, but the molecular mass seems to be lower than expected:
25 kDa versus the theoretic 27.8 kDa.
Figure 2.102: Expression trial of OctaVII 07
SDS-PAGE of OctaVII 07 before and after induction at 37◦C. The non induced sample (NI) is compared
with the sample induced for 4 hours (4h).
Puriﬁcation of the soluble fraction
OctaVII 07 was produced in 1 L culture with induction at 18◦C overnight. After cell
disruption, the crude extract was centrifuged in order to separate the soluble fraction
from the insoluble one. In lanes 1 and 2 of Figure 2.103b the crude extract is shown
before and after the centrifugation step. OctaVII 07 is highly produced but mainly in
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inclusion bodies. Again, its size appears to be also lower than 25 kDa, suggesting that it
is truncated as OctaVII 02 and OctaVII 03. However, the soluble fraction of the protein
was loaded on the HisTrap HP column for puriﬁcation (the chromatogram is shown in
Figure 2.103a). The majority of the proteins were eluted in the ﬂow-through (lanes 3 to
5 in the SDS-PAGE), and the few ones that bound the column were eluted at 75 mM
of imidazole, a concentration too low for the dissociation of the HisTag from the matrix.
The SDS-PAGE gel conﬁrmed that the elution peak is composed only by contaminants
of the crude extract and the protein is not visible in the elution fractions.
OctaVII 07, as OctaVII 02 and OctaVII 03, is discarded from further analysis for its
low molecular mass.
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Figure 2.103: Puriﬁcation of OctaVII 07, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 07: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the crude extract; 2 the input
sample; 3-5 the ﬂow-through; 6-7 the elution peak.
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2.4.12 OctaVII 08
OctaVII 08 has 250 residues and it is the best representative of Family 13 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 08 (gBlock®), was manipulated for digestion, ligation,
transformation and sequencing as described for OctaVII 06 in Section 2.4.10, page 129.
The results of the sequencing conﬁrmed the correct sequence of the OctaVII 08 gene in 3
clones out of 4. The plasmid bearing the good sequence was then used for a transformation
in E. coli BL21 (DE3) cells for expression trials and in DG1 competent cell for stock
preparation.
Expression Trials
Expression trials for OctaVII 08 were done in 2 conditions: induction at 18◦C overnight
(Figure 2.104a) and at 37◦C for 4 hours (Figure 2.104b). In both cases the protein is highly
expressed in inclusion bodies (I). The low quality of the gel do not allow us to understand
if part of the protein is present in the soluble fraction, however we will test it in the next
section.
(a) (b)
Figure 2.104: Expression trials of OctaVII 08
(a) Expression trials of OctaVII 08 at 18◦C overnight and (b) at 37◦C for 4 hours: total fraction (T),
insoluble fraction (I) and soluble fraction (S).
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Puriﬁcation of the soluble fraction
OctaVII 08 was produced in 1 L of culture with induction at 37◦C for 4 hours. The
crude extract obtained after disruption (lane 1 in Figure 2.105b) was centrifuged, ﬁltered
and loaded on the HisTrap HP column. The input sample (soluble fraction) is shown in
lane 2 of the SDS-PAGE gel, and the chromatogram of the puriﬁcation in Figure 2.105a.
The majority of the proteins are eluted in the ﬂow-through (lanes 3 to 5) and the remaining
ones that bound the column are eluted at low concentration of imidazole. As shown in
the SDS-PAGE, the elution peak is composed only by contaminants, and OctaVII 08 is
not produced in the soluble fraction.
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Figure 2.105: Puriﬁcation of OctaVII 08, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 08: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the crude extract; 2 the input
sample; 3-5 the ﬂow-through; 6-7 the elution peak.
Puriﬁcation of the insoluble fraction
The pellet of 1 L culture was washed twice and resuspended in buﬀer with urea 8
M overnight at room temperature. After centrifugation, a consistent pellet was found in
the tube, and as for OctaVII 06, OctaVII 08 did not completely dissolve in urea. The
sample in urea before and after centrifugation is shown in lanes 1 and 2, respectively,
in Figure 2.106b. The supernatant was anyway ﬁltered and loaded on the HisTrap HP
column but only few contaminants were eluted (Figure 2.106a). As for OctaVII 06, the
pellet was dissolved in a buﬀer containing GdmCl 6 M and loaded again in the HisTrap
column. Finally, a small amount of protein was puriﬁed. The chromatogram of the
puriﬁcation of the sample in GdmCl is shown in Figure 2.106c. Since GdmCl and the
SDS-PAGE technique are incompatible, the gel of the second puriﬁcation is not shown.
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Figure 2.106: Puriﬁcation of OctaVII 08, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 08 dissolved in a buﬀer with urea 8 M: the blue
line is the absorbance at 280 nm, the green line is the concentration of the elution buﬀer (Imidazole 0.5
M), the red line is the concentration of the denaturing buﬀer (Urea 8M or GdnCl 6M) and the black
squares represent the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the sample
before centrifugation; 2, the input sample after centrifugation; 3-5 the ﬂow-through; 6-7 the elution
peak. (c) Elution proﬁles of the insoluble fraction of OctaVII 08 dissolved in a buﬀer with GdnCl 6 M.
Desalting
The fractions collected after the puriﬁcation of the OctaVII 08 in GdmCl were pooled
together and centrifuged in order to remove possible aggregates. The sample was then
ﬁltered (lane 1 in Figure 2.107b) and loaded on the desalting column to remove the
imidazole. The elution peak is shown in the chromatogram (Figure 2.107a) and in lanes
2 to 7 of the SDS-PAGE gel. As for OctaVII 06, the negative peak centered at 140 mL
is noticeable only because the scale of absorbance is short (20 mAU maximum), but it is
always present in the desalting chromatogram.
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Figure 2.107: Puriﬁcation of OctaVII 08, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 08: the blue line is the absorbance
at 280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-7 the elution peak.
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Biophysical characterization
The fractions containing the refolded OctaVII 08 were pooled together and centrifuged
in order to remove possible aggregates. The protein concentration was measured (blue
line in Figure 2.108a), and it resulted low, as for OctaVII 06. Steps of concentration
by ultraﬁltration lead to the formation of aggregates (green line), that are precipitated
by centrifugation at high speed and ﬁltration (red line). OctaVII 08 reached a ﬁnal
concentration of 0.16 mg/mL that was enough for analysis by far-UV circular dichroism
(Figure 2.108b). The spectrum is typical of a protein containing helices and its analysis by
CDpro, using the program CDSSTR, indicates that the sample contains 37.2% of helices
and 22% of strands. As for the previous OctaVIIs, the CD results are not in agreement
with the DSSP analysis on the model of OctaVII 08 that should contain 48.7% of helices
and 17.5% of strands.
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Abs280 = 0.035, [C] = 0.034 mg/mL
Abs280 = 0.276, [C] = 0.270 mg/mL
Abs280 = 0.167, [C] = 0.164 mg/mL
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Figure 2.108: Biophysical characterization of OctaVII 08
(a) Absorption spectrum of OctaVII 08 after desalting (blue), after concentration (green) and after
centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b) CD spectra
of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at [Θ]=0.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 37.2 22.0 16.6 23.6
DSSP 48.7 17.5 14.6 19.1
Table 2.14: Secondary structures content, OctaVII 08
As for all the previous proteins, we were not able to reach a concentration higher that
1 mg/mL, and also OctaVII 08 is discarded from further analysis.
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2.4.13 OctaVII 09
OctaVII 09 has 250 residues and it is the best representative of Family 23 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
and inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 09 (gBlock®), was manipulated for digestion, ligation,
transformation and sequencing as described for OctaVII 06 in Section 2.4.10, page 129.
The results of the sequencing conﬁrmed the correct sequence of the OctaVII 09 gene in 1
clone out of 2. The plasmid bearing the good sequence was then used for transformation
in E. coli BL21 (DE3) cells for expression trials and in DG1 competent cell for stock
preparation.
Expression trials of OctaVII 09
Expression trials for OctaVII 09 were performed in two conditions: induction at 37◦C
for 4 hours (Figure 2.109) and at 18◦C overnight (not shown). In both cases the protein
is highly expressed in inclusion bodies (I). The low quality of the gel did not allow us to
understand if part of the protein was present in the soluble fraction, however we looked
for the target protein in the soluble fraction.
Figure 2.109: Expression trials of OctaVII 09
SDS-PAGE shows the expression of OctaVII 09 at 37◦C for 4 hours for the fractions: total (T), soluble
(S) and insoluble (I).
Puriﬁcation of OctaVII 09, soluble fraction
OctaVII 09 was produced in 1 L of culture. The soluble fraction was separated from
the insoluble one by centrifugation. After ﬁltration the sample was loaded onto HisTrap
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HP column for puriﬁcation (line 1 of Figure 2.110b). The chromatogram is shown in
Figure 2.110a. The ﬂow-through is shown in lanes 2 and 3 and the elution peak in lanes
4 to 8. The peak is composed only by contaminants that elute at low concentration of
imidazole (50 mM).
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Figure 2.110: Puriﬁcation of OctaVII 09, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 09: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-3 the
ﬂow-through and 4-8 the elution peak at imidazole 50-200 mM.
Puriﬁcation of OctaVII 09, insoluble fraction
The insoluble fraction of the 1 L culture was washed twice and dissolved in buﬀer
containing 8 M urea. The sample was centrifuged, ﬁltered and loaded on the HisTrap
HP column for refolding and puriﬁcation. The input sample is visible in lane 1 of Fig-
ure 2.111b, OctaVII 09 is the main band but few contaminants are visible at higher
molecular mass. The chromatogram of the puriﬁcation is shown in Figure 2.111a: the
protein completely binds the matrix and almost all the contaminant are removed with
the ﬂow-through (lanes 2-4). The refolding did not caused elution of OctaVII 09 (lane 5),
that is then eluted starting from imidazole 200 mM. Except for the ﬁrst sharp peak that
contains contaminants, the protein seems to be the only band in lanes 7 to 11 of the gel.
Puriﬁcation of OctaVII 09, desalting
The fractions containing the refolded OctaVII 09 were pooled together and concen-
trated by ultracentrifugation in Amicon ﬁlters. After concentration the protein was cen-
trifuged at 20000 rpm and ﬁltered. The samples shown in Figure 2.112b were isolated
before concentration (lane 1), after ultraﬁltration (lane 2), and after centrifugation and ﬁl-
tration to remove aggregates (lane 3). The ﬁltrated sample was loaded onto the desalting
column and the chromatogram of the puriﬁcation is shown in Figure 2.112a.
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Figure 2.111: Puriﬁcation of OctaVII 09, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 09: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration of
the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b), the
SDS-PAGE gel. In lane 1 there is the input sample; 2-4 the ﬂow-through; 5 a fraction after the refolding
and 6-11 the elution peak.
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Figure 2.112: Puriﬁcation of OctaVII 09, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 09: the blue line is the absorbance
at 280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the pool of refolded OctaVII 09; 2 the same pool after concentration
by ultraﬁltration; 3 the input sample and 4-14 the elution peak.
Puriﬁcation of OctaVII 09, size exclusion
The refolded protein was loaded on a size exclusion column to verify its oligomerization
state, and the chromatogram is shown in Figure 2.113a. The calibration of the column was
reported in Section 4.7.7, page 208. A main peak is eluted in the void volume, suggesting
that OctaVII 09 has a molecular mass higher to 75 kDa. Two shoulders are visible at
10 mL and at 11.5 mL of elution volume, but analysis on gel (Figure 2.113b) shows that
there are no diﬀerences among any fraction of the entire peak. The peak at 11.4 mL
may however be composed by the monomer of OctaVII 09: the molecular mass that is
calculated from the calibration curve is 30.2 kDa, that is in agreement with the size of
the protein.
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Figure 2.113: Puriﬁcation of OctaVII 09, size exclusion
(a) Size exclusion elution proﬁle of the pool of the refolded OctaVII 09: the blue line is the absorbance at
280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-13 the elution peak.
Biophysical characterization
The refolded and desalted OctaVII 09 was concentrated by ultraﬁltration. The pro-
tein concentration was measured by absorbance spectrometry in three conditions: before
concentration (blue line in Figure 2.114a), after 5 cycles of ultraﬁltration (green line), and
after centrifugation at high speed to remove possible aggregates (red line).
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Abs280 = 0.440, [C] = 0.511 mg/mL
Abs280 = 2.329, [C] = 2.701 mg/mL
Abs280 = 1.831, [C] = 2.123 mg/mL
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 λmax = 333 nm










































































Figure 2.114: Biophysical characterization of OctaVII 09
(a) Absorption spectrum of OctaVII 09 after desalting (blue), after concentration (green) and after
centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b) CD spectra
of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at [Θ]=0. (c)
Emission ﬂuorescence spectra of OctaVII 09 in standard conditions and in GdmCl 6 M; the dotted line
at 354 nm indicates the theoretic maximum for unfolded proteins.
For the ﬁrst time in this work, the protein was stable in solution at a concentration
higher than 1 mg/mL! The ﬁnal concentration reached in this experiment was 2.1 mg/mL,
but in later trials we were able to reach 4 mg/mL.
The sample was diluted for analysis by far-UV circular dichroism (Figure 2.114b) and
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by intrinsic ﬂuorescence (Figure 2.114c) measurements.
The CD signal is very similar to the ones obtained for the other OctaVIIs, presenting
two minima at 208 nm and 222 nm, typical of proteins containing α-helices. The analysis
of the spectrum by CDPro, with the program CDSSTR, indicates that the sample contains
30% of helix, 22.5% of strands and 20% of turns. The comparison of these values with the
one obtained from the DSSP analysis on the model shows similar results with the other
OctaVIIs: although the strand content is generally in agreement, the helix content in the
sample is at least 10% lower than the expected one. In this case, the model has 47.5% of
helices while the experimental sample contains only 30% of them.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 29.2 22.5 20.0 27.8
DSSP 47.5 19.2 15.8 17.5
Table 2.15: Secondary structures content, OctaVII 09
For ﬂuorescence analysis, the refolded protein was diluted in both standard and dena-
turing buﬀers (GdmCl 6 M) (Figure 2.114c). The λmax is 333 nm for the native protein
and 354 nm for the unfolded one. This 20 nm shift clearly indicates that in the native
conformation the aromatic residues are not exposed to the solvent and that the protein
is not in a molten globule state.
Thanks to the higher concentration of OctaVII 09 compared to the other artiﬁcial pro-
teins, we were able to perform additional analysis, such as chemical unfolding, thermal
unfolding and near-UV CD.
The chemical unfolding was followed by both CD and ﬂuorescence. The protein was
diluted in diﬀerent concentrations of denaturing buﬀer using the pipetting workstation at
the Robotein Platform (the robot).
For the CD analysis, only the denaturing agent GdmCl was used (urea is not suitable
for the technique). The robot prepared 48 samples ranging from 0 to 5.5 M of GdmCl. The
CD signal at 222 nm was then measured for each of the 48 samples for 60 seconds, and its
average value was plotted against the concentration of denaturing agent (Figure 2.115a).
The signal at 222 nm is stable up to 2 M of GdmCl, suggesting that the folding
of the protein is not aﬀected below this concentration. The unfolding transition occurs
between 2 M and 5 M and the signal stabilizes after 5 M of GdmCl. It is not clear
why there is a big “jump” in the curve at 2 M GdmCl. Since OctaVII 09 is present in
solution in a high oligomeric form, the jump in the transition may indicate dissociation
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to a monomeric form. The same samples were recorded in the same conditions 15 days
after the ﬁrst measurement and the jump was not present anymore (data not shown).
This evidence may be suggest that samples with less than 2 M GdmCl require more time
of equilibration compared to samples with an high concentration of denaturant. This
experiment was performed only once. However, the transition does not correspond to a
cooperative unfolding one. CD spectra were recorded every 0.5 M of denaturing agent,
and they are shown in Figure 2.115b.
The same 48 samples were used for ﬂuorescence analysis, and their intensities at 318
nm are reported versus the concentration of GdmCl in Figure 2.115c. At that wavelength
there is the major diﬀerence in the folded (0 M GdmCl) and unfolded (5.5 M) curves. In
this experiment the signal is stable up to 1.5 M GdmCl and the transition is observed
between 1.5 M and 5 M of denaturing agent, again showing a non-cooperative behavior.
The same analysis was done on 48 samples of OctaVII 09 in diﬀerent concentration of
urea, ranging from 0 to 8 M (Figure 2.115e). The intensity at 318 nm is stable until 3
M of denaturant. The transition is again non-cooperative and spans from 3 M to 8 M of
urea, suggesting that the protein is not completely unfolded at that concentration.
All the experiments of chemical unfolding shows that the protein is moderately resis-
tant to the chemical agents, with stable signals up to 2 M GdmCl and 3 M of urea. The
transition curves however are spanned on a large range of concentrations and do not show
the typical sigmoidal curve of a cooperative unfolding.
For the thermal unfolding of OctaVII 09, the sample was heated from 25◦C to 96◦C
and then cooled back to 25◦C. Changes in the tertiary and secondary structures were
followed by ﬂuorescence (Figure 2.116a) and by far-UV CD (Figure 2.117a), respectively.
In the ﬂuorescence analysis, the unfolding transition is shown in blue (from 25◦C to
96◦C). Although the intensity is decreasing proportionally to the temperature, there is
not the typical transition of the thermal unfolding. The green line in the ﬁgure is the
refolding curve (from 96◦C to 25◦C). Again the transition is not present, but the intensity
increases proportionally to the decrease of temperature. These results may suggest that
the protein recover some of its compactness after thermal unfolding. Regular ﬂuorescence
spectra are recorded before and after the unfolding and are shown in Figure 2.116b with
the same color code. The native protein (blue line) has the λmax centered at 338 suggest-
ing that the 3D structure is compacted. After heating and cooling, the sample does not
recover the same initial intensity (green line), and the λmax is centered at 344 nm. There
are two possible explanations for this result: in one case, the proteins recovered part of
their folding but in a less compacted structure than the native one; in the second case,
only a fraction of the sample recover the native folding, while the remaining fraction is

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 2.115: Chemical unfolding of OctaVII 09
(a) Chemical unfolding of OctaVII 09 in GdmCl followed by CD, and (b) their CD spectra. (c) Chemical
unfolding of OctaVII 09 in GdmCl followed by ﬂuorescence, and (d) their emission ﬂuorescence spectra.
(e) Chemical unfolding of OctaVII 09 in urea followed by ﬂuorescence, and (f) their emission ﬂuorescence
spectra.
in an unfolded state. Although we do not know which case corresponds to our results, in
both cases a partial re-folding is obtained.
Thermal unfolding of OctaVII 09 was followed also by CD at 222 nm, and the signal is
shown in blue in Figure 2.117a. As for the ﬂuorescence experiment, no transition is visible
during the thermal unfolding. In order to force the unfolding of the protein, we repeated





































































































































































































































































I_max = 338 nm
I_max = 344 nm
Figure 2.116: Thermal unfolding of OctaVII 09 by ﬂuorescence
(a) Thermal unfolding (blue line) and refolding (green line) followed at 319 nm. (b) Emission ﬂuorescence
spectra obtained before (blue) and after (green) the thermal unfolding. The dotted line at 354 nm
indicates the theoretic maximum for unfolded proteins.
the experiment with OctaVII 09 in 1, 2 and 3 M of GdmCl (green, red and orange curve,
respectively). The unfolding transition is not visible in any of the 3 additional conditions.
In particular the protein behaves in the same way for the conditions with 0, 1 and 2
M of denaturant, with a per-residue molar ellipticity of -8000 mdeg cm2 mol−1 at 25◦C
and of -6000 mdeg cm2 mol−1 at 90◦C. The condition with 3 M GdmCl is aﬀected by
the presence of the denaturant already at 25◦C, with a value of -6000 mdeg cm2 mol−1
that decrease to around -4000 mdeg cm2 mol−1 at 90◦C. This result is in agreement with
the chemical unfolding experiment, shown in Figure 2.115a, which indicates that the
secondary structures of the protein start to unfold with a concentration of GdmCl higher
than 2 M.
For each of the 4 conditions, 3 CD spectra were recorded: at 25◦C before the thermal
unfolding, at 96◦C and at 25◦C after cooling of the samples. The results are shown in
Figures 2.117b to 2.117e with the same color code. In the conditions with 0, 1 and 2 M of
GdmCl the protein recovers part of its signal after the cooling, suggesting that the process
is reversible. For the condition with 3 M of GdmCl the reversibility of the denaturation
is less evident, but in all the cases the protein still contains deﬁned secondary structures,
also at 90◦C. The protein with 0 M of denaturant was also successfully tested for unfolding
and reversibility after incubation at 90◦C for 60 minutes, suggesting that OctaVII 09 is
thermostable and that its unfolding is reversible.
Finally, OctaVII 09 was tested by near-UV circular dichroism. The protein was tested
in 3 diﬀerent concentration: 0.8, 1.2 and 1.9 mg/mL, and the curves are shown in Fig-
ure 2.118.
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Figure 2.117: Thermal unfolding of OctaVII 09 by circular dichroism
(a) Thermal unfolding followed at 222 nm for OctaVII 09 in 4 diﬀerent conditions: standard buﬀer (blue
line), GdmCl 1M (green line), GdmCl 2 M (red line) and GdmCl 3 M (orange line). (b-e) CD spectra
of the 4 samples at 25◦C before unfolding, at 96◦C and at 25◦C after cooling of the sample. The color
scheme is the same of the thermal unfolding.
The near-UV signal is present and it is concentration dependent for the concentrations
of 0.8 and 1.2 mg/mL. The concentration of 1.9 mg/mL still shows a similar signal, but
it is not concentration dependent compared to the other two conditions. This can be
explained by the fact that OctaVII 09 forms oligomers at high concentration, and their
presence in solution may aﬀect the near-UV CD signal.
Crystallization trials
OctaVII 09 was subjected to 2 trials of crystallization, each of them consisting in 480
diﬀerent conditions. The ﬁrst one was done with the protein in phosphate buﬀer at a
concentration of 2 mg/mL. After ∼12 months of incubation, only one condition formed
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Figure 2.118: Near-UV CD of OctaVII 09
Near-UV CD signal of OctaVII 09 in three diﬀerent concentrations (top) and high-tension proﬁle (bot-
tom).
crystals (20% PEG 1000, 100 mM Sodium acetate pH 4.5, 200 mM Zinc acetate). The
crystals have not been tested for X-ray diﬀraction yet, so we do not know if they are
formed by the protein or by salt.
The second trial of crystallization was done with the protein in a Tris buﬀer with a
concentration of 4 mg/mL. After 8 months of incubation there is no evidence of crystal
formation.
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2.4.14 OctaVII 09 WS
OctaVII 09 WS (Weak Spot) is a mutant of OctaVII 09 that was designed in collab-
oration with Jens Meiler at the Vanderbilt University in Nashville, USA. OctaVII 09 was
designed in 2015 with the Rosetta software, version 3.5. Over the years many improve-
ments have been done on the software and in particular on its scoring function. In 2018,
we tested the model of OctaVII 09 with the new scoring function of Rosetta, version 3.8,
and we decided to improve its design according to the suggestions of the software. All
the computational work described hereafter in the design of OctaVII 09 WS was done by
Samuel Schmitz, a graduate student in the laboratory of Jens Meiler.
In silico saturated mutagenesis
The pdb structure of OctaVII 09 was tested with Rosetta version 3.5 (used in 2015)
and with Rosetta version 3.8 (2018). The energy score obtained with the old version is
-484 REU, while the one obtained with the new version is -777 REU. The two scores are
not comparable, because they are calculated with diﬀerent scoring functions. However, in
order to see if there are mutations that may improve the energy score of OctaVII 09, the
model was subjected to in silico saturated mutagenesis with the recent version of Rosetta:
the 240 residues in the sequence were individually substituted with each of the remaining
19 amino acids (for a total of 4560 models). 50 out of the 4560 single point mutations
improved the design and the energy score of OctaVII 09 (Figure 2.119). 27 out of the
50 improved the score of at least 0.5 REU, 16 out of them of at least 1.0 REU, and the
mutation S93L alone improved the score by 3.81 REU.
Figure 2.119: In silico saturated mutagenesis of OctaVII 09
The 50 best single point mutations of OctaVII 09 after saturated mutagenesis. The mutations are reported
on the x-axis, while the Rosetta energy gain is plotted on the y-axis.
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All the mutations were analyzed at structural level in order to understand their contri-
bution to the total energy score. For example the mutation N70S (Figure 2.120a) improves
the score by formation of an H-bond with the residue D40. This interaction may improve
the folding and the stability of the protein because it connects residues that are localized
on two diﬀerent loops. Another example is the mutation A114M (Figure 2.120b), that
ﬁlls an empty space at the interface between two helices and a strand, improving the
packing. A last example is T221P (Figure 2.120c), that is localized in the last loop of the
TIM-barrel. This mutation stabilizes the kink of the loop and supports the alignment of
the last helix to the β-sheet.
14 mutations were combined in the design of OctaVII 09 WS: 4 were localized in the
loops, 6 on the helices (4 exposed to the solvent and 2 buried in the protein core) and 4
on the strands. The 14 mutations improved the score (calculated with Rosetta, version
3.8), from -777 REU to -796 REU, a total of 19 REU (more than 1 REU per mutation!).
(a) (b) (c)
Figure 2.120: Single point mutations of OctaVII 09
Structural details of the single mutations: (a) N70S, (b) A114M and (c) T221P. The wild-type residues
is colored in green and the mutation in blue. The single poin mutations do not introduce structural
changes.
The 14-residue mutant is called OctaVII 09 WS (Weak Spot) and it has 250 residues.
Its gene was synthesized by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 09 WS (gBlock®), was manipulated for digestion, lig-
ation, transformation and sequencing as described for OctaVII 06 in Section 2.4.10,
page 129. The results of the sequencing conﬁrmed the correct sequence of the OctaVII 09
WS gene in 1 clones out of 4. The plasmid bearing the good sequence was then used for
transformation in E. coli BL21 (DE3) cells for expression trials and in DG1 competent
cell for stock preparation.
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Expression Trials
Expression trials for OctaVII 09 WS were done with 4 diﬀerent clones at 37◦C, with
induction with IPTG 1 mM for 4 hours (Figure 2.121a). All of them expressed the protein
at a molecular mass of ∼27 kDa. The protein expression was also tested at 18◦C with
diﬀerent concentrations of IPTG: 0, 5, 10, 50, 100, 500 and 1000 µM. Figure 2.121b shows
the total fractions of the non-induced (NI) and the overnight (T) samples, and the protein
is clearly expressed at ∼27 kDa. The samples with diﬀerent concentrations of IPTG were
sonicated, and the soluble fraction was separated from the pellet by centrifugation. Lanes
1 to 7 of the SDS-PAGE show the soluble fractions only. A band corresponding to the
molecular mass of OctaVII 09 WS is present in all the fractions except the one without
IPTG (lane 1). The intensity of the band increases between 0 and 50 µM of IPTG,
however it remains constant between 50 and 1000 µM. In order to verify if the band is
eﬀectively due to OctaVII 09 WS, a western blot anti-HisTag was performed on the same
samples, (shown in Figure 2.121c). The band clearly corresponds to OctaVII 09 WS that
is expressed in the soluble fraction of the cell.
(a) (b) (c)
Figure 2.121: Expression of OctaVII 09 WS
(a) Expression trial for OctaVII 09 WS at 37◦C; the 4 lanes show the total fraction of 4 diﬀerent clones.
(b) Total fractions of the non-induced sample (NI) and of the overnight sample (T) at 18◦C, and expression
trials with diﬀerent concentration of IPTG: lane 1, IPTG 0 µM; 2, IPTG 5 µM; 3, IPTG 10 µM; 4,
IPTG 50 µM; 5, IPTG 100 µM; 6, IPTG 500 µM and 7, IPTG 1000 µM. (c) western blot anti-HisTag
of the same fractions described in (b).
Puriﬁcation of OctaVII 09 WS, soluble fraction
The results obtained with the expression trials at both 37◦C and 18◦C, suggested that
OctaVII 09 WS is partially expressed in the soluble fraction. OctaVII 02, OctaVII 04
and OctaVII 05 were found in the soluble fractions, but the experiments with OctaVII 05
(see Section 2.4.8, page 117) suggested that this is due to the interaction of the free
cysteines with endogenous proteins rather than spontaneous folding. OctaVII 09 WS
does not contain cysteines, so we are convinced that the 14 mutations that diﬀerentiate
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OctaVII 09 from OctaVII 09 WS improved its solubility in the cell. In order to purify
the protein from the soluble fraction, 1 L of culture was produced. The crude extract
was obtained after 4 cycles of disruption, and the soluble fraction was separated from the
pellet through centrifugation. The soluble fraction was ﬁltered and loaded on HisTrap
HP column for puriﬁcation (Figure 2.122a). The input sample is visible in lane 1 of
Figure 2.122b; a consistent band at ∼27 kDa seems to be present. The majority of the
proteins are eluted in the ﬂow-through (lanes 2 to 4). Two peaks of elution are visible
on the chromatogram: the ﬁrst is at 75 mM of imidazole and it is composed only by
contaminants (lanes 5 and 6 in the gel), while the second one is eluted at 100 mM of
imidazole. A consistent band is present at the expected molecular mass for OctaVII 09
WS (lanes 7 to 14).
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Figure 2.122: Puriﬁcation of OctaVII 09 WS, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 09 WS: the blue line is the absorbance at 280 nm,
the green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the input sample; 2-4 the
ﬂow-through; 5-6 the ﬁrst elution peak and 7-14 the second elution peak.
Puriﬁcation of OctaVII 09 WS, size exclusion
The fractions containing OctaVII 09 WS, obtained from the puriﬁcation of the soluble
fractions were pooled together and centrifuged in order to remove aggregates. An aliquote
of the pool was then ﬁltered and loaded on the Superdex-75 column for a size exclusion
chromatography. The chromatogram is reported in Figure 2.123a; Figure 2.123b shows
the one obtained with refolded OctaVII 09 for comparison. The initial concentration of
the two pools was diﬀerent, however it seems clear that OctaVII 09 WS is eluted in a
single peak that correspond to the void volume of the column (7.4 mL). The 2 shoulders
that are present in the refolded OctaVII 09 and that may correspond to the monomer
and the dimer of the protein are completely absent in the chromatogram of OctaVII 09
WS. This results suggest that OctaVII 09 WS is in an higher oligomerization state.
2.4. EXPERIMENTAL VALIDATION 155
(a)





































































































Figure 2.123: Puriﬁcation of OctaVII 09 WS, desalting
(a) Size exclusion chromatography of OctaVII 09 WS from the soluble fraction and (b), of the refolded
OctaVII 09. The blue line is the absorbance at 280 nm and the brown line is the conductivity.
Puriﬁcation of OctaVII 09 WS, desalting
Despite the apparently high oligomerization state of OctaVII 09 WS, we decided to
load the sample in the desalting column in order to remove the imidazole. The pool
obtained after puriﬁcation is shown in lane 1 of Figure 2.124b. Many contaminants at
higher and lower molecular mass are present, and they were not removed after centrifu-
gation and ﬁltration (lane 2). The sample was loaded on the desalting column and the
chromatogram is presented in Figure 2.124a. The conductivity curve (brown) forms a
negative peak because of the buﬀer exchange, the Tris buﬀer has a higher conductivity
than the phosphate one. The fractions of the elution peak are shown in lanes 3 to 9 of
the SDS-PAGE.
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Figure 2.124: Puriﬁcation of OctaVII 09 WS, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 09 WS: the blue line is the
absorbance at 280 nm, the brown line is the conductivity and the black squares represent the fractions
that are shown in (b), the SDS-PAGE gel. Lane 1 the pool after desalting; 2 the input sample and 3-9
the elution peak.
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Puriﬁcation of OctaVII 09 WS, boiling
The sample obtained from the desalting puriﬁcation was highly contaminated and it
was necessary to perform an extra step of puriﬁcation prior to possible crystallization.
Since OctaVII 09 resulted to be thermostable at high temperature, we attempted to re-
move some contaminant by increasing the temperature of the sample. For this experiment,
9 samples of 100 µL of OctaVII 09 WS were used. Except for the untreated sample (lane
1 in Figure 2.125), the remaining 8 were incubated at 95◦C for 1, 5, 10, 20, 30, 40, 50
and 60 minutes, and then centrifuged at high speed to remove possible aggregates (lanes
2 to 9, respectively). The SDS-PAGE shows that OctaVII 09 WS is thermostable as
OctaVII 09 and it does not precipitate despite 60 minutes at high temperature. The con-
taminants at high molecular mass are on the contrary precipitating just after 5 minutes
of incubation at high temperature. However, the contaminants at lower molecular mass
seems as thermostable as OctaVII 09 WS and it was not possible to remove them from
the solution.
The pool containing OctaVII 09 WS was then incubated at 60◦C for 90 minutes and
then centrifuged at high speed.
Figure 2.125: Puriﬁcation of OctaVII 09 WS, boiling
SDS-PAGE of the puriﬁcation of OctaVII 09 WS by heat: the same sample is boiled at 95◦C for 0, 1, 5,
10, 20, 30, 40, 50 and 60 minutes (Lanes 1-9, respectively).
Crystallization trials
OctaVII 09 WS was tested for crystallization trial in 480 diﬀerent conditions. The
protein was in a phosphate buﬀer at a concentration of 2.3 mg/mL. After 5 months of
incubation, 4 conditions presented crystals. The ﬁrst one is the same that gave crystals
for OctaVII 09: 20% PEG 1000, 100 mM Sodium acetate pH 4.5, 200 mM Zinc acetate.
The remaining three are: 1- 28% PEG 400, 100 mM HEPES sodium pH 7.5, 200 mM
CaCl2; 2- 20% 2-propanol, 100 mM Sodium acetate pH 4.6, 200 mM CaCl2; and 3- 30%
PEG 400, 100 nM TRIS-HCl pH 8.5, 200 mM MgCl2. Crystals have not been tested for
X-ray diﬀraction, so we do not know yet if they are formed by the protein or by salts.
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2.4.15 OctaVII 10
OctaVII 10 has 250 residues and it is the best representative of Family 05 according
to the Rosetta energy score (details in Section 2.3.9, page 68). The gene was synthesized
and inserted in the pET28a plasmid by IDT, that shipped it as dry pellet.
Sequencing
The DNA pellet of OctaVII 10 (gBlock®), was manipulated for digestion, ligation,
transformation and sequencing as described for OctaVII 06 in Section 2.4.10, page 129.
The results of the sequencing conﬁrmed the correct sequence of the OctaVII 10 gene in 1
clone out of 10. The plasmid bearing the good sequence was then used for a transformation
in E. coli BL21 (DE3) cells for expression trials and in DG1 competent cell for stock
preparation.
Expression Trials
Expression trials of OctaVII 10 were performed in two conditions: overnight induction
at 18◦C (Figure 2.126) and 4 hours induction at 37◦C (not shown). OctaVII 10 is visible
in the total fraction at the correct size.
Figure 2.126: Expression trials of OctaVII 10
Expression trials of OctaVII 10: the non-induced sample is on the left (NI) and the sample with overnight
induction at 18◦C is on the right (ON).
Puriﬁcation of the soluble fraction
OctaVII 10 was produced in 1 L culture with induction at 37◦C for 4 hours. The
crude extract (lane 1 in Figure 2.127b) was centrifuged and ﬁltered. The majority of
the target protein was removed from the soluble fraction (lane 2). The chromatogram in
Figure 2.127a shows that most proteins were eluted in the ﬂow-through, whereas a minor
fraction only was eluted in a peak at 75 mM of imidazole. The SDS-PAGE conﬁrms that
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OctaVII 10 is not produced in the soluble fraction because the elution peak is composed
of contaminants only.
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Figure 2.127: Puriﬁcation of OctaVII 10, soluble fraction
(a) Elution proﬁles of the soluble fraction of OctaVII 10: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M) and the black squares represent
the fractions that are shown in (b), the SDS-PAGE gel. In lane 1 there is the crude extract, 2 the input
sample; 3-9 the ﬂow-through and 10-12 the elution peak.
Puriﬁcation of the insoluble fraction
The pellet collected after centrifugation of the crude extract of OctaVII 10 was washed
twice and dissolved in the buﬀer containing 8 M urea. Following centrifugation, the super-
natant was ﬁltered and loaded in the HisTrap HP column for refolding and puriﬁcation.
The chromatogram is shown in Figure 2.128a and the input sample in lane 1 of Fig-
ure 2.128b. The ﬂow-through contains the target protein, suggesting that the column
reached saturation. The refolding did not cause unbinding of the protein from the ma-
trix, that is then eluted at 250 mM of imidazole buﬀer. The fractions of the elution peak
(lanes 6 to 12 of the SDS-PAGE) are highly pure. Few contaminants of 28 to 35 kDa are
visible in the gel, however OctaVII 10 is always the predominant band.
Desalting
The fractions containing the refolded OctaVII 10 were pooled together, centrifuged
and ﬁltered before desalting. The chromatogram is shown in Figure 2.129a, the input
sample is shown in lane 1 of Figure 2.129b and the elution peak in lanes 2 to 10.
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Figure 2.128: Puriﬁcation of OctaVII 10, insoluble fraction
(a) Elution proﬁles of the insoluble fraction of OctaVII 10: the blue line is the absorbance at 280 nm, the
green line is the concentration of the elution buﬀer (Imidazole 0.5 M), the red line is the concentration
of the denaturing buﬀer (Urea 8 M) and the black squares represent the fractions that are shown in (b),
the SDS-PAGE gel. In lane 1 there is the input sample; 2-5 the ﬂow-through and 6-12 the elution peak.
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Figure 2.129: Puriﬁcation of OctaVII 10, desalting
(a) Elution proﬁle of the desalting of the pool of the refolded OctaVII 10: the blue line is the absorbance
at 280 nm, the brown line is the conductivity and the black squares represent the fractions that are shown
in (b), the SDS-PAGE gel. Lane 1 the input sample; 2-10 the elution peak.
Biophysical characterization
The desalted sample of OctaVII 10 was analyzed by absorbance spectroscopy under 3
conditions: before concentration (blue line in Figure 2.130a), after ultraﬁltration (green
line), and after centrifugation to remove the aggregates (red line).
The ﬁnal concentration of the protein corresponds to 0.22 mg/mL. Trials to bring the
protein to a higher concentration failed, and lead to precipitation of the sample.
However, it was possible to record a far-UV CD spectrum, shown in Figure 2.130b.
The percentages of secondary structures were calculated from the spectrum with CDpro,
using the program CDSSTR. The results are compared with the predicted percentages
calculated by DSSP on the 3D model in Table 2.16.
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Abs280 = 0.068, [C] = 0.050 mg/mL
Abs280 = 0.602, [C] = 0.447 mg/mL
Abs280 = 0.296, [C] = 0.220 mg/mL
(b)















































Figure 2.130: Biophysical characterization of OctaVII 05 NoCys
(a) Absorption spectrum of OctaVII 10 after desalting (blue), after concentration (green) and after
centrifugation and ﬁltration (red). Abs280 is used to calculate the protein concentration. (b) CD spectra
of the protein (top) and high-tension (bottom); the dotted line indicates the baseline at [Θ]=0.
% α-Helix % β-Strand % Turn % Unstruc
CDpro (CDSSTR) 22.9 28 20.5 28.4
DSSP 47.5 19.2 15.8 17.5
Table 2.16: Secondary structures content, OctaVII 10
The percentages from CDpro and DSSP are highly diﬀerent: the helix content is
25% lower of the expected one, while the strand one is 10% higher. It is quite unlikely
that the protein is folded in the correct structure. OctaVII 10 is discarded from further
characterization due to its low solubility and to the results of circular dichroism.
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2.4.16 Comparison of OctaVIIs
The results obtained for the 15 artiﬁcial proteins designed and produced in this thesis







06 07 08 09
09
10
YQ NC WS NC WS
Expr. 37◦C x V V V V V V V V V V V V V V
Expr. 18◦C x V V V V V V x x V V V V V V
Mass - x x x V V V V V V x V V V V
Purif. Soluble - V - - V x x V x x x x x V x
Purif. Pellet - V - - V V V V V V - V V - V
Far-UV CD - - - - V V V V V V - V V - V
Fluorescence - - - - V V V V - - - - V - -
mg/mL - - - - 0.2 0.2 0.7 0.2 0.3 0.2 - 0.1 4 2 0.2
Crystallization - - - - - - - - - - - - V V -
Table 2.17: Experimental validation of the 15 OctaVIIs
Codes: “V” = succesfull experiment; “x” = unsuccesfull experiment and “-” = not performed experiment.
Expression Trials (Expr. 37◦C and Expr. 18◦C in Table 2.17)
Among the 15 proteins, only OctaVII 01 could not be expressed at all, neither at 37◦C
nor at 18◦C. We did not further inquire the reasons why the protein was not expressed
under our experimental conditions since this was not the goal of this work. However,
similar observation was reported by Winther and co-workers in their publication on the
re-design of the thioredoxin (described in the Introduction, Section 1.1.2, page 7) [31].
Thus, among the 48 models chosen for experimental validation, 16 were not expressed.
Considering that: 1- thioredoxin is∼110 residues, less than half of the size of the OctaVIIs,
and 2- their design was done starting from natural backbones, we can be happy of our
yield in which only 1 protein out of 10 is not expressed (vs. 1 out of 3 with thioredoxin).
The remaining 14 proteins could all be expressed at 37◦C and 18◦C, with the excep-
tion of OctaVII 05 and its mutant OctaVII 05 NoCys that were not expressed at lower
temperature. Since there is no diﬀerence in the plasmid sequences of all constructs, those
exceptions rely only on the gene sequence of OctaVII 05 and OctaVII 05 NoCys. We
did not inquire further the reasons why this phenomenon occurs and there are no similar
results in the literature. Indeed, temperature changes during growth and induction of E.
coli are widely suggested to tune the expression and the folding of recombinant proteins.
Molecular Mass (MM in Table 2.17)
Among the 10 artiﬁcial proteins, 3 are truncated: OctaVII 02, OctaVII 03 and Oc-
taVII 07. Attempts to recover the full length of OctaVII 02 with the mutation Y57Q
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failed. Many examples of protein truncation in E. coli can be found in the literature
[132]. In a review about recombinant protein expression in E. coli, Rosano and Cec-
carelli [133] pointed out that this phenomenon may be due to codon bias: depletion of
low-abundant tRNA causes amino acid misincorporation and/or truncation during the
protein production. However, we exclude this hypothesis for two reasons: ﬁrst, the gene
sequences were designed with a codon optimization for the production in E. coli, and sec-
ond, tRNA depletion aﬀects mainly the C-terminal part of the expressed protein, while
the truncations in the OctaVII proteins are all located at the N-terminus.
An alternative explanation for protein truncation is the presence in the gene of an
internal ribosome binding site (internal RBS), which alters the starting point for protein
translation [134, 135]. Whitaker and co-workers [136] demonstrated that eukaryotic genes
expressed in E.coli are more prone to contain internal RBS compared to prokaryotic ones.
This is due to the fact that bacterial genes have been subjected to negative selection
pressure against RBS, while eukaryotic genes have not. Since artiﬁcial sequences are
not subjected to evolutionary selection pressure, they have higher probability to present
internal RBS that causes N-terminal truncations. We did not inquire further for the
presence alternative ribosome binding sites in the sequences of OctaVII 02, OctaVII 03
and OctaVII 07.
Purﬁcation from the soluble fraction (Purif. Soluble in Table 2.17)
12 proteins have been tested for puriﬁcation from the soluble fraction, using aﬃnity
chromatography on a HisTrap HP column. Only 4 of them could be observed on SDS-
PAGE following puriﬁcation: OctaVII 02, OctaVII 04 and OctaVII 05 and OctaVII 09
WS. In all cases, however, most or all of the protein of interest was found in inclusion
bodies.
Three variants, OctaVII 02, OctaVII 04 and OctaVII 05, contain free cysteines that
may interact with endogenous proteins. This interaction may shift part of the protein
production from the insoluble fraction (inclusion bodies) to the soluble one. This hypoth-
esis is not fully demonstrated, but in Section 2.4.8, page 117, we showed how OctaVII 05,
puriﬁed from the soluble fraction, forms covalent bond with endogenous proteins that are
broken only in presence of both reducing and denaturing agents (β-mercaptoethanol and
SDS). The fact that the mutants without cysteines of OctaVII 04 and OctaVII 05 are not
observed in the soluble fraction also supports this hypothesis.
The situation is diﬀerent for OctaVII 09 WS, which is also partially found in the
soluble fraction. This protein is a 14-residue mutant of OctaVII 09. Both contains no
cysteines, but OctaVII 09 is produced only in inclusion bodies. The 14 mutations are
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responsible for the improved solubility of the protein upon expression, but we do not
know if they contribute as a whole or not. However, this protein is the only one out of 15
that, at least in part, spontaneously folds in the soluble fraction of the cell.
In the work of Winther [31], 9 designs out of 48 were partially expressed in the soluble
fraction, and 3 out of them could be successfully puriﬁed. These results are in good
agreement with the ones presented in this work: 1 protein out of 15 is obtained from the
soluble fraction.
Other results found in the literature are less detailed for a comparison. For example,
in the work of Huang (reported in Section 1.4.2, page 30), 22 proteins out of 22 are highly
expressed in E. coli, without showing troubles as non-expression, truncation or insolubility
[117].
Puriﬁcation from the insoluble fraction (Purif. Pellet in Table 2.17)
10 OctaVIIs out of 15 were successfully puriﬁed from the insoluble fraction of the
cellular extract. Solubilization of inclusion bodies 8 M in urea is a standard procedure for
refolding of insoluble proteins, however it did not work with two of our artiﬁcial proteins,
OctaVII 06 and OctaVII 08. The use of guadinidium chloride, a more powerful chaotropic
agent than urea, led to a partial dissolution of the inclusion bodies. The amount of protein
obtained by extraction with GdmCl was, however, much lower than that obtained with
urea for the other OctaVIIs. The fact that inclusion bodies do not dissolve in urea 8 M
is not reported in literature, however there is a post on the forum of ResearchGate that
mention a similar result:
www.researchgate.net/post/Problem with protein puriﬁcation not soluble in 8M urea
Unfortunately, nobody had an explanation for this phenomenon. It may be that the
inclusion bodies of OctaVII 06 and OctaVII 08 are too much insoluble for dissolution in
urea.
The observation that urea may not be the best chaotropic agent to dissolve inclusion
bodies is also supported by the chemical unfolding experiment performed on the refolded
OctaVII 09 in Section 2.4.13, page 141. The unfolding transition followed by ﬂuorescence
(see Figure 2.115e), does not reach a plateau at high concentration of urea, indicating
that the protein is not fully unfolded. It is possible that, during solubilization, inclusion
bodies were not completely dissolved and that this contributed to the aggregation issues
of OctaVII 09.
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Secondary structures (Far-UV CD in Table 2.17)
All the OctaVIIs that were analyzed by far-UV circular dichroism shows presence of
secondary structures: in particular clear minima at 208 and 222 nm revealed a signiﬁcant
content in α-helical content. In all cases, however, this was lower (23 to 39%) than ex-
pected (46 to 49%)
In contrast, the percentage of β-strands is in general consistent with the expectation
(17-21%). Only OctaVII 04 WS (30%) and OctaVII 10 (28%) are out of the range.
OctaVII 04 WS has 22 mutations of diﬀerence compared to OctaVII 04 NoCys. The
mutations seem to increase the percentage of β-strands from 18% to 30%. The content of
helices and of turns remains the same, while the unstructured regions decrease from 29%
to 19%. The 22 mutations are probably involved in the folding of portions of the protein
that were previously unstructured.
OctaVII 10 is unlikely to be folded as expected, in fact its content of secondary struc-
tures is 10% higher for the strands (28% instead of 19%), and 25% lower for the helices
(23% instead of 48%) compared to the model ones.
OctaVII 09 is the best model according to solubility and thermostability, but its helical
content is less in agreement with the model than the other OctaVIIs. In fact, the expected
percentage is 47.5% and the experimental one is 29%.
The remaining six OctaVIIs have more or less the same content in the strands (17.2%
to 22.0%), in the helices (33.7% to 39.6%) and in turn regions (15.7% to 19.5%). The
similarity in their secondary structure content may be due to the fact that the proteins
descend from the same structural ancestor (the parametric structure described in Sec-
tion 2.2.1). In fact, their 3D models are similar, and the percentages extracted with
DSSP spans in short ranges: 17.0%-20.5% for the strands, 46.6%-48.7% for the helices
and 14.1%-19.5% for the turns. The content of strands and turns is in good agreement
with the expectation, while the helical content is always higher in the model of by least
10%.
Remarkably, the percentages of secondary structures obtained for most proteins are in
good agreement with those obtained for the natural TIM-barrel of Thermotoga marittima:
18% of strands, 36% of helices and 19% of turns (unpublished data of Matagne’s Lab).
We can not know if the proteins are folded in a TIM-barrel fold based only on the CD
results. As reported for OctaV.1 in Section 1.3.5, page 24, the helix and strand contents
may be in the range of natural TIM-barrels, but their folding may not correspond to the
desired one.
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Tertiary structures (Fluorescence in Table 2.17)
Fluorescence emission spectra were recorded for 5 variants. The expected λmax for
completely unfolded proteins is at 355 nm, due to full exposure of the tryptophan indole
groups (shown with OctaVII 09 in Figure 2.114c). All of the 5 OctaVIIs have the λmax in
the range of 333-338 nm, indicating that the structure is compact and that the aromatics
are not fully exposed to the solvent. Unfortunately, only one protein out of the 5 could
be concentrated up to 2 mg/mL, the concentration requested for the analysis by near-UV
circular dichroism. In this case, a signiﬁcant CD signal (Figure 2.118) demonstrated the
occurence of stable tertiary contents.
Solubility (mg/mL in Table 2.17)
10 out of 15 OctaVIIs have been subjected to cycles of ultraﬁltration in order to
increase their concentration. However, the majority of them aggregated and precipitated
already in the ﬁrst steps and their ﬁnal concentration was always < 1 mg/mL.
The low solubility of artiﬁcial proteins is quite common, especially in the Octarellin
history (see Chapter 1.3). In the work of Winther [31] on the re-design of thioredoxin,
the majority of the protein have low solubility. Out of the 48 proteins they produced,
only 9 were tested for puriﬁcation. Among these, 7 were discarded due to precipitation
on column, low stability in solution and low solubility. Also the two remaining proteins,
successfully isolated by size exclusion chromatography in a monomeric form, showed low
solubility: one reached a concentration of ∼0.35 mg/mL, the other was more soluble, but
only at low pH. In the work of Huang [117] on the symmetric TIM-barrel, there is no
evidence for poor solubility of their models.
Interestingly, the 22 mutations that distinguish OctaVII 04 NoCys and OctaVII 04
WS improved the solubility from 0.20 mg/mL to 0.74 mg/mL. 10 out of the 22 mutations
are localized in loop regions, 9 in β-strands and the remaining 3 in the last α-helix. We did
not inquired further which residues are involved in the improved solubility of OctaVII 04
WS, however the improvement is signiﬁcant. OctaVII 09 and its mutant OctaVII 09
WS are the only proteins that passed the limit of 1 mg/mL, reaching 4 and 2 mg/mL,
respectively.
Oligomerization and aggregation (in Table 2.17)
All the 10 refolded proteins showed signs of oligomerization or aggregation. In par-
ticular, all the proteins except OctaVII 09 and its mutant have low solubility. They
precipitate at low concentration, and aggregates were visible in solution. OctaVII 04, Oc-
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taVII 04 NoCys, OctaVII 04 WS, OctaVII 05, OctaVII 05 NoCys and OctaVII 09 have
been tested by dynamic light scattering (DLS) and showed the presence of aggregates
(data not presented in this work). However, for OctaVII 09, the aggregates were stable in
solution for months, and the protein could be concentrated at 4 mg/mL without precipi-
tation. This stability overtime and upon concentration may be due to an oligomerization
process more than aggregation, however we did not inquired further.
In the history of the Octarellins, there are evidences of aggregation in solution only for
OctaV and OctaVI. Following refolding, OctaV is present in solution in both a monomeric
and an aggregated form [4], that are then separated by size-exclusion chromatography.
Instead, OctaVI is refolded in a monomeric form only, but it forms aggregates when heated
above 74◦C.
In the work of Winther [31] on the re-design of the thioredoxin, the authors stated
that most of the protein they tried to purify did not elute from the column, probably
because of on-column aggregation, but there are no evidence to support their theory.
Among the 4 Symmetrins designed by Nagarajan [116], only one resulted present in
solution in a high oligomeric state (Symmetrin-3). It is interesting to notice that its
Tm is ∼20◦C higher than the one of the other Symmetrins (63◦C versus 44◦C). High
thermostability is often associated to high oligomerization state [137], and this may be
the case also for OctaVII 09, that is both thermostable and oligomeric.
Crystallization (Table 2.17)
OctaVII 09 and its mutant OctaVII 09 WS are the only proteins that underwent
crystallization trials, since they were concentrated to 4 mg/mL and 2 mg/mL, respectively.
One crystal was obtained after a year of incubation for OctaVII 09, while 4 crystals
were obtained for OctaVII 09 WS after only 5 months. Interestingly, one condition of
crystallization is common in both proteins. This result seems promising, however the
5 crystals have not been tested for X-ray diﬀraction yet. It is possible that they are
composed only by salts. The diﬀraction experiment is planned and soon we will obtain
an answer. If the crystals are formed by the protein, we have a stock sample to repeat
the crystallization and possibly to determine the 3D structure of the proteins.
The Weak Spot mutant
Two of the 15 proteins, OctaVII 04 WS and OctaVII 09 WS, are mutant that have
been designed in order to improve the properties of OctaVII 04 NoCys and OctaVII 09,
respectively.
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OctaVII 04 WS has been created in collaboration with the laboratory of Wim Vranken.
The software they used to analyze OctaVII 04 NoCys was supposed to improve its folding
to form a TIM-barrel structure. However, its secondary structure content, as estimated
from the analsis of far-UV CD data, is not in agreement with that of the model, nor with
the results obtained with the natural TIM-barrel of Thermatoga maritima. In fact, it
presents 30% of β-strands instead of 20%. The biophysical results seem to suggest that
the 22-mutations present in OctaVII 04 WS do not really fold into a TIM-barrel, but it
is impossible to determinate it without resolution of the structure.
However, the mutations contributed to increase the solubility of the protein after
refolding of 3-4 times. Moreover, according to the results obtained by far-UV CD, 12%
of the unstructured regions of OctaVII 04 NoCys resulted structured in OctaVII 04 WS.
These results are impressive if we consider that the HMM-TIM methodology did not use
direct structural information of the protein.
On the contrary, OctaVII 09 WS is the mutant of OctaVII 09, designed in collabora-
tion with the laboratory of Jens Meiler, using structural informations. The 14-mutations
led to an improved solubility after expression, in fact OctaVII 09 WS is partially produced
in the soluble fraction.
In the history of the Octarellins, the expression of OctaV was shifted from the inclusion
bodies to the soluble fraction thanks to directed evolution. We obtained the same results
in OctaVII 09 WS thanks to a rational analysis of the protein structure (and an improved
software). This is remarkable because we were able to mimic at computational level the
directed evolution process. This means reduced experimental time (one month in silico
versus 6 at the bench), and reduced costs.
There is only a single drawback of the 14-mutation of OctaVII 09 WS: the low per-
centage of monomeric protein in solution found by size-exclusion with OctaVII 09 is com-
pletely lost in the mutant, that is present in solution only in an high oligomerization
state.
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Chapter 3
Computational Protocols
3.1 Natural TIM-barrel analysis
3.1.1 Collection of natural TIM-barrels
85 pdb structures were downloaded from DATE (web-link, page 231). After visual
inspection with Pymol [118], 33 out of them were discarded because presenting one or
more extra domains in their structure. The presence of other folds, rather then the TIM-
barrel one, will aﬀect the next step of structural alignment. In fact, alternative domains
might be found in proteins that do not contain the TIM-barrel fold, leading to a mixed
collections of TIM-barrels and other folds. For this reason the 33 multi-domains structures
were discarded. The remaining 52 were individually uploaded to the PDBeFOLD web-
service [119], (web-link, page 231). 1623 diﬀerent natural TIM-barrels were obtained
after structural alignment with PDBeFOLD. Fasta sequences were loaded on PISCES
web-service [121] (web-link, page 231), and were reﬁned according to sequence identity,
lower than 80%, and to structure resolution, lower than 2A˚. The 229 output sequences
were reduced to 219 after visual inspection with Pymol. The 10 discarded proteins did
not contained the TIM-barrel fold in their structure. For a description of the software,
see Annexes 6.1, page 231, and for the list of 219 pdb IDs see Annex 6.5.4, page 247. The
total length of the proteins was extracted from the PISCES output.
3.1.2 Secondary structure assignment
For each of the 219 pdb ﬁles, N- and C-terminal domains not involved in the TIM-
barrel fold (extra-domains) were deleted from the pdb with Pymol. Secondary structure
assignment was done with the program DSSP [138]; the command line is reported in An-
nex 6.5.1.
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Information about α-helices (H,G and I in the DSSP output) and β-strands (E) was ex-
tracted and the secondary structures not involved in the TIM-barrel fold (extra-elements),
were discarded. For each natural structure, the element number in the TIM-barrel fold
(i.e. 1st strand, 1st helix, 2nd strand, etc.) and the residue numbers at the beginning and
at the end of the secondary structures were assigned. The length of each element was
calculated by subtraction of the residue numbers.
Loops were deﬁned in this work as the connection between β-strands and α-helices
involved in the TIM-barrel fold, and they can include extra-domains and individual sec-
ondary structures. The calculation of loop length was done by subtraction of the residue
numbers.
3.1.3 Energy scores in natural TIM-barrels
The 219 natural TIM-barrels were subjected to energy minimization (or relax) with
the Relax package of Rosetta [38], (version 2015.19.57819 bundle). The energy function
used by rosetta is Talaris2013. It is possible to modify the energy function and adapt
it to speciﬁc system, however in this work we used the default one that is preferable for
soluble globular proteins. The command line is reported in Annex 6.5.2, page 245. The
program produced as outputs the relaxed pdb and a ﬁle with the corresponding energy
scores.
Total energy values were extracted after minimization (the total score column in
the score ﬁle) and plotted against amino acid length of the structures (see Section 2.1.5,
page 38). The R-square value was calculated with R-language [139].
Energy values that depends only on H-bonds between the strands backbones (and
not on side-chain/side-chain and side-chain/main-chain interactions), were automatically
calculated in the score ﬁle and extracted after minimization (the hbond lr bb column
in the score ﬁle). They will be deﬁned as β-energies here on. The number of residues
belonging to β-strands were extracted with DSSP and plotted against the β-energy values
(see Section 2.1.6, page 40)
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3.1.4 Amino acid composition
The 219 natural TIM-barrels were analyzed for their amino acid content. Each of the
20 natural amino acids was counted in each protein sequence and the resulting value was
transformed in percentage according to the protein length. The range of percentages in
the collection of natural TIM-barrel for each natural amino acid is shown in Figure 2.1.
A similar analysis was done by grouping amino acids according top the following
properties (property groups):
1. Small: Alanine (A), Cysteine (C), Glycine (G), Serine (S)
2. Polar: Aspartic acid (D), Glutamic Acid (E), Histidine (H), Lysine (K), Serine (S),
Asparagine (N), Glutamine (Q), Arginine (R), Threonine (T), Cysteine (C)
3. Charged: Aspartic acid (D), Glutamic Acid (E), Lysine (K), Arginine (R)
4. Positive: Lysine (K), Arginine (R)
5. Negative: Aspartic acid (D), Glutamic Acid (E)
6. Apolar: Tryptophan (W), Tyrosine (Y), Phenylalanine (F), Valine (V), Proline (P),
Leucine (L), Isoleucine (I), Alanine (A), Glycine (G), Methionine (M)
7. Aromatics: Tryptophan (W), Tyrosine (Y), Phenylalanine (F)
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3.2 Protein design
3.2.1 Parametric design
The design of the artiﬁcial TIM-barrel backbones can be done in two ways: from
scratch using geometrical information extracted from natural TIM-barrels (parametric
design), or through homology modelling of multiple existing TIM-barrel structures (com-
parative modelling). Both techniques were preliminary tested and only the ﬁrst one
resulted optimal for the design. The comparative design had three major problems. The
ﬁrst is that it was not possible to perform multiple structure alignment on all the 219 natu-
ral TIM-barrels structures that have been described in the previous chapter. We were able
to obtain valid alignments using only 30 proteins out of the 219, decreasing dramatically
the heterogeneity of our dataset. The second problem is bound to the characteristic of
natural TIM-barrels to have extra-structures and extra-domains in their loops. Since they
are not conserved, they negatively aﬀect the comparative modelling and output structures
lacked multiple loop regions. The third problem was related to the characteristic of nat-
ural TIM-barrels to have a low sequence identity (in certain cases also less than 5%). It
was really hard to ﬁnd a consensus sequence in agreement with all the 30 structures used
as input. This led to outputs that collapsed on themself at the ﬁrst energy minimization.
The comparative modelling is an excellent technique when the starting inputs have high
similarity in both sequence and structure, but it became poorly accurate when they are
more variable. For this reason we decided to design our backbones with the parametric
method that is described hereafter.
The parametric design of the artiﬁcial TIM-barrel backbones was performed with the
package BundleGridSampler of the Rosetta software (version 2015.19.57819 bundle). This
program required 8 parameters to design each element, 5 of them were common to both
α-helices and β-strands and 3 were for strand only. The common parameters for each el-
ement were: the radius (r0), the length (helix length), the localization in space around
the bundle axis (delta omega0), the orientation around the internal axis (delta omega1)
and the inclination (omega0). Parameters for β-strands only were: the strand deﬁnition
to diﬀerentiate from the helix (crick params file); the orientation of N- to C-terminus
that is opposite to the helix one (invert), and the vertical shift of the elements in order
to align them with the α-barrel (delta t).
The radius values used for the design of the β- and of the α-barrels were calculated
from natural TIM-barrel structures with DeepView [140], and set 7.5 A˚ and 17.4 A˚, re-
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spectively. The chosen length of the β-strands was 9 aa: 5 aa for the strand itself plus
2 aa at the N-term and 2 aa at the C-term in order to form the loop connection in the
following steps of design (see Loop Closure, in Sections 3.2.3, page 176). The chosen
length of the α-helices was 21 aa: 16 aa for the helix itself plus 3 aa at the N-term and 2
aa at the C-term. The localization in space of the ﬁrst β-strand was set at 0.0 rad on the
β-circumference with r0=7.5 A˚, and the following strands were positioned at intervals
of 0.78539816 rad (that equals to 1/8th of circumference in radians). In a similar way,
the ﬁrst α-helix was set at 5.890486230 rad on the α-circumference with r0=17.4 A˚ and
the following were positioned at intervals of 0.78539816 rad. The orientation and the
inclination of the secondary structure elements were found by comparison with natural
TIM-barrel. For helices, the orientation around the helical axis was set at 3.14 rad and
the inclination at 0.04 rad. For the strands, the inclination value was set at 0.32 rad,
while the orientation value diﬀered for even and odd elements: respectively 4.31 rad and
1.57 rad. The vertical shift values was set 0.25 aa for even strands and 1 aa for odd ones.
All these parameters were inserted in the PARAMETER ﬁle, one of the 3 input ﬁles
necessary to run the program. The second input was a FASTA ﬁle to assign side-chains to
each residue (in our case, all the residues will be Ala), and the last one was the OPTION
ﬁle, in order to deﬁne the number of output (one in our case), the energy function for the
scoring (talaris2014), and other standard option required by the software. The command
line and the 3 input ﬁles are reported in Annex 6.5.3, page 245.
3.2.2 Alanine substitution
The alanine substitution was performed with the Design package of Rosetta software
(version 2015.19.57819 bundle). The program required as inputs a PARAMETER ﬁle, an
OPTION ﬁle, a pdb ﬁle and a RESFILE that contains the instructions for the amino acid
substitution. Description of the RESFILE usage is reported in Section 6.1, page 231.
Alanine substitution was divided into 4 steps, according to the structure layer: core,
boundary, surface and loop. This separation was necessary to create multiple combina-
tions of amino acids and increase the sequence variability; trials with a single step of
substitution resulted in low sequence diﬀerentiation. The substitution instructions corre-
spond to the overall characteristics of globular proteins, in which the hydrophobic core
is mainly composed by apolar residues, the protein surface by polar amino acids and the
boundary regions by a mix of both. Loops can be composed by both apolar and polar
residues depending on their position, so they can be considered as “boundaries”. How-
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ever, in this work, we separated loops from “rigid” boundaries (belonging to structured
α-helices or β-strands) in order to avoid larger residues in the loop (W,F,Y and K), and
to avoid ﬂexible residues in the rigid structure (G,A).
All the steps shared the same PARAMETER and OPTION ﬁles while the RESFILE
and the input pdb were changing. RESFILEs for the alanine substitution are shown in
Section 6.5.4, page 247.
The ﬁrst step of alanine substitution targeted the hydrophobic core of the protein: 7
residues of each β-strand and 5 of each α-helix that faces the internal β-barrel, for a total
of 96 out of 240 aa. The input pdb was the output of the parametric design described in
Section 2.2.1, page 45. 200 outputs were produced and ranked by energy score by Rosetta.
The substitution instructions (RESFILE 1) were:
- 4 residues on each β-strand that face the center of the barrel, can be substituted
only with valine (V), isoleucine (I) or leucine (L).
- 3 residues on each β-strand that face the α-barrel, can be substituted with any apolar
amino acid with the exception of glycine (G) and cysteine (C).
- 5 residues on each α-helix that face the β-barrel can be substituted with any apolar
amino acid with the exception of glycine (G) and cysteine (C).
The second step targeted the boundary amino acids between the hydrophobic core and
the hydrophilic surface of the protein, 40 out of 240 aa. 8 input pdb were chosen between
the best of the previous step for the energy score and, for each of them, 50 outputs were
produced and ranked. The substitution instructions (RESFILE 2) were:
- 5 residues on each α-helix, can be substituted with any amino acid with the exception
of alanine (A), prolines(P), glycine (G) and cysteine (C).
The third step targeted the amino acids on surface of the protein, 40 out of 240 aa.
24 input pdb were chosen between the best of the previous step for the energy score and,
for each of them, 50 outputs were requested. The substitution instructions (RESFILE 3)
were:
- 5 residues on each α-helix can be substituted with any polar amino acid with the
exception of glycine (G) and cysteine (C).
The fourth step targets the amino acids that will form the loops of the protein, 64
out of 240 aa. 50 input pdb structures are chosen between the best of the previous step
for the energy score and, for each of them, 80 outputs are requested. The substitution
instructions (RESFILE 4) are:
- 2 residues on each β-strand and 6 on each α-helix can be substituted with any amino
acid with the exception of glycine (G), cysteine (C), tryptophan (W), tyrosine (Y), lysine
(K) and phenylalanine (F).
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After each step, the models were checked for sequence duplicates (redundant outputs
were discarded), and for energy score. At the end of the substitution, a total of 3968
diﬀerent models were created.
Command lines and PARAMETER, OPTION and RESFILE ﬁles are reported in
Annex 6.5.4, page 247.
3.2.3 Loop closure
Loop closure was performed with the package Loopmodel of Modeller. The program
formed the loop connection bringing the selected residues of the ﬁrst and of the second
chain close enough in space to form a peptide bond. Two residues were selected from the
strand, at both N- and C-termini, and three from the helix. Out of this 5, one was the
boundary residue with the β-strand, one with the α-helix and the central ones are the
ﬁnal loop.
For each of the 3968 models an instruction ﬁle was prepared (details in Annex 6.5.5,
page 255). Instructions included the input pdb name, the method to use (loopmodel),
the residue number at the beginning and at the end of the connection and the number
of outputs (one). In our case the ﬁrst loop was formed from aa 8 to 12; the second loop
from aa 27 to 31, etc. The residues that were involved in the loop formation were shortly
minimized by the program, but not the α-helices and β-strands.
3.2.4 Energy minimization
Energy minimization of the 3968 models was performed with the package Relax of the
Rosetta software (version 2015.19.57819 bundle). The program required as input only
the pdb ﬁles of interest and produced as outputs the relaxed pdb and a ﬁle with the
corresponding energy scores.
The option relax:constrain relax to start coords was used in order to restrict
the relaxation to the initial coordinates of the structure.
3.2.5 Sequence design
28 backbone structures were selected among the 3968 models (see Section 2.2.6,
page 52) and were subjected to 10 cycles of sequence design and energy minimization
with the packages Design and Relax of Rosetta, (version 2015.19.57819 bundle).
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The ﬁrst cycle of design targeted the 96 aa that form the hydrophobic core of the
proteins (see Section 3.2.2 for details, page 174), and allowed them to be changed in any
apolar residue. For each input structure, 100 outputs were requested, for a total of 2800
structures. After energy minimization, the models were checked for sequence redundancy
and ranked by both total energy and RMSD against the initial structure. 106 were se-
lected based on the best score in both categories, at least 3 models from each of the 28
initial families.
2nd-4th cycles targeted all the 240 aa of the selected 106 models. The 96 residues of
the core layer were allowed to be changed only in apolar aa, the 40 residues of the surface
layer only in polar aa and the 104 aa of boundaries and loops layers in any residue. For
each input, 10 outputs were requested. After 3 cycles of design and energy minimization,
the models were checked for sequence redundancy, ranked for total energy and for the
RMSD against the initial structures, and 88 best candidates were selected, at least 2 for
each of the 28 input structure.
5nd-7th cycles targeted all the 240 aa of the selected 88 models, with the same re-
strictions described in the previous paragraph. For each input, 10 to 15 outputs were
requested. After 3 cycles of design and energy minimization, the models were checked
for sequence redundancy, ranked for total energy and for the RMSD against the initial
structures, and 80 models were selected for each of the input structure.
8nd-10th cycles targeted all the 240 aa of the selected 80 models and allowed them to
be changed in any other residue without restrictions. For each input, 35 outputs were
requested.
Command lines and PARAMETER, OPTIONS and RESFILE ﬁles containing the in-
struction for each layer of the proteins are reported in Section 6.5.7, page 256.
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3.3 In silico validation
For experimental validation, 10 out of 7949 models were selected in 6 consecutive steps
by in silico validation. Each step was ﬁrst applied to the natural TIM-barrel collection
(Section 2.1.1, page 33) in order to establish cut-oﬀ values that were then applied to the
artiﬁcial models. The ﬁrst 4 steps of validation were already described in the previous
sections: analysis of the total energy (Step 1) and β-energy (Step 2) in Section 3.1.3,
page 170; analysis of amino acid composition (Step 3) and properties (Step 4) in Sec-
tion 3.1.4, page 171. Secondary structure prediction (Step 5) and molecular dynamic
simulations (Step 6) are described in this chapter.
3.3.1 Secondary structure prediction
Secondary structure predictions were performed with SSpro and Jpred4. For both
programs, the predictions are based on the amino acid propensity to form α-helix and
β-strands, but SSpro also integrates evolutionary information that increases the precision
of the prediction for natural proteins.
SSpro was installed and run locally. Fasta sequences were the input ﬁles and each
residue of the protein was assigned to one of three structural elements: C for coil (un-
structured regions), H for α-helix and E for β-strand. For example, the SSpro output of





JPred4 is a web-service, and the fasta sequences were uploaded to the web-site (the
web-link is reported in Annex 6.1, page 231). Outputs included both the amino acid
sequence and the secondary structure prediction, and diﬀerently from SSpro, unstructured








Output ﬁles of both SSpro and JPred4 were modiﬁed afterwards to annotate the un-
structured regions with the identiﬁer “L”, and then compared with the DSSP outputs
180 CHAPTER 3. COMPUTATIONAL PROTOCOLS
(that use the “L” identiﬁer). JPred4 and SSpro assigned the secondary structure ele-
ments based on the amino acid sequence, while DSSP assigned them based on the 3D
coordinates of pdb structure ﬁles (See Section 3.1.2, page 169). If the residue has the
same conformation in the comparison between SSpro and DSSP or between JPred4 and
DSSP the prediction is considered valid, otherwise not.
The pool of natural TIM-barrels was analyzed and for each software a cut-oﬀ value
was chosen for the evaluation of the artiﬁcial sequences.
3.3.2 Molecular dynamics
Molecular dynamic simulations were done with GROMACS. The procedure consisted
in 7 steps: the ﬁrst six for the preparation of the protein structure and its environment,
and the last one for the proper simulation. Command lines and PARAMETER ﬁles for
each step are reported in Annex 6.5.8, page 275.
1. Generate the topology: pdb structure ﬁles (downloaded from RCBS-PDB or
created with Rosetta) cannot be used as input ﬁles by GROMACS directly, they
have ﬁrst to be converted into the GROMACS format (topology ﬁles), that includes
information on atom type, charges, bonds, angles, dihedral angles, force-ﬁelds and
water-type. The program pdb2gmx, included in the GROMACS package, was used
to transform the pdb ﬁles in topology ﬁles. The force-ﬁeld in all the simulations
was AMBER99SB, and the water-type was TIP3P.
2. Add periodic boundaries: the program editconf of the GROMACS package
was used to create a “box” around the protein in order to deﬁne the dimensions of
the simulation. The choice of the box geometry is important, because the number
of atoms in the box directly inﬂuences the time of the simulation. For this reason
a dodecahedron shape was chosen, which has 30% less of volume compared to the
cubic shape. The box was created at least at 1 nm distance from the protein atoms.
3. Add water molecules: all simulations were performed in an aqueous environment.
Water molecules were added with the package solvate of GROMACS arranged in
multiple layers around the surface of the protein.
4. Add ions: ions were added to the system to mimic the eﬀect of buﬀer solutions
and to balance the charges present on the protein surface. Na+ and Cl− atoms were
added to the system (protein + water) with the package genion of GROMACS, to
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mimic a ﬁnal concentration of 150 mM NaCl, which will be used in experimental
conditions.
5. Energy minimization: to remove overlapping atoms, clashes or empty regions
which may have been created in the previous steps, energy minimization was run
on all the atoms of the system (protein, water and ion). The package for energy
minimization was mdrun, included in GROMACS.
6. Temperature and pressure coupling: after energy minimization the protein
structure is ready for the simulation, however the solvent is still not completely
equilibrated and oriented in the correct way. Simulations in these conditions can
collapse the system and 2 steps of equilibration are recommended: ﬁrst temperature
and then pressure coupling. In both cases the protein structure was restricted in its
position while the solvent molecules and ions were free to move around the protein.
When temperature was reached, pressure was applied to the system in order to
reach the proper density. As for the energy minimization, the package mdrun was
used.
7. Molecular dynamic simulation: after preparation of the structure, addition of
water molecules and ions, energy minimization and equilibration, the system is ready
for the simulation. It lasted 50 ns, with 25x106 steps of 2 fs each. Atom coordinates,
velocities and energies were saved every 10000 fs, for a total of 5000 data-points.
The package used for the simulation was mdrun.
Molecular dynamics is time-consuming and it is not possible to simulate all the 598
models that are left after the ﬁrst 5 steps of in silico validation. For each of the 28 Families,
the best model in terms of Rosetta energy scores was selected for the simulation. Two
natural TIM-barrels (1K77 of 260 aa and 4AAJ of 200 aa) and the model of the artiﬁcial
TIM-barrel described in Section 1.4.2, page 30, (sTIM-11 of 184 aa) were simulated as
positive controls. The model of Octarellin V.1, described in Section 1.3.5, page 24, was
simulated as negative control.
3.3.3 Sequence Alignment
The 10 models that were chosen for experimental validation (see Section 2.3.9, page 68)
were tested for sequence alignment against a not-redundant database of natural protein
sequences with BLAST (web-link, page 231).
Fasta sequences were pasted into the “Enter Query Sequence” box and “Non-redundant
protein sequences (nr)” was selected in the “Database” drop down menu. None of the
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other options were selected and the “BLAST” button was chosen to start the alignment.
3.3.4 Cysteine removal
Cysteine removal was done with Rosetta, a round of Design, to substitute the side-
chain atoms, followed by a round of Energy Minimization, to relax the structure. The
procedure is the same that was used in the Sequence Design chapter (Section 2.2.6,
page 52). OctaVII 04 contained 6, OctaII 05 contained 3, OctaVII 06 contained 2, Oc-
taVII 09 contained 5 and OctaVII 07, OctaVII 08 and OctaVII 10 contained 6 cysteines
each. Command lines and OPTION, PARAMETERS and RESFILE ﬁles are reported in




4.1.1 Chemicals and consumables
Chemicals have been purchased from the following suppliers: Carl Roth, Filter Com-
pany, Merck Chemicals, MP Biomedicals, Thermo Fisher Scientiﬁc and VWR. Consum-
ables have been purchased from the following suppliers: BD Medical Technology, Filter
Company, Rocc, Sarstedt and VWR.
4.1.2 Commercial kits, enzymes and buﬀers
Commercial kits, enzymes and buﬀers are reported in Table 4.1.
Name of kit or enzyme Supplier Method
NcoI, 10000 units/mL NEB DNA Digestion
XhoI, 20000 units/mL NEB DNA Digestion
Buﬀer SmartCut, 10x NEB DNA Digestion
NucleoSpin® Gel and PCR Clean-up Macherey-Nagel DNA puriﬁcation
T4-DNA Ligase Bioke Ligation
T4-DNA Ligase Buﬀer Bioke Ligation
GeneJET Plasmid Miniprep Kit Thermo Fisher Scientiﬁc Plasmid puriﬁcation
NucleoBond® Xtra Midi/Maxi Macherey-Nagel Plasmid puriﬁcation
QuickChange II XL Site-Directed Mutagenesis Kit Agilent Technologies Mutagenesis
Midori Green Advance Nippon Genetics Europe Agarose electrophoresis
Gel Loading Dye Purple 6x NEB Agarose electrophoresis
O’GeneRuler 1kb DNA ladder Thermo Scientiﬁc Agarose electrophoresis
Benzonase, 250000 units/mL Merck Protein extraction
Precision Plus™ Unstained Protein Standards Bio-Rad SDS-PAGE
Unstained Protein Molecular Weight Marker Thermo Scientiﬁc SDS-PAGE
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Name of kit or enzyme Supplier Method
His-Tag Antibody HRP Conjugate kit Merck Chemicals Western-Blot
Clarity™ Western ECL substrate Bio-Rad Western-Blot
Gel Filtration Calibration Kit GE Healthcare Protein puriﬁcation
Table 4.1: Commercial kits, enzymes and buﬀers
4.1.3 Primers
Primers for sequencing and for in-situ mutagenesis are reported in Table 4.2.
Primer Name Length Sequence Method
T7 prom 20 nt TAATACGACTCACTATAGGG Sequencing
T7 term 19 nt CTAGTTATTGCTCAGCGGT Sequencing
Y57Q forward 39 nt CAGAGCTGGCACGTGATCAGAGCTGTGGTGGTATGGGTC Mutagenesis
Y57Q reverse 39 nt GACCCATACCACCACAGCTCTGATCACGTGCCAGCTCTG Mutagenesis
Table 4.2: Oligonucleotides
The Y57Q pair of primers are used to introduce a site point mutation in OctaVII 02.
The codon “TAC”, that codiﬁes for a tyrosine (Y), is changed in “CAG”, that codiﬁes for a
glutamine (Q). This codon is reported in bold to highlight the losation of the mismatching
nucleotides.
4.1.4 Bacterial strains
Commercial E. coli competent cells are reported in Table 4.3.
Strain Genotype Supplier Method
BL21 (DE3) fhuA2 ompT gal γ DE3 [dcm] ΔhsdS NEB Protein production
DG1 mcrA ΔM15 ΔlacX74 recA1 araD139 Δ(ara-leu)7697 Eurogentec Plasmid replication
Table 4.3: E. coli strains
4.1.5 Growth media
Media for bacterial growth are reported in Table 4.4. All media were autoclaved prior
to use.
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Medium Components Concentration Method
LB broth
Tryptone 10.0 g/L























Table 4.4: Growth media
4.1.6 Kanamycin
Kanamycin stock was prepared dissolving 1 g of kanamycin-sulphate powder in 20
mL of mQ water and ﬁltering the solution with 0.22 µm ﬁlters. Aliquots of 1.5 mL were
prepared and frozen for later use. The kanamycin stock of 50 mg/mL was diluted to a
ﬁnal concentration of 50 µg/mL.
4.1.7 IPTG
Isopropyl-3-thiogalactopyranoside (IPTG) stock was prepared dissolving 4.76 g of
IPTG powder in 20 mL of mQ water and ﬁltering the solution with 0.22 µm ﬁlters.
Aliquots of 1.5 mL were prepared and frozen for later use. The IPTG stock of 1 M was
diluted to a ﬁnal concentration of 1 mM.
4.1.8 Buﬀers
Buﬀers were prepared with fresh mQ water and their pH was adjusted with hydrochlo-
ric acid (HCl, 37%) and sodium hydroxide (NaOH, 5 N). Buﬀers are listed in Table 4.5.









Sample buﬀer 2, pH=7
Na2HPO4 50 mM
NaCl 150 mM
Sample buﬀer 3, pH=8
Na2HPO4 50 mM
NaCl 150 mM
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4.2 Vector construction
4.2.1 Gene and vector design
The vector chosen for E. coli protein production is pET28a by Novagen, that carries a
T7lac promoter, a kanamycin resistance gene and a 6-His Tag that can be added at both
the N- or/and the C- terminal parts of the protein. The restriction sites chosen for gene
insertion are NcoI at the 5’ and XhoI at the 3’ of the gene. The target sequence of the
NcoI restriction site is CCATGG. It contains the starting codon ATG that codiﬁes for
the initial methionine and it forces the use of a triplet GXX in the second amino acid
position. Valine, alanine, aspartic acid, glutamic acid and glycine are the residues codiﬁed
by the GXX triplet. OctaVII 01, OctaVII 05 and OctaVII 09 had allowed residues and
only the methionine was added at the N-terminal part of the sequence. The remaining
OctaVIIs were not compatible with the restriction site sequence and two residues were
added at the N-term of the proteins: methionine and glycine.
The XhoI restriction site was necessary in order to insert the 6-His Tag coding sequence
at the 3’ part of the gene sequence. It involved the addition of 2 codons for leucine and
glutamic acid (LE) between the gene and the 6x His-tag coding sequence. In total, 8
residues are added at the C-terminal part of the protein. In Table 4.6 there is a summary
of the genes design and in Figure 4.1 there is an example of the ﬁnal construct.
Figure 4.1: pET28a-OctaVII vector
Representation of the ﬁnal construct pET28a-OctaVII. In evidence there are the sequences for sequencing
(T7-prom and T7-term), restriction sites for the insertion of the OctaVII genes (NcoI and XhoI), the 6x
His-tag coding sequence and the kanamycin resistance gene. The picture is realized with PlasMapper
[141].
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The ﬁnal amino acid sequences of the 10 OctaVII were retro-translated to nucleotide
sequences with the program “Codon Optimization Tool” of Integrated DNA Technologies
(IDT), the company that synthesizes the gene fragments. The program is available at:
www.idtdna.com/CodonOpt, and the amino acid sequences were pasted in the “Single
Entry” box. The options “Amino Acids”, “gBlocks Gene Fragments” and “Escherichia
coli K12” were chosen for the queries “Sequence Type”, “Product Type” and “Organism”,
respectively.
Gene sequences for OctaVII 01 to OctaVII 05 were synthesized and directly cloned in
the pET28a vector by IDT, while OctaVII 06 to OctaVII 10 were synthesized by IDT as
DNA fragments of 750 nb, called gBlocks®, and cloned in vector by us (see Section 4.2.2,
page 190). In each gBlock®, the gene sequence of the OctaVII is 723 or 726 nb long. The
remaining 24 nb are ﬂanking region with the exact sequence of the pET28a vector, 12 nt
upstream the NcoI and 12 nt downstream the XhoI restriction sites. Gene sequences for
each OctaVII are reported in Annex 6.4, page 241.
N-term aa C-term aa Total Length Order type
OctaVII 01 M- -LEHHHHHH 249 plasmid
OctaVII 02 MG- -LEHHHHHH 250 plasmid
OctaVII 03 MG- -LEHHHHHH 250 plasmid
OctaVII 04 MG- -LEHHHHHH 250 plasmid
OctaVII 05 M- -LEHHHHHH 249 plasmid
OctaVII 06 MG- -LEHHHHHH 250 gBlocks®
OctaVII 07 MG- -LEHHHHHH 250 gBlocks®
OctaVII 08 MG- -LEHHHHHH 250 gBlocks®
OctaVII 09 M- -LEHHHHHH 249 gBlocks®
OctaVII 10 MG- -LEHHHHHH 250 gBlocks®
Table 4.6: Post-design modiﬁcations to the protein sequence
4.2.2 Digestion with NcoI and XhoI
gBlocks® with 500 ng of DNA fragments for the genes of OctaVII 06 to 10 were
shipped by IDT as dry pellet. Centrifugation at 4000 rpm was done for 5 seconds to
collect the DNA at the bottom of the tube, that was then resuspended in 20 µL of auto-
claved and ﬁltered mQ water. The ﬁnal concentration of the gBlocks® solution was 25
ng/µL.
The 5 gene fragments and the pET28a plasmid were digested with NcoI and XhoI as
ﬁrst step in the vector construction. pET28a vectors were available in the stock of the
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lab. The reaction mix (for both gBlocks® and plasmid) is reported in Table 4.7. The
reaction tubes were incubated at 37◦C for 1 hour.
gBlocks® pET28a
Buﬀer SmartCut (10x) 5 µL 5 µL
NcoI (10 U/µL) 1 µL 1 µL
XhoI (10 U/µL) 1 µL 1 µL
DNA 125 ng 1 ug
Total 50 µL 50 µL
Table 4.7: Digestion mixes
4.2.3 DNA clean-up
The digested gBlocks® fragments and pET28a plasmids were puriﬁed from the re-
striction enzymes using the NucleoSpin® Gel and PCR Clean-up Kit by Macherey-Nagel
according to the protocol of the supplier. DNA was eluted in autoclaved and ﬁltered mQ
water.
4.2.4 DNA quantiﬁcation
DNA ﬁnal concentrations were measured with the NanoVue Plus instrument by GE
Healthcare using 4 µL of DNA solution. The concentrations of the gene fragments are
reported in Table 4.8.
4.2.5 Ligation
The ligation was performed with the T4 Ligase enzyme in the T4 Ligase Buﬀer and the
20 µL reaction mixes are reported in Table 4.8. Sample tubes were left at 4◦C overnight
and the reactions were completed at room temperature for 30 min in the morning, fol-
lowing an home made protocol that is widely used in the laboratory.
[DNA] Insert pET28a Buﬀer T4 Ligase mQ water
OctaVII 06 28.5 ng/µL 3 µL 1.25 µL 2 µL 1µL 12.75µL
OctaVII 07 17.0 ng/µL 5 µL 1.25 µL 2 µL 1µL 10.75µL
OctaVII 08 27.5 ng/µL 3 µL 1.25 µL 2 µL 1µL 12.75µL
OctaVII 09 23.9 ng/µL 4 µL 1.25 µL 2 µL 1µL 11.75µL
OctaVII 10 22.0 ng/µL 4 µL 1.25 µL 2 µL 1µL 11.75µL
pET28a 76.5 ng/µL / / / / /
Table 4.8: DNA concentrations and ligation mixes
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4.2.6 DNA agarose gel electrophoresis
Agarose gels were prepared melting in a microwave 1 g of agarose in 100 mL of TAE
buﬀer (see Table 4.5). 10 µL of Midori Green Advance 10000x from Nippon Genetics
Europe were added to the solution, and then poured in the electrophoresis chamber with
a 6-wells comb inserted to generate the loading wells. DNA samples were mixed with Gel
Loading Dye, Purple 6x by NEB, and loaded in the wells. 5 µL of O’GeneRuler markers
by Thermo Fisher were added in a separated well. The voltage was set at 110 V and the
electrophoresis lasted 30 min. DNA bands could be detected with a Gel Doc EZ Imager
machine by Bio-Rad.
4.2.7 Site-directed mutagenesis
Site-directed mutagenesis was performed with the kit QuickChange II XL Site-Directed
Mutagenesis from Agilent Technologies. The primers Y57Q forward and reverse were
designed following the instruction of the supplier and are reported in Table 4.2 in the
Material chapter.
The procedure for the site-directed mutagenesis is described in the supplier protocol.
After transformation, diﬀerent clones were subjected to sequencing in order to conﬁrm
the presence of the mutation (see Section 4.3.4, page 193).
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4.3 Transformation and sequencing
4.3.1 Transformation
Transformation was performed with all the 10 pET28a-OctaVII vectors in both BL21(DE3)
and DG1 E.coli competent cells. Aliquots of 50 µL of competent cells were mixed with
10-100 ng of pET28a-OctaVII vector and incubated in ice for 30 min. Cells were then
heat-shocked at 42◦C for 30 s and immediately transfered in ice for 5 min. 200 µL of
room-temperature SOC medium was added to the competent cells and the mixtures were
incubated at 37◦ for 60 min in shaking condition (250 rpm). 100 µL of cells culture were
then spread onto selection plates (LB-Kan) and incubated overnight at 37◦C.
4.3.2 Plasmid replication
E. coli DG1 transformants were used to produce the plasmid for sequencing and
storage. Colony picking of 2 to 4 colonies for each OctaVII was done in 5 mL of fresh
LB-Kan medium. The culture was grown for ∼8 hours at 37◦C in shacking conditions
(200 rpm). For a mini-preparation, 100 µL of culture were transferred into 5 mL of fresh
LB-Kan medium. For a maxi-preparation, 4 mL of culture were transferred into 200 mL
of fresh LB-Kan medium. In both cases, the ﬂask were kept overnight at 37◦C in shacking
conditions (200 rpm).
4.3.3 Mini and maxi prep
Extraction of the plasmid from E.coli DG1 cells was done with two diﬀerent kits:
GeneJET Plasmid Miniprep Kit by Thermo Fisher Scientiﬁc for 5 mL cultures, and Nu-
cleoBond® Xtra Midi/Maxi by Macherey-Nagel for 200 mL cultures. In both cases the
elution of the plasmid was done in ﬁltered and autoclaved mQ water. Plasmid concen-
trations were measured as described in Section 4.2.4, page 191.
4.3.4 Sequencing
Sequencing of the OctaVII genes was done by the platform Sanger Cycle Sequencing of
the GIGA-Genomics department at the University of Lie`ge. Each plasmid was sequenced
twice, in the forward direction with T7 prom primer and in the reverse direction with the
T7 term primer. Each reaction mix was composed by 10 µL of primer 5 µM and by 10
µL of template pET28a-OctaVII 40-50 ng/µL.
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4.4 Protein expression trials and production
4.4.1 Protein expression trials
After gene sequencing, the correct sequences were selected and used for transformation
of BL21(DE3) E.coli cells (see Section 4.3.4 for details, page 193). Expression trials were
done considering diﬀerent induction times: 1h, 2h, 3h and 4h at 37◦C or overnight at
18◦C. Colonies were picked from the plates and grown for ∼8 hours at 37◦C in shacking
conditions (200 rpm). Cultures were done with a dilution 1:100 in 25 ml of fresh LB-Kan
medium in the same conditions. Induction with IPTG 1 mM was done at 37◦C for 1h, 2h,
3h or 4h or at 18◦C overnight. At the end of the induction, cultures were diluted to reach
Abs600=0.6. Aliquots of 1 mL were centrifuged 5 min at 6000 rpm and the supernatant
was discarded.
4.4.2 Sonication
The cell pellets of the expression trials were resuspended in 300 µL of Wash buﬀer
2 (see Section 4.1.8, page 185) and the proteins were extracted by sonication with the
machine BioRuptor Plus by Diagenode. Each sample underwent to 10 cycles of 1 min (30
s of sonication and 30 s of pause) at 4◦C. Aliquots of the crude extract (or total fraction,
T) were centrifuged at 14000 rpm for 20 min at 4◦C to produce the soluble fraction (S)
and the insoluble fraction (I). Inclusion bodies were collected in the insoluble fraction.
Analysis of the expression trials was performed by SDS-PAGE, see Section 4.5.1, page 195
for details.
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4.5 Blotting techniques
4.5.1 SDS-PAGE
Sodium Dodecyl Sulphate Poly Acrylamide Gel Electrophoresis (SDS-PAGE) was used
to separate proteins according to their molecular mass.
Gel preparation
During this project, both commercial and home-made polyacrylamide gels were used.
Commercial polyacrylamide gels (Mini-PROTEAN® TGX™ Precasted Gel by Bio-Rad)
presented a gradient from 4% of acrylamide in the top of the gel to 20% at the bottom.
Home-made poly-acrylamide gels were composed of 2 parts, the stacking gel for the loading
of the samples with 4% of acrylamide, and the running gel for the separation of the protein
with 12% of acrylamide. 2 gels were prepared with the following reagents:
Running Gel (12%) Stacking Gel 4%
mQ water 3.4 mL 3.2 mL
Tris (1.5 M pH=8.8 / 0.5 M pH=6.8) buﬀers 2.5 mL 1.5 mL
Acrylamide / Bis-acrylamide 4 mL 1.2 mL
SDS 10% 100 µL 60 µL
Ammonium Persulfate 10% 100 µL 60 µL
TEMED 10 µL 6 µL
Table 4.9: Acrylamide gels preparation
Sample preparation
Sample solutions were mixed with SDS-PAGE Loading buﬀer (see Table 4.5) and
heated at 95◦C for 5 minutes. After a short spin-down, 20 or 10 µL of sample were
loaded in the wells of the gel, depending on their capacity. 5 µL of marker (Precision
Plus™Unstained Protein Standards by Bio-Rad or Unstained Protein Molecular Weight
Marker by Thermo Scientiﬁc) were added in the gel wells.
Electrophoresis settings
Prior to sample loading, the gels were mounted in the Bio-Rad chamber for SDS-
PAGE. The central chamber was ﬁlled with fresh SDS-PAGE TGS-buﬀer. After sample
and marker loading, the chamber was closed and electrophoresis was performed for com-
mercial gels at 120 V for 30 min. Hand-made gels were run at 100 V for the ﬁrst 30 min
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and at 150 V for the remaining time.
Gel staining
Gels were colored by immersion in the commercial InstantBlue buﬀer by Expedeon for
a minimum of 15 min. The gels did not need decoloration steps and the gels were scanned
with the Gel Doc EZ Imager instrument by Bio-Rad.
4.5.2 Western-Blot
Western blots were done on unstained SDS-PAGE with the His-Tag Antibody HRP
Conjugate kit by Merck Chemicals that targets the histidine tag present at the C-terminal
of the artiﬁcial proteins.
Protein transfer
Protein samples were loaded on SDS-PAGE gels and run as described in Section 4.5.1,
page 195, but they were not stained at the end of the electrophoresis. Instead, the proteins
in the acrylamide gel were transfered to a nitrocellulose membrane with the Trans-Blot
Turbo machine by Bio-Rad.
The transfer pack (or blotting sandwich) was composed of 4 layers: the bottom ion
reservoir, the nitrocellulose membrane, the acrylamide gel and the top ion reservoir. Each
reservoir was composed by 3 Waterman papers soaked in Transfer buﬀer (see Table 4.5
for the composition, page 187). The nitrocellulose membrane was activated by a short
immersion in ethanol 100% and equilibration in the Transfer buﬀer. The blotting sandwich
was inserted into the cassette, in which the bottom and top trays were the anode and the
cathode, respectively.
The program “Mixed MW” was chosen among the pre-programmed protocols of the
Bio-Rad machine since it is well-suited for the transfer of a broad range of molecular
masses (5-150 kDa).
Immuno-blotting
The nitrocellulose membrane was washed twice for 10 min with 15 mL 1x TBS buﬀer
(see Table 4.5, page 187). It was incubated overnight in the blocking solution provided
by the His-Tag Antibody HRP Conjugate kit. It was then washed twice for 10 min in 20
mL TBSTT buﬀer and one more time for 10 min in 15 mL TBS buﬀer. The antibody
included in the kit was diluted 1:1500 in the blocking solution and it was incubated for 1
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hour with the membrane. Three wash of 10 min were then performed, the ﬁrst two in 20
mL TBSTT and the last one in 15 mL TBS.
Chemiluminescent detection
The substrate for chemiluminescent detection was prepared immediately before use
with the Clarity™ Western ECL substrate kit by Bio-Rad. 1 mL of Luminol/Enhancer
was mixed with 1 mL of Stable Peroxide Solution. The membrane was incubated for 1
min in the substrate solution. The chemiluminescence was detected with an ImageQuant
LAS4000 instrument by GE Healthcare after 1 to 10 min exposure.
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4.6 Protein production
4.6.1 Protein production in ﬂasks
Colony picking
Individual colonies were picked with a sterile tip from the selection plate and were
transferred to 5 mL of fresh LB-Kan medium. Culture was grown at 37◦C for 8 to 15
hours in shacking conditions (200 rpm).
Pre-culture
The pre-culture was prepared starting from the 5 mL of the colony picking culture
with a dilution of 1:100 in fresh LB-Kan medium. The pre-culture was grown at 37◦C for
8 to 15 hours in shacking conditions (200 rpm).
Culture
The culture was prepared with a dilution 1:100 of the pre-culture in 2-4 L of fresh LB-
Kan. The culture was grown at 37◦C for 8h or at 18◦C overnight in shacking condition
(200 rpm). Induction was done with a ﬁnal concentration of IPTG of 1 mM at 18◦C
overnight, or at 37◦C for 1-4 hours.
4.6.2 Protein production by fermentation
Colony picking and pre-culture preparation were performed as described in the previ-
ous ection. The minimal volume for the pre-culture preparation was 500 mL.
Cultures of 10 L were prepared in New Brunswick™ BioFlo® 415 fermenters. The
medium 2XYT 2% Glucose was autoclaved directly in the fermenter and the kanamycin
was added together with the pre-culture. The culture was grown for 8h at 37◦C, and
induction was done overnight at 18◦C with 1 mM IPTG.
4.6.3 Cell harvesting
Separation of the cells from the medium was done by centrifugation at 6000 rpm for
10 minutes at 4◦C. The pellet was then resuspended in Wash buﬀer 2 (see Section 4.1.8,
page 185) and stirred for 30 min at 4◦C. Centrifugation was performed in the same
conditions to re-collect the cells that were weighted for the next step of cell disruption.
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4.6.4 Cell disruption
Each gram of pellet was resuspended in 4 mL of Sample buﬀer (1, 2 or 3 depending
on the protein, see Section 4.1.8 for details, page 185). For each liter of culture, 4 µL of
Benzonase were added to the resuspension. The sample was loaded in the Emulciﬂex-C3
homogenizer by ATA Scientiﬁc, and 3 to 4 cycles of disruption were performed. Centrifu-
gation of the crude extract at 20000 rpm for 20 min at 4◦C caused the separation of the
soluble fraction (supernatant) from the insoluble fraction (inclusion bodies).
4.6.5 Inclusion bodies preparation
Inclusion bodies contains many soluble contaminants, and 2 washing cycles with the
Wash buﬀer (see Section 4.1.8, page 185) were recommended. The pellet was collected by
centrifugation at 20000 rpm for 20 min at 4◦C and frozen for later use.
4.6.6 Protein N-sequencing
Sequencing of the N-terminus of OctaVII 02 was done at the University of Lie`ge by
Nicole Otthiers. The instrument is a “Precise Protein Sequencing System” produced
by Perkin Elmer Corporation. The method is based on the sequential degradation of
proteins, developped in the ’50s by Pher Edman. The N-term of the ﬁrst amino acid was
ﬁrst labeled, then cleaved and extracted from the protein solution for identiﬁcation.
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4.7 Protein puriﬁcation
4.7.1 Sample and buﬀer preparation
Prior to any type of puriﬁcation, the sample was centrifuged at 20000 rpm for 20 min
at 4◦C and the supernatant was ﬁltered on 0.22 µm ﬁlters. All the buﬀers used for protein
puriﬁcation were ﬁltered on 0.22 µm ﬁlters.
4.7.2 System preparation
Puriﬁcations were performed with a A¨KTA-Explorer chromatography system by GE
Healthcare. Prior to any type of puriﬁcation, the inlets, the system and the columns were
washed with mQ water in order to remove the EtOH 20%. After equilibration in mQ
water, inlets were washed with the correct buﬀer solution and the column is equilibrated
with the loading buﬀer for 1 to 10 CV.
At the end of the puriﬁcation, the samples were analyzed by SDS-PAGE as described
in Section 4.5.1, page 195.
4.7.3 IMAC for soluble fraction
Column type
The puriﬁcation of the soluble fraction of the crude extract was done with 2x 5 mL
HisTrap HP columns by GE Healthcare. The ﬂow rate and pressure setting were 5 mL/min
and 0.3 MPa respectively. After each puriﬁcation the columns were cleaned and stripped
according to the protocol of the supplier.
Program Setting
The puriﬁcation of the soluble fraction of the crude extract by IMAC was done in 6
steps: 1- short equilibration, 2- sample loading, 3- wash, 4- ﬁrst step of elution at 15%
of Imidazole buﬀer (75 mM), 5- second step of elution by gradient from 15 to 100% of
imidazole buﬀer (0.5 M) and 6- post-elution step in which the imidazole buﬀer is kept
at 100% for 5 CV. The program settings for each step are shown in Table 4.10 and a
schematic gradient proﬁle is shown in Figure 4.2a.
Three inlets were used in this puriﬁcation: A11 for the equilibration buﬀer (Sample
buﬀer), B1 for the elution buﬀer (Elution buﬀer, IMAC) and A12 for the sample loading.
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Step Variable Setting
General setting
Column HisTrap HP 5 mL
FlowRate Equil 5 mL/min
Column PressureLimit 0.3 MPa
Wavelength 1 280 nm
Wavelength 2 260 nm
Averaging Time UV 5.12 sec
BuﬀerValve A1 Inlet A11
1 Column Equilibration
Compensation Volume 8 mL
Equilibrate with 1 CV
FlowRate WashOut 5 mL/min
Flowthrough FracSize 4 mL
2 Sample Loading
SampleInlet A12
Injection Flow rate 5 mL/min
Sample Volume XXX mL
3 Wash
Complete Flow rate 5 mL/min
Complete Sample Load 20 mL
Wash column with 5 CV
4 Elution with 15% imidazole
1 ConcB Step 15 %B
1 Fraction Size 4 mL
1 PeakFraction Size 0 mL
1 Length of Step 4 CV
5 Gradient of elution
2 Fraction Size 4 mL
2 PeakFraction Size 0 mL
2 Target ConcB 100 %B
2 Length of Gradient 20 base
6 Post-Elution
3 ConcB Step 100 %B
3 Fraction Size 4 mL
3 PeakFraction Size 0 mL
3 Length of Step 5 CV
Gradient Delay 8 mL
Table 4.10: Settings for soluble fraction puriﬁcation by IMAC
4.7.4 IMAC for insoluble fraction and refolding
Prior to puriﬁcation, inclusion bodies were dissolved in a denaturing buﬀer overnight
at room temperature. Thanks to the 6x HisTag at the C-term of the proteins it was
possible to perform both the refolding and the puriﬁcation in one single step (called on
column refolding). Elution proﬁles of IMAC puriﬁcation from the soluble and from the
insoluble fractions are shown in Figure 4.2 as example.
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Figure 4.2: Example of IMAC elution proﬁles
(a) Puriﬁcation of the soluble fraction and (b) puriﬁcation and refolding in column of the insoluble
fraction by IMAC chromatography.
Column type
Puriﬁcation and refolding were done with 2x 5 mL HisTrap HP columns by GE Health-
care. The ﬂow rate and pressure setting were 5 mL/min and 0.3 MPa respectively. After
each puriﬁcation the column was cleaned and stripped according to the protocol of the
supplier.
Program Setting
The puriﬁcation and refolding of the inclusion bodies by IMAC was done in 7 steps:
1- short equilibration, 2- sample loading, 3- wash, 4- refolding, 5- short equilibration, 6-
elution and 7- post-elution step in which the imidazole buﬀer is kept at 100% for 5 CV.
The program settings for each step are shown in Table 4.11 and a schematic gradient
proﬁle is shown in Figure 4.2b.
Four inlets were used in this puriﬁcation: A11 for the denaturation buﬀer (Denaturing
buﬀer urea or GdmCl based), B1 for the refolding buﬀer (Sample buﬀer), A12 for the
elution buﬀer (Elution buﬀer, IMAC) and A13 for the sample loading.
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Step Variable Setting
General setting
Column HisTrap HP 5 mL
FlowRate Equil 5 mL/min
Column PressureLimit 0.3 MPa
Wavelength 1 280 nm
Wavelength 2 260 nm
Averaging Time UV 5.12 sec
BuﬀerValve A1 Inlet A11
1 Column Equilibration
Compensation Volume 8 mL
Equilibrate with 1 CV
FlowRate WashOut 5 mL/min
Flowthrough FracSize 4 mL
2 Sample Loading
SampleInlet A13
Injection Flow rate 5 mL/min
Sample Volume XXX mL
3 Wash
Complete Flow rate 5 mL/min
Complete Sample Load 20 mL
Wash column with 5 CV
4 Refolding
InletValve A11
2 Fraction Size 4 mL
PeakFraction Size 0 mL
Target ConcB 100 %B
Length of Gradient 20 base
5 Equilibration
1 ConcB Step 100 %B
Fraction Size 4 mL
PeakFraction Size 0 mL
Length of Step 5 CV
6 Gradient elution
InletValve A12
2 Fraction Size 4 mL
PeakFraction Size 0 mL
Target ConcB 0 %B
Length of Gradient 20 base
7 Post-Elution
InletValve A12
3 ConcB Step 0 %B
Fraction Size 4 mL
PeakFraction Size 0 mL
Length of Step 5 CV
Gradient Delay 8 mL
Table 4.11: Settings for insoluble fraction puriﬁcation by IMAC
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4.7.5 Desalting
After puriﬁcation by IMAC, a step of desalting was necessary to remove imidazole
from the protein sample.
Column type
Desalting was done with a 135 mL Sephadex G-25 column by GE Healthcare. The
ﬂow rate and pressure setting were 5 mL/min and 0.3 MPa respectively.
Program Setting
Desalting of the imidazole sample was done in 3 steps: 1- short equilibration, 2- loading
of the sample and 3- elution. The program settings for each step are shown in Table 4.12.
The inlets A11 was used for the Sample buﬀer. The sample was injected by a loop,
with a maximum volume of 20 mL.
Step Variable Setting
General setting
Column SephadexG25 26/40 135 mL
FlowRate Equil 5 mL/min
Column PressureLimit 0.3 MPa
Wavelength 1 280 nm
Wavelength 2 260 nm
Averaging Time UV 0.01 sec
BuﬀerValve A1 Inlet A11
1 Equilibration
Compensation Volume 8 mL
Equilibrate with 0.1 CV
FlowRate WashOut 5 mL/min
2 Sample Loading
Injection Flow rate 5 mL/min
Empty loop with 30 mL
3 Elution
Elution Flow rate 5 mL/min
Eluate Frac Size 4 mL
Length of Elution 1.5 CV
Table 4.12: Program setting for desalting
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4.7.6 Size exclusion: Superdex75
Size exclusion chromatography (SEC) was performed in two ways. For OctaVII 02 was
used a preparative column, that allows bigger volumes to be loaded and that contributes to
the puriﬁcation of the protein. For the following proteins we decided to use an analytical
column, that uses smaller volumes of sample and that is faster compared to the preparative
one.
Column type
The two columns are: a preparative 120 mL Superdex 75 16/60 column and an ana-
lytical 24 mL Superdex-75 10/300GL column, both by GE Healthcare. The ﬂow rate and
pressure setting for the preparative column were 1 mL/min and 0.5 MPa, while for the
analytical one were 0.5 mL/min and 1.8 MPa.
Program Setting
In both cases, size exclusion was done in 3 steps: 1- short equilibration, 2- loading of
the sample and 3- elution. The program settings for each step are shown in Table 4.13 for
the preparative column and in Table 4.14 for the analytical one. One inlets was used in
this puriﬁcation: A11 for the buﬀer. The sample was injected by a loop, with a maximum
volume of 5 mL for the preparative column and of 500 µL for the analytical one.
Step Variable Setting
General setting
Column Superdex-75 16/60GL 120 mL
FlowRate Equil 1 mL/min
Column PressureLimit 0.5 MPa
Wavelength 1 280 nm
Wavelength 2 260 nm
Averaging Time UV 5.12 sec
BuﬀerValve A1 Inlet A11
1 Equilibration
Compensation Volume 8 mL
Equilibrate with 0.1 CV
FlowRate WashOut 1 mL/min
2 Sample Loading
Injection Flow rate 1 mL/min
Empty loop with 5 mL
3 Elution
Elution Flow rate 1 mL/min
Eluate Frac Size 2 mL
Length of Elution 1 CV
Table 4.13: Settings for preparative SEC
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Step Variable Setting
General setting
Column Superdex-75 10/300GL 23 mL
FlowRate Equil 0.5 mL/min
Column PressureLimit 1.8 MPa
Wavelength 1 280 nm
Wavelength 2 260 nm
Averaging Time UV 5.12 sec
BuﬀerValve A1 Inlet A11
1 Equilibration
Compensation Volume 8 mL
Equilibrate with 0.1 CV
FlowRate WashOut 0.5 mL/min
2 Sample Loading
Injection Flow rate 0.5 mL/min
Empty loop with 500 µL
3 Elution
Elution Flow rate 0.5 mL/min
Eluate Frac Size 1 mL
Length of Elution 1 CV
Table 4.14: Settings for analytical SEC
Column calibration
Calibration was done only for the analytical column with the standards: Aprotinin,
RNAse A, Ovalbumin and Conalbumin of the Gel Filtration Calibration Kit by GE
Healthcare, and the Trypsin Inhibitor by Sigma. Three mixes were prepared:
• Mix A: Aprotinin 100 µL, Ovalbumin 100 µL, Sample buﬀer 100 µL
• Mix B: RNase A 100 µL, Conalbumin 100 µL, Sample buﬀer 100 µL
• Mix C: Trypsin inhibitor 100 µL, Sample buﬀer 200 µL
The three mixes were ﬁltered on 0.22 µm ﬁlters and 100 µL were loaded in the
Superdex-75 column. The elution proﬁle is shown in Figure 4.3a. Molecular weight
of the standards and their elution volumes are reported in Table 4.15.
Standard Molecular weight Elution volume
Aprotinin 6500 Da 15.22 mL
RNAse A 13700 Da 13.46 mL
Trypsin inhibitor 21000 Da 11.94 mL
Ovalbumin 44000 Da 10.21 mL
Conalbumin 75000 Da 9.45 mL
Table 4.15: Calibration standards
The calibration curve was calculated using the equation 4.1, in which Kav is the gel-
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phase distribution coeﬃcient, Ve is the elution volume (reported in Table 4.15), Vc is the
geometric column volume (24 mL) and V0 is the void volume (7.43 mL).
Kav =
Ve − V0
Vc − V0 (4.1)


















































































































































































































































































Figure 4.3: Superdex-75 calibration
(a) Elution proﬁle of the standard proteins for calibration of Superdex-75 column and (b) plot of the
molecular weight versus the gel-phase distribution coeﬃcient (calibration curve).
4.7.7 Concentration
Protein concentration was performed by ultraﬁltration with Amicon® Ultra centrifu-
gal ﬁlters by Merck’s Millipore Ltd with cut-oﬀ of 10 kDa and 15 mL of capacity. The
sample solution was loaded onto the pre-equilibrated membrane and centrifuged at 4000
rpm at 4◦C in 5 min cycles. When the ﬁnal concentration was reached, the sample solution
was centrifuged at 14000 rpm for 30 min at 4◦C and ﬁltered on 0.22 µm ﬁlters.
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4.8 Biophysical Characterization
4.8.1 Absorbance
Absorption spectroscopy is a common technique to evaluate the concentration of a
protein sample. At 280 nm aromatic residues (tryptophan and tyrosine) absorb part of
the incident light, proportionally to the protein concentration. The Beer-Lambert law
(Equation 4.2) explains the correlation between absorbance and protein concentration:
A280 = d · ε · C (4.2)
where A280 is the absorbance at 280 nm, d is the path length (cm), ε is the molar extinction
coeﬃcient (M−1cm−1) and C the molar concentration of the protein sample (M). The





d · ε (4.3)
The molecular mass (MM) and the theoretic ε can be calculated from the amino acid
sequence of the protein. For all the OctaVIIs, the theoretic extinction coeﬃcient (ε),
the molecular mass (MM) and the theoretic isoelectric point (pI) were calculated with
ProtParam by ExPASy (see Table 4.16 for details).
Molecular Mass Theoretic ε Theoretic pI
(Da) (M−1cm−1)
OctaVII 01 28296.93 56950 6.90
OctaVII 02 27504.13 12950 6.46
OctaVII 03 28181.49 41940 6.60
OctaVII 04 27920.87 41480 6.27
OctaVII 04 NC 27930.87 41480 6.27
OctaVII 04 WS 27936.77 34490 6.02
OctaVII 05 28013.08 37930 6.01
OctaVII 05 NC 27974.98 37930 6.01
OctaVII 06 28410.09 42970 8.84
OctaVII 07 27888.90 48470 6.32
OctaVII 08 27811.14 28420 6.18
OctaVII 09 27773.58 23950 6.81
OctaVII 09 WS 27760.62 22460 6.21
OctaVII 10 27802.73 37470 5.90
Table 4.16: OctaVIIs: MW, ε and pI
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Absorbance spectra were recorded with a JASCO V-630 spectrophotometer. The
wavelength range was 230-350 nm, and data were collected at intervals of 1 nm with a
scan speed of 100 nm/min at room temperature. The spectrum of the buﬀer (blanc) was
subtracted to the sample spectrum before calculation of the protein concentration.
4.8.2 Far UV-CD
Circular dichroism (CD) in the far-UV region is a technique that allows evaluation
of the secondary structure content in a protein sample. The principle of the technique
is based on the fact that asymmetric molecules (i.e. proteins) may absorb in a diﬀerent
extend left- and right-handed circularly polarized light. The CD signal is the result of the
diﬀerence in absorption of the two polarized lights, as shown in Equation 4.4.
ΔA = AR − AL (4.4)
where ΔA is the diﬀerence in absorbance (or CD signal) and AR and AL are the ab-
sorbances of right-handed and the left-handed circularly polarized lights respectively. The
Beer-Lambert law, shown in Equation 4.5, is at the basis of the circular dichroism spec-
troscopy:
A = ε · d · C (4.5)
where A is the absorbance, ε the molar extinction coeﬃcient, d the path length and C the
sample concentration. The CD signal is related to the Beer-Lambert law by the following
equation:
ΔA = (εR − εL) · d · C = Δε · d · C (4.6)
where εR and εR are the molar extinction coeﬃcients for right-handed and left-handed
circularly polarized lights respectively, and Δε is their diﬀerence.
For historical reasons, CD is usually expressed in ellipticity (Θ) that is related to ΔA
with the equation:
Θ = 32.98 ·ΔA (4.7)
The ellipticity can be transformed in molar ellipticity ([Θ]) according to the following
equation:
[Θ] =
Θ · 100 ·MM
C · d (4.8)
where MM is the molecular weight of the protein. The CD signal can also be expressed
as mean residue ellipticity ([Θ]MRW ):
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[Θ]MRW =
[Θ]
Naa − 1 (4.9)
where (Naa - 1) is the number of peptide bonds in the protein sample.
CD spectra were recorded with a JASCO J-810 spectropolarimeter at 20◦C, with
a wavelength range between 260 and 185 nm. Protein samples were pipetted in 1mm
pathlength quartz Suprasil cell (Hellma) at a concentration between 0.05 and 0.15 mg/mL
and maximum volume = 300 µL. Four scans (10 nm/min, 1 nm bandwidth, 0.2 nm data
pitch and 1 s DIT) were averaged. The high-tension voltage (HT) was recorded in parallel
to the CD spectrum. If the HT signal was higher than 600 V, the CD signal was not reliable
and those data-point were discarded. The spectrum of the buﬀer (blanc) was subtracted
to the protein spectrum and the CD signal was transformed in mean residue ellipticity
according to the following equation:
[Θ]MRW =
Θ · 100 ·MM
C · d ·Naa (4.10)
4.8.3 Intrinsic Fluorescence
Aromatic amino acids (tryptophan and tyrosine) of proteins can absorb light at 280
nm (excitation wavelength) and release energy through ﬂuorescent emission. Depending
on the environment that surrounds the aromatic residues, the ﬂuorescence emission may
change. This phenomenon is an useful tool to inquire the tertiary structure and the fold-
ing status of proteins.
Fluorescence spectra were recorded on a Cary Eclipse spectroﬂuorimeter by Varian,
with the excitation wavelength at 280 nm and the emission spectrum in the range of
300 to 400 nm. The sample was pipetted in a quartz cuvette of 1 mL of volume, in a
concentration between 0.01 and 0.2 mg/mL.
4.8.4 Chemical Unfolding
Unfolding of protein was measured with both CD and ﬂuorescence techniques with
the sample in diﬀerent concentrations of denaturing agent (GdmCl or urea).
Sample preparation
The samples were prepared with the use of a pipetting robot, Microlab STAR Hamil-
ton, hosted at the Robotein platform of the Center for Protein Engineering (CIP) of the
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University of Liege. Three solutions were requested: the protein sample (minimal con-
centration = 2 mg/mL), the standard buﬀer of the protein and the denaturing buﬀer
(GdmCl 6M or urea 8M). The three solutions were pipetted in a 48-wells plate with 2 mL
of capacity each. The ﬁnal protein concentration was 0.1 mg/mL and the concentration
of the denaturing agent increased from 0 M to the maximum.
Chemical unfolding followed by CD
For each sample, the CD signal was measured on a JASCO J-810 spectropolarimeter
at a ﬁxed wavelength of 222 nm for 60 s. Protein samples were pipetted in quartz cuvettes
of 1 mm of path length (maximum volume = 300 µL) and the recording was done at room
temperature.
The average of the CD signal at 222 nm was plotted versus the concentration of the
denaturant to obtain the unfolding curve of the protein.
Chemical unfolding followed by ﬂuorescence
For each sample, the ﬂuorescence spectrum was recorded with a Cary Eclipse spec-
troﬂuorimeter by Varian in the same conditions as described in Section 4.8.3, page 211.
The intensity of the signal at a ﬁxed-wavelength was plotted versus the concentration of
the denaturing agent to obtain the unfolding curve of the protein. The ﬁxed-wavelength
was chosen as the wavelength at which the diﬀerence between the unfolded and folded
protein spectra is the biggest.
4.8.5 Thermal Unfolding
Temperature-mediated protein unfolding was measured with both CD and ﬂuorescence
techniques. The samples were in the native buﬀer at a ﬁnal concentration of 0.1 mg/mL. A
drop of mineral oil was added in the cuvette to avoid evaporation of the protein sample. A
thermo-coupler sensor (Testo 926 by Testo) was inserted in the protein solution to record
the actual temperature of the sample.
Thermal unfolding followed by CD
A full CD spectrum was recorded at 25◦C before the thermal unfolding experiment
as described in Section 4.8.2, page 210. For the thermal unfolding, the CD signal was
measured on a JASCO J-810 spectropolarimeter at a ﬁxed wavelength of 222 nm. The
initial and ﬁnal temperatures were 25◦C and 95◦C respectively. Temperature increased
at a rate of 0.5◦C per minute. At the end of the thermal unfolding, at 95◦C, a full CD
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spectrum was recorded, as described in Section 4.8.2, page 210. The sample was then
cooled down to 25◦C and another full CD spectrum was recorded.
The CD signal at 222 nm was plotted versus the temperature to obtain the unfolding
curve of the protein. The 3 full spectra were analyzed as described in Section 4.8.2,
page 210.
Thermal unfolding followed by ﬂuorescence
A ﬂuorescence spectrum was recorded before unfolding with a Cary Eclipse spectroﬂu-
orimeter by Varian in the same conditions described in Section 4.8.3, page 211. Then the
ﬂuorescence was measured at a ﬁxed-wavelength from 25◦C to 95◦C, with a speed of 0.5◦C
per minute and from 95◦C to 25◦C, at the same speed. At the end of the experiment a
full ﬂuorescence spectrum (described in Section 4.8.3, page 211) was recorded.
4.8.6 Near UV-CD
Contrary to the far-UV CD that measures secondary structure percentages in the
protein sample, near-UV CD give information on the tertiary structure of the protein.
The diﬀerence is due to the diﬀerent targets of the 2 techniques, the ﬁrst works on the
peptide bonds, while the latter on the aromatic amino acids (tryptophan, tyrosine and
phenylalanine).
Near-UV spectra were recorded on a JASCO J-810 spectropolarimeter with a wave-
length range between 250 and 340 nm. Protein samples were pipetted in quartz cuvettes
of 10 mm of path length (volume ≥ 1.7 mL) at a concentration between 0.5 and 2.5
mg/mL. The recording was done at room temperature and the spectrum of the buﬀer
(blanc) was subtracted to the protein spectrum.
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4.9 Crystallization
Protein crystallization was tested with the sitting drop vapor diﬀusion method. Water
in the protein solution evaporates in order to equilibrate with solution in the reservoir,
that is more concentrated. This vapor diﬀusion leads to a slow concentration of the pro-
tein sample, that eventually will form crystals.
480 diﬀerent combinations of buﬀers, salts, pHs and detergents were tested with the
use of the Mosquito robot by TTP Labtech, hosted at the Biological Macromolecule
Crystallography lab at the Center of Protein Engineering (CIP) of the University of Liege.
iQ-plates from TTP Labtech contains 96-wells, and each of them is divided into 4
sections: a reservoir that contains 40 µL of buﬀer solutions and 3 spots of 0.6 µL for
the protein drops. Crystallization kits for the 480 diﬀerent conditions are reported in
Table 4.17.
Once the plates were ﬁlled by the robot, they were hermetically closed with a ﬁlm in
order to create a closed system. The preparation and the storage of the crystallization
plates were done at a constant temperature of 20◦C. Plates were visually inspected at 3,
7 and 30 days after the preparation and every following months.
Kit name Producer Conditions
Crystal Screen Hampton Research 48
Crystal Screen 2 Hampton Research 48
Index Hampton Research 96
Wizard Classic Emerald 48
Wizard Classic 2 Emerald 48
Salt CIP 96
SPE CIP 96
Table 4.17: Crystallization kits
Chapter 5
Conclusions and perspectives
Protein de novo design is a recent and challenging research area. In this work we
presented the design of a new generation of Octarellins, artiﬁcial proteins modelled on
the TIM-barrel fold. More than 8000 diﬀerent sequences have been created with the
software Rosetta and Modeller. They have been tested and ranked according to dif-
ferent parameters: the Rosetta energy, the amino acid composition, the prediction of
secondary structures and molecular dynamic simulations. 10 among them have been cho-
sen for experimental validation, and 5 mutants have been created meanwhile. During the
experimental validation, we faced many issues that were not predictable during the de-
sign, as non-expression of the protein (OctaVII 01), N-terminal truncations (OctaVII 02,
OctaVII 03 and OctaVII 07), and high insolubility of inclusion bodies (OctaVII 06 and
OctaVII 08).
OctaVII 01 is not expressed in E. coli BL21(DE3) cells, and we showed that cells
carrying this plasmid grow slower compared to cells with the OctaVII 02 gene (see Fig-
ure 2.57). These results suggest that the metabolism of the cell is altered by the presence
of OctaVII 01 construct. In order to obtain the expression of OctaVII 01, it is possible
to try diﬀerent E. coli strains or alternative host (i.e. yeast). However, the problem
might be bound to the DNA or mRNA sequences (i.e. sites recognized by DNA-binding
or RNA-binding repressors). In this case, a re-optimization of the gene sequence might
solve the problem.
This solution, the re-optimization of the gene sequences, might be applied also to
the truncated proteins OctaVII 02, OctaVII 03 and OctaVII 07. We demonstrated for
OctaVII 02 that the truncation is not due to endogenous proteolysis, since its mutant
OctaVII 02 Y57Q also resulted truncated (see Figure 2.63). A second hypothesis to ex-
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plain the N-terminal truncations of the three variants is the presence of internal ribosome
binding sites (RBS) in the gene sequences. Re-optimizing the sequences to avoid internal
RBS might be the solution to recover the full length of the proteins.
The third unexpected issue previously mentioned is the high insolubility of the in-
clusion bodies of OctaVII 06 and OctaVII 08. Indeed, these inclusion bodies were not
solubilized in 8 M urea and just partially solubilized in 6 M GdmCl. This result is ex-
tremely uncommon and it is not reported in the literature. In order to fully solubilize
the proteins it is possible to increase the incubation time of the inclusion bodies in the
denaturing buﬀer to several days. Moreover, preliminary treatments with detergents such
SDS and Tween may help in the solubilization of the inclusion bodies.
The high insolubility of the inclusion bodies of OctaVII 06 and OctaVII 08 is ex-
ceptional. On the contrary, protein insolubility upon expression and inclusion bodies
formation are common problems in the ﬁeld of de novo design and in the Octarellin his-
tory (see details in Chapter 1.3, page 19). In the present work, all the expressed proteins
were produced in inclusion bodies, with only 4 partially present in the soluble fraction.
We suggested, following experiments on OctaVII 05 (see Figure 2.90), that the presence
of OctaVII 02, OctaVII 04 and OcatVII 05 in the soluble fraction was due to disulﬁde
formation with endogenous proteins. This covalent interaction prevented the segrega-
tion of part of the protein in inclusion bodies. When free cysteines of OctaVII 04 and
OctaVII 05 were substituted by other residues, the proteins were produced only in in-
clusion bodies. The fourth protein partially found in the soluble fraction is OctaVII 09
WS, which has no cysteines. This protein is a 14-residue mutant of OctaVII 09, which
was produced only in inclusion bodies. The 14 mutations were rationally designed with
the use of a recent version of Rosetta. The same method might be applied to OctaVII 04
and OctaVII 05 in order to shift part of their production to the soluble fraction of the cell.
Protein insolubility, however, is not only bound to protein over-expression in E.coli.
With the exception of OctaVII 09 and OctaVII 09 WS, all the artiﬁcial proteins consid-
ered for further characterization were poorly soluble after refolding and prone to aggre-
gation and precipitation, even at concentrations lower than 0.5 mg/mL. Despite the low
solubility, these proteins presented deﬁned secondary structures according to the far-UV
CD analysis. The content of α-helices in the experimental proteins is lower than expected
from the computational models. However, the content of secondary structures of most
proteins corresponds to the one of the natural TIM-barrel of Thermotoga maritima, with
about 36% of α-helices, 18% of β-strands and 19% of turns. Fluorescence measurements
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conﬁrmed the presence of compact tertiary structures. Since the λmax of the refolded
proteins ranged between 333 and 339 nm, we could exclude the presence in solution of
molten globule states.
Among the 15 artiﬁcial proteins designed and produced in this work, OctaVII 09 and
its mutant OctaVII 09 WS are the most promising. Only the ﬁrst one was further charac-
terized by chemical and thermal unfolding and by near-UV CD. It has a non-cooperative
folding, however it is well folded and extremely thermostable. In order to conﬁrm that
the 14 mutations between OctaVII 09 and OctaVII 09 WS do not aﬀect the secondary
structure content and the overall folding, a full biophysical characterization has to be done
on OctaVII 09 WS. Both proteins were soluble enough to be tested for crystallization,
however we do not have yet information about the quality of the crystals that we obtained
so far. As for Octarellin V.1 described in Chapter 1.3.5, page 24, crystallization helpers
may help to stabilize the protein and to promote crystallization. Alternatively, structural
analysis of both proteins may also be observed by cryogenic electron microscopy (cryo-
EM). This is an emerging technique that has made huge progressions in terms of resolution
(near-atomic), minimal size requirements (64 kDa) and applicability to challenging bio-
logical systems [142]. This technique is currently used in complement to NMR and X-ray
crystallography. Its main advantage is that it does not require crystallization or labeling
of the sample. Currently, many diﬀerent biological structures obtained by cryo-EM are
reported in the Protein Data Bank, including challenging biological molecules: viruses,
membrane proteins, receptors, amyloid ﬁbrils and large cellular machinery such as spliceo-
some and 26S proteasome [143]. Since OctaVII 09 and OctaVII 09 WS have been shown to
form aggregates with a molecular mass higher than 70 kDa (see Section 2.4.14, page 155),
they could potentially be interesting candidates for cryo-EM experiments. Indeed, our
results obtained by circular dichroism and ﬂuorescence on OctaVII 09 (see Section 2.4.13,
page 144), conﬁrmed the presence of secondary structures and a compact tertiary struc-
ture. This suggests that the aggregates are not composed by unordered structures and
are therefore interesting to analyze. The cryo-EM technique can be extremely helpful not
only to solve the structure of OctaVII 09, but also to analyze the aggregates that it forms
in solution and elucidate their dimension, shape and heterogenity. The resolution of the
structure remains the only method to judge the designs, and eﬀorts have to be made in
this direction.
To conclude, the design of artiﬁcial proteins is extremely challenging, and the results
are not always the one that are expected. Improvements have to be done on both the
computational side and the experimental one in order to reduce the “unexpected” results.
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Chapter 6
Annexes
6.1 Annex 1, List of software and programs
1. BLAST [144]
The Basic Local Alignment Search Tool (BLAST) is a web-service created in 1990
by Lipman group at the National Institute of Health in Bethesda (USA) to align and
compare biological sequences. Although is possible to align nucleotide sequences,
in this work the main use of BLAST is for protein sequences alignment (Protein
BLAST). The amino acid sequence of interest can be aligned against a database
(i.e. not redundant protein sequences), or against a personal list of sequences. The
algorithm of the program calculates the total score of the alignment, the query
coverage and the sequence identity for all the paired sequences. The link to the
web-service is:
www.blast.ncbi.nlm.nih.gov/Blast.cgi
2. DATE, DAtabase for Tim-barrel Enzymes
The web-site was created by S. Kumar Singh and M. Madan Babu at the MRC Lab-
oratory of Molecular Biology in Cambridge (UK). It is intended to be a support for
all the researchers that are working with TIM-barrel proteins, in order to get quick
and comprehensive information about the protein of interest. The database includes
85 TIM-barrel enzymes, that are analyzed for composition and residue conforma-
tion (Ramachandran plot). Information such as sequence, length, oligomeric status,
function and metabolic pathways are included in the description of the enzymes.
The web-site last update was in July 2001, and the information are limited to the
protein structures that were available at that moment. It is a good starting point
to work with TIM-barrel structures but, up to date, it is obsolete. The database
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can be found at:
www.mrc-lmb.cam.ac.uk/genomes/date/
3. DeepView, Swiss-Pdb Viewer [140]
The program was developed in 1994 by Nicolas Guex at the SIB Swiss Institute of
Bioinformatics, Biozentrum in Basel (CH) and represents an user-friendly applica-
tion for the visualization and modeling of protein structures. The software is free
and the web-site have detailed user guides and tutorials for training. One of the
advantages of this pdb viewer over the other ones is that it allows to calculate the
distances by atoms in just few clicks. For this reason, it was used in this project.
The program can be downloaded at the address:
www.expasy.org/spdbv/
4. DSSP, Dictionary of Protein Secondary Structure [138]
The program was designed in 1983 by Wolfgang Kabsch and Chris Sander at the
Biophysics department of the Max Planck Institute of Medical Research in Heidel-
berg (DE). DSSP calculates the H-bond energy between all atoms of pdb ﬁles and
assign to each residue its class of secondary structures. It can diﬀerentiate between
α-helices (H), residue in isolated β-bridge (B), β-strands (E), 3-helix (G), 5-helix
(I), hydrogen bonded turn (T) and bend (S). It also calculate geometrical features
and solvent exposure of proteins. The program can be downloaded at:
www.swift.cmbi.umcn.nl/gv/dssp/index.html.
5. GROMACS [110]
The program for molecular dynamic simulation was developed in 1995 by the Berend-
sen’s group at the department of Biophysical Chemistry of the University of Gronin-
gen (NL) for the analysis of biochemical molecules. Its high performance and ac-
curacy make it the best tool overtime for dynamic simulation and it is used today
worldwide, in complex biological system as proteins, lipids and nucleic acids, and in
non-biological systems as polymers. Simulations can be done in both full-atom or
coarse-grained mode, with implicit or explicit solvent and with diﬀerent force-ﬁelds
(AMBER, CHARMM, GROMOS and OPLS). The program can be found at:
www.gromacs.org
6. JPred4 [125]
The Jpred server was developed the ﬁrst time in 1998 by the Barton’s group and
Jpred4 is its more recent version released in 2015. The server does prediction of
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secondary structures, of solvent accessibility and of coiled coil regions. For the
secondary structure prediction the accuracy is more than 82%, calculated in a blind
test. It can work with single sequences, multiple sequences (batch mode) or with
multiple alignments as input ﬁles. Evolutionary information can be included in
the prediction for a higher accuracy. Limitations of the server are the length of
the sequences (maximum 800 residues) and the number of uploads (max 200 fasta
sequences). The web-service is at:
www.compbio.dundee.ac.uk/jpred4/index.html
7. Modeller [145]
Modeller is a program developed in 1993 by A. Sali and T.L. Blundell at the Crys-
tallography Birkbeck College in London (UK). In its ﬁrst version Modeller was
developed to perform comparative protein modeling, in which a given sequence is
threaded on related structures in order to obtain a 3D model (also called homol-
ogous modeling). Nowadays Modeller is implemented with new packages and can
perform de novo modeling of loops [123], multiple alignment of sequences/struc-
tures, clustering and comparison of protein structures. The documentation and the
user manual of the program are well organized and it can be used also from people
that are not expert in structural biology. Modeller can be found at:
www.salilab.org/modeller/documentation.html.
8. PDBeFOLD [119]
The web-service for structural alignment was developed in 2003 by E. Krissinel
and K. Henrick at the European Bioinformatic Institute in Cambridge (UK). It
can perform 3D structure comparison between two structures (pairwise) or more
(multiple), and it can look for protein similarity with the whole RCBS-PDB archive.
The web-service is at:
www.ebi.ac.uk/msd-srv/ssm/.
9. PeptideCutter [129]
PeptideCutter is one of the multiple programs that are present on the ExPASy
Bioinformatics Resource Portal (Expert Protein Analysis System), developed in
2011 by the Swiss Institute of Bioinformatic (SIB). The web-service is a predictor
of cleavage sites in a protein sequence, that may be due to proteases activity or
to chemical reactions. Diﬀerent options of reﬁnement are available, such as the
selection of the enzymes or of the chemicals from their database. The web-service
can be found at:
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www.expasy.org/peptide cutter/.
10. PISCES [121]
The web-service was developed by the Dunbrack’s group in 2003 at the Institute for
Cancer Research in Philadelphia (USA) in order to cull protein sequences according
to their structure quality and sequence identity. The culling can be done on the
whole RCBS-PDB archive or on a personal list of proteins. It accepts diﬀerent
identiﬁers, such as FASTA, GenBank and SwissProt and the BLAST output. The
web-service can be found at:
www.dunbrack.fccc.edu/Guoli/PISCESOptionPage.php.
11. PlasMapper [146]
PlasMapper is a web-service developed in 2004 by Wishart group at the University
of Alberta in Edmonton, Canada. The program generates the graphical output of
a plasmid starting from its DNA sequence. Multiple option of annotation are pos-
sible and it automatically identiﬁes common sequences as promoters, terminators,
reporter genes, replication origins, multi-cloning sites, marker genes and so on. It
is also extremely versatile because it is possible to add personalized annotations
deﬁning the ﬁrst and the last nucleotide of the sequence of interest and the interface
is easy to use. The program can be found at:
www.wishart.biology.ualberta.ca/PlasMapper/.
12. PROSPER [130]
PROSPER is a web-service developed in 2012 by Pike group at the Monash Univer-
sity in Melbourne, Australia. It predicts the cleavage sites mediated by proteases on
a protein sequence, as PeptideCutter, but it is integrated with advanced features,
including a machine learning approach. The amino acid sequence of the target pro-
tein is analyzed for secondary structure predictions, solvent accessibility and native
disorder predictions, in order to ﬁnd the part of the proteins that are more accessible
to a protease cleavage. The results are more precise and speciﬁc than PeptideCut-
ter. On the other hand its database of proteases is limited to 24 enzymes and the
program is less versatile than PeptideCutter because it does not include multiple
options of search among enzymes. The web-service can be found at:
https://prosper.erc.monash.edu.au/home.html.
13. ProtParam [129]
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ProtParam is one of the multiple programs that are present on the ExPASy Bioin-
formatics Resource Portal (Expert Protein Analysis System), developed in 2011
by the Swiss Institute of Bioinformatic (SIB). This web-service calculates diﬀerent
physic-chemical properties starting from an amino acid sequence, such as: a- molec-
ular weight (MW), b- extinction coeﬃcient, c- theoretical isoelectric point (pI), d-
amino acid content, e- atomic composition, f- protein estimated half-life, g- insta-




Pymol is a software for structures visualization developed in 2000 by the company
DeLano Scientiﬁc LLC (today it is commercialized b Schrodinger, Inc.). It allows
the visualization and partial modeling of biomolecules such as proteins, DNA and
small molecules. Diﬀerent functionalities are available in the program, such as the
structural alignment of multiple proteins. Its main features are the high quality of
the graphical outputs, and the possibility to create video of the molecule of interest.
All the picture of protein structures presented in this work are made with Pymol.
The program is available at:
www.pymol.org/2/.
15. R-language [139]
R is a programming language for statistical analysis and graphics developed at Bell
Laboratories (now maintained by Lucent Technologies). Despite it is extremely
well-suited for statistical analysis (linear and non-linear models, clustering, basic
statistic, and so on), R is mainly used in this project for its graphical features: all
the scatter plots, histogram plots and bar plots that are presented in this work are
made with R. The program is available at:
www.r-project.org/.
16. RAMPAGE [147]
RAMPAGE is a web-service developed in 2003 by Richardson group at the Univer-
sity of Cambridge in Cambridge, UK. The program calculates the dihedral angles
for any structure that is uploaded on the web-site, and creates its Ramachandran
plot. Despite the fact that multiple programs are available for the same task, the
graphical output of RAMPAGE is better and nicer. The most populated area (i.e.
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the α-helix or the β-strand regions) are highlighted in blue, while the less common
are in orange. All the Ramachandran plots presented in this work are created with
RAMPAGE, that is available at the address:
www.mordred.bioc.cam.ac.uk/ rapper/rampage.php.
17. RCBS-PDB [120] The RCBS Protein Data Bank is a database for 3D structures
of proteins that was at ﬁrst announced in 1971 as a collaboration between the Uni-
versity of Cambridge, UK, and the Brookhaven National Laboratory, USA. The ob-
jective of the database is to allow world-wide researchers to share protein structural
data obtained through X-ray crystallography, NMR and, nowadays, cryo-electron
microscopy. Up to date, it contains more than 45000 distinct protein sequences, and




Rosetta was developed in the ’90ies by David Baker and it is nowadays the best
software for macromolecular modeling and analysis of protein structures. It is nowa-
days developed thanks to the collaboration between 49 Universities and Research
Institutes world-wide and present numerous tools for protein modeling and design.
Among the more interesting there are: a- RosettaAbinitio, for the prediction of a
3D structure starting from an amino acid sequence; b- RosettaDesign to ﬁnd low
free energy sequences for a given target backbone (used in this work); c- Rosetta-
Dock for the prediction of protein-protein interactions, d- RosettaLigand for small
molecule-protein docking; e- RosettaEnzDes for the design of enzymes and f- Roset-
taMembrane for modeling of membrane proteins. The software is available at:
https://www.rosettacommons.org/.
19. SSpro [124]
SSpro is one of the computational tools that are available in the SCRATCH suite,
developed in 2002 by Baldi’s group at the University of California, USA. SSpro
is a predictor of secondary structures as JPred4, but its recent implementations
improved its accuracy in the prediction up to 93% against 75% of JPred4. This
high accuracy is due to two main things: the use of evolutionary information (i.e.
homologous sequences), and the use of machine learning approaches. It is deﬁnitely
the best program nowadays for secondary structure prediction of natural proteins,
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anyway in the context of this work with artiﬁcial sequences its performances drop
to the same level of JPred4. The program is available at:
www.scratch.proteomics.ics.uci.edu/.
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(AA) (A˚) (AA) (A˚) (AA) (A˚)
1OYCA 400 2 2NZLA 392 1.35 1LQAA 346 1.6
1KBLA 873 1.94 3E96A 316 1.8 1D3GA 367 1.6
2G50A 530 1.65 1WCGA 464 1.1 2VRQA 496 2
1WDDA 477 1.35 1VYRA 364 0.9 1LUCB 324 1.5
1GVFA 286 1.45 2QF7A 1165 2 1P7TA 731 1.95
1Z41A 338 1.3 3DAQA 292 1.45 1FOBA 334 1.8
1ZFJA 491 1.9 3ERPA 353 1.55 1KWGA 645 1.6
1X1ZA 252 1.45 2QULA 290 1.79 3DZ1A 313 1.87
1VQTA 213 2 1TQJA 230 1.6 1TVNA 293 1.41
1O1ZA 234 1.6 3EBVA 302 1.5 1G5AA 628 1.4
1US0A 316 0.66 1VD6A 224 1.3 2CZDA 208 1.6
1GTEA 1025 1.65 1WDDS 128 1.35 2HMCA 344 1.9
1EZWA 349 1.65 1MXGA 435 1.6 1WZAA 488 1.6
2ZBTA 297 1.65 2OO6A 409 1.8 1UC4A 554 1.8
2UY2A 294 1.6 1VC4A 254 1.8 1O94C 264 2
1AJ2A 282 2 1XKYA 301 1.94 1I1WA 303 0.89
1JI1A 637 1.6 3CNYA 301 1.85 2CYGA 312 1.45
3C8NA 356 1.9 1JNDA 420 1.3 1WZLA 585 2
1TWDA 256 1.7 3CBWA 353 1.27 1GOIA 499 1.45
2C0HA 353 1.6 2F2HA 773 1.95 1NTHA 458 1.55
2QW5A 335 1.78 2NT0A 497 1.79 2G0WA 296 1.7
1SR9A 644 2 2NQ5A 755 1.9 2NX9A 464 1.7
2I7GA 376 1.73 1W5QA 337 1.4 1VEMA 516 1.85
1EYEA 280 1.7 1VZWA 244 1.8 2OX4A 403 1.8
1M04A 512 1.95 2V2HA 242 1.18 1QO2A 241 1.85
2A4AA 281 1.84 1VCVA 226 2 2VEFA 314 1.8
3E49A 311 1.75 1YKWA 435 2 2H9AA 445 1.9
1P4CA 380 1.35 1HL2A 297 1.8 1NSJA 205 2
2NWRA 267 1.5 1QW9A 502 1.2 2GJLA 328 2
2D3NA 485 1.9 3EAUA 327 1.82 3BMVA 683 1.6
1ZJAA 557 1.6 5RUBA 490 1.7 1GCYA 527 1.6
1UWSA 489 1.95 1W3IA 293 1.7 1TA3A 274 1.7
1REQA 727 2 2OEMA 413 1.7 3CZGA 644 1.8
1XX1A 285 1.75 2C6QA 351 1.7 1KKOA 413 1.33
1BQCA 302 1.5 1H1NA 305 1.12 1ITXA 419 1.1
3CO4A 312 1.92 1TQXA 227 2 2ZOXA 469 1.9
2YW3A 207 1.67 2QAPA 391 1.59 1EOKA 290 1.8
1VHCA 224 1.89 2I57A 438 1.97 1NVMB 312 1.7
3CM4A 349 1.85 1A53A 247 2 1M5WA 243 1.96
2EPOA 627 1.56 3E2VA 401 1.5 3B9OA 440 1.9
3CIWA 348 1.35 2VM8A 501 1.9 2R8WA 332 1.8
2HK0A 309 2 1SGJA 284 1.84 2A0NA 265 1.64
1TZZA 392 1.86 1CNVA 299 1.65 1LUCA 355 1.5
2QJJA 402 1.8 1GVEA 327 1.38 3B4UA 294 1.2
1N7KA 234 2 2ZUVA 759 1.85 3CWNA 337 1.4
1U5HA 273 1.65 1VF8A 377 1.31 1VHNA 318 1.59
1UB3A 220 1.4 3F4WA 211 1.65 3BPWA 342 1.7
1I60A 278 1.6 1KFWA 435 1.74 2CHOA 716 1.85
1P1XA 260 0.99 2ISWA 323 1.75 1WA3A 205 1.9
3B40A 417 2 1YDYA 356 1.7 1YNPA 317 1.25
1WBHA 214 1.55 1DOSA 358 1.67 1P0KA 349 1.9







(AA) (A˚) (AA) (A˚) (AA) (A˚)
2DSKA 311 1.5 3DHUA 449 2 1US3A 530 1.85
3BOFA 566 1.7 1UJPA 271 1.34 1NOFA 383 1.42
1ZP4A 304 1.85 2RFGA 297 1.5 1L6WA 220 1.93
2CKSA 306 1.6 3BLEA 337 2 1W8SA 263 1.85
1HT6A 405 1.5 1GKPA 458 1.29 1WDPA 495 1.27
1XI3A 215 1.7 2PZ0A 252 1.91 1X38A 602 1.7
1F74A 293 1.6 3CHVA 284 1.45 1VR6A 350 1.92
1ZZMA 259 1.8 1AVAC 181 1.9 2BHUA 602 1.1
1SVDM 110 1.8 1O94A 729 2 1OHLA 342 1.6
1GQIA 708 1.48 1W9PA 433 1.7 3C6CA 316 1.72
1CB7B 483 2 3CUZA 532 1.04 2DDXA 333 0.86
2DVTA 327 1.7 3BMXA 642 1.4 1PIIA 452 2
1OF8A 370 1.5 1V93A 296 1.9 1CB7A 137 2
1ZGDA 312 1.7 1Q6OA 216 1.2 1YX1A 264 1.8
3CH0A 272 1.5 3CLMA 352 1.14 1PXGA 382 1.7
1O94D 320 2 2FHFA 1083 1.65 2VCCA 891 2
1UC4B 224 1.8 1UC4G 173 1.8 1QTWA 285 1.02
1UG6A 431 0.99 2GUYA 478 1.59 1D8WA 426 1.6
1REQB 637 2 2NLIA 368 1.59 2HS8A 402 1.9
1NVMA 345 1.7 1ONWA 390 1.65 3CMGA 667 1.9
2V3GA 283 1.2 1O5KA 306 1.8 2E6FA 314 1.26
2GDQA 382 1.8 1E6QM 501 1.35 2BG5A 324 1.82
7A3HA 303 0.95 3BC9A 599 1.35 1NARA 290 1.8
1H4PA 408 1.75 3CU2A 237 1.91 1VKFA 188 1.65
2TPSA 227 1.25 1EDQA 540 1.55 1RHCA 330 1.8
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6.3 Annex 3, Loops length distribution
(a)
































































































































































Figure 6.1: Loops length distribution
Length distributions for N-term (a) and C-term loops (b), and their corresponding plot
for individual position in the TIM-barrel fold (c and d).
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6.5 Annex 5, Command lines and scripts
6.5.1 Secondary structures assignment
Secondary structure assignment is performed with the program DSSP. the pdb ﬁle is
the only input requested.
Command line:
mkdssp INPUT.pdb -o OUTPUT.txt
6.5.2 Energy minimization of the natural TIM-barrels
Energy minimization of the natural TIM-barrels is performed with the package Relax
of the Rosetta software (version 2015.19.57819 bundle). All the input pdb structures are




e/ -l listpdb -in:file:fullatom
6.5.3 Parametric design
The parametric design of the artiﬁcial TIM-barrel backbones is performed with the
package BundleGridSampler of the Rosetta software (version 2015.19.57819 bundle). Three















-chemical:exclude_patches LowerDNA UpperDNA Cterm_amidation SpecialRotamer VirtualBB Sho
veBB VirtualNTerm VirtualDNAPhosphate CTermConnect sc_orbitals pro_hydroxylated_case1 pr
o_hydroxylated_case2 ser_phosphorylated thr_phosphorylated tyr_phosphorylated tyr_sulfat
ed lys_dimethylated lys_monomethylated lys_trimethylated lys_acetylated glu_carboxylated











<BundleGridSampler name=Octa7 scorefxn="tala" set_bondlengths=true set_bondangles=true
set_dihedrals=true r0=17.4 dump_pdbs=false pdb_prefix="out">
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=0.000000000 delta_omega1=1.57
crick_params_file=beta_strand helix_length=9 delta_t=1 />
<Helix omega0=0.04 delta_omega0=5.890486230 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=5.497787140 delta_omega1=4.31
crick_params_file=beta_strand helix_length=9 delta_t=0.25/>
<Helix omega0=0.04 delta_omega0=5.105088060 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=4.712388980 delta_omega1=1.57
crick_params_file=beta_strand helix_length=9 delta_t=1 />
<Helix omega0=0.04 delta_omega0=4.319689900 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=3.926990820 delta_omega1=4.31
crick_params_file=beta_strand helix_length=9 delta_t=0.25/>
<Helix omega0=0.04 delta_omega0=3.534291740 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=3.141592650 delta_omega1=1.57
crick_params_file=beta_strand helix_length=9 delta_t=1 />
<Helix omega0=0.04 delta_omega0=2.748893570 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=2.356194490 delta_omega1=4.31
crick_params_file=beta_strand helix_length=9 delta_t=0.25/>
<Helix omega0=0.04 delta_omega0=1.963495410 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=1.570796330 delta_omega1=1.57
crick_params_file=beta_strand helix_length=9 delta_t=1 />
<Helix omega0=0.04 delta_omega0=1.178097250 delta_omega1=3.14 helix_length=21/>
<Helix r0=7.5 invert=1 omega0=0.32 delta_omega0=0.785398163 delta_omega1=4.31
6.5. ANNEX 5, COMMAND LINES AND SCRIPTS 247
crick_params_file=beta_strand helix_length=9 delta_t=0.25/>










The alanine substitution is performed in 4 steps with the Design package of Rosetta
software (version 2015.19.57819 bundle). Three input ﬁles are requested: OPTIONS,
PARAMETERS and RESFILE.
COMMAND LINE step 1:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag1.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach
i_cutoff 0 -nstruct 200















<ReadResfile name="rrf" filename="design1.resfile" />
</TASKOPERATIONS>
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<MOVERS>
<SavePoseMover name=init_struct reference_name=init_struct/>
<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE step 1: design1.resﬁle
NATAA
START
2 A PIKAA VIL
3 A APOLAR NOTAA GC
4 A PIKAA VIL
5 A APOLAR NOTAA GC
6 A PIKAA VIL
7 A APOLAR NOTAA GC
8 A PIKAA VIL
13 A APOLAR NOTAA GC
17 A APOLAR NOTAA GC
20 A APOLAR NOTAA GC
21 A APOLAR NOTAA GC
24 A APOLAR NOTAA GC
32 A PIKAA VIL
33 A APOLAR NOTAA GC
34 A PIKAA VIL
35 A APOLAR NOTAA GC
36 A PIKAA VIL
37 A APOLAR NOTAA GC
38 A PIKAA VIL
43 A APOLAR NOTAA GC
47 A APOLAR NOTAA GC
50 A APOLAR NOTAA GC
51 A APOLAR NOTAA GC
54 A APOLAR NOTAA GC
62 A PIKAA VIL
63 A APOLAR NOTAA GC
64 A PIKAA VIL
65 A APOLAR NOTAA GC
66 A PIKAA VIL
67 A APOLAR NOTAA GC
68 A PIKAA VIL
73 A APOLAR NOTAA GC
77 A APOLAR NOTAA GC
80 A APOLAR NOTAA GC
81 A APOLAR NOTAA GC
84 A APOLAR NOTAA GC
92 A PIKAA VIL
93 A APOLAR NOTAA GC
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94 A PIKAA VIL
95 A APOLAR NOTAA GC
96 A PIKAA VIL
97 A APOLAR NOTAA GC
98 A PIKAA VIL
103 A APOLAR NOTAA GC
107 A APOLAR NOTAA GC
110 A APOLAR NOTAA GC
111 A APOLAR NOTAA GC
114 A APOLAR NOTAA GC
122 A PIKAA VIL
123 A APOLAR NOTAA GC
124 A PIKAA VIL
125 A APOLAR NOTAA GC
126 A PIKAA VIL
127 A APOLAR NOTAA GC
128 A PIKAA VIL
133 A APOLAR NOTAA GC
137 A APOLAR NOTAA GC
140 A APOLAR NOTAA GC
141 A APOLAR NOTAA GC
144 A APOLAR NOTAA GC
152 A PIKAA VIL
153 A APOLAR NOTAA GC
154 A PIKAA VIL
155 A APOLAR NOTAA GC
156 A PIKAA VIL
157 A APOLAR NOTAA GC
158 A PIKAA VIL
163 A APOLAR NOTAA GC
167 A APOLAR NOTAA GC
170 A APOLAR NOTAA GC
171 A APOLAR NOTAA GC
174 A APOLAR NOTAA GC
182 A PIKAA VIL
183 A APOLAR NOTAA GC
184 A PIKAA VIL
185 A APOLAR NOTAA GC
186 A PIKAA VIL
187 A APOLAR NOTAA GC
188 A PIKAA VIL
193 A APOLAR NOTAA GC
197 A APOLAR NOTAA GC
200 A APOLAR NOTAA GC
201 A APOLAR NOTAA GC
204 A APOLAR NOTAA GC
212 A PIKAA VIL
213 A APOLAR NOTAA GC
214 A PIKAA VIL
215 A APOLAR NOTAA GC
216 A PIKAA VIL
217 A APOLAR NOTAA GC
218 A PIKAA VIL
223 A APOLAR NOTAA GC
227 A APOLAR NOTAA GC
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230 A APOLAR NOTAA GC
231 A APOLAR NOTAA GC
234 A APOLAR NOTAA GC
COMMAND LINE step 2:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag2.txt -s INPUTs.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrac
hi_cutoff 0 -nstruct 50



















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE step 2: design2.resﬁle
NATAA
START
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14 A NOTAA CPGA
16 A NOTAA CPGA
23 A NOTAA CPGA
25 A NOTAA CPGA
27 A NOTAA CPGA
44 A NOTAA CPGA
46 A NOTAA CPGA
53 A NOTAA CPGA
55 A NOTAA CPGA
57 A NOTAA CPGA
74 A NOTAA CPGA
76 A NOTAA CPGA
83 A NOTAA CPGA
85 A NOTAA CPGA
87 A NOTAA CPGA
104 A NOTAA CPGA
106 A NOTAA CPGA
113 A NOTAA CPGA
115 A NOTAA CPGA
117 A NOTAA CPGA
134 A NOTAA CPGA
136 A NOTAA CPGA
143 A NOTAA CPGA
145 A NOTAA CPGA
147 A NOTAA CPGA
164 A NOTAA CPGA
166 A NOTAA CPGA
173 A NOTAA CPGA
175 A NOTAA CPGA
177 A NOTAA CPGA
194 A NOTAA CPGA
196 A NOTAA CPGA
203 A NOTAA CPGA
205 A NOTAA CPGA
207 A NOTAA CPGA
224 A NOTAA CPGA
226 A NOTAA CPGA
233 A NOTAA CPGA
235 A NOTAA CPGA
237 A NOTAA CPGA
COMMAND LINE step 3:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag3.txt -s INPUTs.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrac
hi_cutoff 0 -nstruct 50
OPTIONS step 3: @ﬂag3.txt
-options
-user

















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE step 3: design3.resﬁle
NATAA
START
15 A POLAR NOTAA GC
18 A POLAR NOTAA GC
19 A POLAR NOTAA GC
22 A POLAR NOTAA GC
26 A POLAR NOTAA GC
45 A POLAR NOTAA GC
48 A POLAR NOTAA GC
49 A POLAR NOTAA GC
52 A POLAR NOTAA GC
56 A POLAR NOTAA GC
75 A POLAR NOTAA GC
78 A POLAR NOTAA GC
79 A POLAR NOTAA GC
82 A POLAR NOTAA GC
86 A POLAR NOTAA GC
105 A POLAR NOTAA GC
108 A POLAR NOTAA GC
109 A POLAR NOTAA GC
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112 A POLAR NOTAA GC
116 A POLAR NOTAA GC
135 A POLAR NOTAA GC
138 A POLAR NOTAA GC
139 A POLAR NOTAA GC
142 A POLAR NOTAA GC
146 A POLAR NOTAA GC
165 A POLAR NOTAA GC
168 A POLAR NOTAA GC
169 A POLAR NOTAA GC
172 A POLAR NOTAA GC
176 A POLAR NOTAA GC
195 A POLAR NOTAA GC
198 A POLAR NOTAA GC
199 A POLAR NOTAA GC
202 A POLAR NOTAA GC
206 A POLAR NOTAA GC
225 A POLAR NOTAA GC
228 A POLAR NOTAA GC
229 A POLAR NOTAA GC
232 A POLAR NOTAA GC
236 A POLAR NOTAA GC
COMMAND LINE step 4:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag4.txt -s INPUTs.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrac
hi_cutoff 0 -nstruct 50















<ReadResfile name="rrf" filename="design4.resfile" />




<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE step 4: design4.resﬁle
NATAA
START
1 A NOTAA GCWYKF
9 A NOTAA GCWYKF
10 A NOTAA GCWYKF
11 A NOTAA GCWYKF
12 A NOTAA GCWYKF
28 A NOTAA GCWYKF
29 A NOTAA GCWYKF
30 A NOTAA GCWYKF
31 A NOTAA GCWYKF
39 A NOTAA GCWYKF
40 A NOTAA GCWYKF
41 A NOTAA GCWYKF
42 A NOTAA GCWYKF
58 A NOTAA GCWYKF
59 A NOTAA GCWYKF
60 A NOTAA GCWYKF
61 A NOTAA GCWYKF
69 A NOTAA GCWYKF
70 A NOTAA GCWYKF
71 A NOTAA GCWYKF
72 A NOTAA GCWYKF
88 A NOTAA GCWYKF
89 A NOTAA GCWYKF
90 A NOTAA GCWYKF
91 A NOTAA GCWYKF
99 A NOTAA GCWYKF
100 A NOTAA GCWYKF
101 A NOTAA GCWYKF
102 A NOTAA GCWYKF
118 A NOTAA GCWYKF
119 A NOTAA GCWYKF
120 A NOTAA GCWYKF
121 A NOTAA GCWYKF
129 A NOTAA GCWYKF
130 A NOTAA GCWYKF
131 A NOTAA GCWYKF
132 A NOTAA GCWYKF
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148 A NOTAA GCWYKF
149 A NOTAA GCWYKF
150 A NOTAA GCWYKF
151 A NOTAA GCWYKF
159 A NOTAA GCWYKF
160 A NOTAA GCWYKF
161 A NOTAA GCWYKF
162 A NOTAA GCWYKF
178 A NOTAA GCWYKF
179 A NOTAA GCWYKF
180 A NOTAA GCWYKF
181 A NOTAA GCWYKF
189 A NOTAA GCWYKF
190 A NOTAA GCWYKF
191 A NOTAA GCWYKF
192 A NOTAA GCWYKF
208 A NOTAA GCWYKF
209 A NOTAA GCWYKF
210 A NOTAA GCWYKF
211 A NOTAA GCWYKF
219 A NOTAA GCWYKF
220 A NOTAA GCWYKF
221 A NOTAA GCWYKF
222 A NOTAA GCWYKF
238 A NOTAA GCWYKF
239 A NOTAA GCWYKF
240 A NOTAA GCWYKF
6.5.5 Loop closure
Loop closure is performed with the package Loopmodel of Modeller version 9.15. The




from modeller import *
from modeller.automodel import *
log.verbose()
env = environ()
























6.5.6 Energy minimization of the backbone structures
Energy minimization of the natural TIM-barrels is performed with the package Relax
of the Rosetta software (version 2015.19.57819 bundle). All the input pdb structures are




e/ -l listpdb -in:file:fullatom -relax:constrain_relax_to_start_coords
6.5.7 Sequence design
The alanine substitution is performed in 4 cycles with the packages Design and Re-
lax of Rosetta software (version 2015.19.57819 bundle). Three input ﬁles are requested:
OPTIONS, PARAMETERS and RESFILE.
COMMAND LINE cycle 1:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag1.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach
i_cutoff 0 -nstruct 100
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<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>











































































































COMMAND LINE cycles 2-4:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag2.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach
i_cutoff 0 -nstruct 10




















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>





























































































































































































































































COMMAND LINE cycles 5-7:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag5.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach
i_cutoff 0 -nstruct 10
OPTIONS cycles 5-7: @ﬂag5.txt
-options


















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






























































































































































































































































COMMAND LINE cycles 8-10:
/path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/source/bin/rosetta_scripts.
linuxgccrelease -database /path-to-rosetta/rosetta_bin_linux_2015.19.57819_bundle/main/d
atabase @flag8.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach
i_cutoff 0 -nstruct 50



















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE cycles 8-10: design8.resﬁle
NATAA
START






















































































































































































































































The molecular dynamic is performed in 7 steps with the GROMACS software (version
5.0.7). The input ﬁle is the protein structure (pdb). PARAMETER ﬁles are reported
when necessary.
COMMAND LINE step 1, Generate the topology:
pdb2gmx -v -f Protein.pdb -o Protein.gro -p Protein.top -ignh -water tip3p -ff amber99sb
COMMAND LINE step 2, Add periodic boundaries:
editconf -f Protein.gro -o 3_PBC.gro -bt dodecahedron -d 1.0
COMMAND LINE step 3, Add water molecules:
genbox -cp 3_PBC.gro -cs spc216.gro -p Protein.top -o 4_Water.gro
COMMAND LINE step 4, Add ions:
grompp -v -f minim.mdp -c 4_Water.gro -p Protein.top -o 5_Setup.trp
COMMAND LINE step 5, Energy minimization:
grompp -v -f minim.mdp -c 5_Ions.gro -p Protein.top -o 6_Setup.tpr
mdrun -v -deffnm 6_Setup -c 6_EM.gro
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PARAMETERS step 5: minim.mdp














COMMAND LINE step 6, Temperature and pressure coupling:
grompp -v -f TempCoupling.mdp -c 6_EM.gro -p Protein.top -o 7_Setup.tpr
mdrun -v -deffnm 7_Setup
grompp -v -f PressCoupling.mdp -c 7_Setup.gro -p Protein.top -o 8_Setup.tpr
mdrun -v -deffnm 8_Setup
PARAMETERS step 6: TempCoupling.mdp
title = NVT simulation
define = -DPOSRES















; OPTIONS FOR BONDS
continuation = no

















tc-grps = Protein Non-Protein
tau_t = 0.1 0.1
ref_t = 300 300
; PRESSURE COUPLING
pcoupl = no
PARAMETERS step 6: PressCoupling.mdp
title = NPT equilibration
define = -DPOSRES















; OPTION FOR BONDS
continuation = yes
constraint_algorithm = lincs














tc-grps = Protein Non-Protein
tau_t = 0.1 0.1










COMMAND LINE step 7, Molecular dynamic simulation:
grompp -v -f MD.mdp -c 8_Setup.gro -p Protein.top -o topol.tpr
mdrun -v
PARAMETERS step 7: MD.mdp
title = Production Simulation
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; Temperature coupling is on
tcoupl = V-rescale
tc-grps = Protein Non-Protein
tau_t = 0.1 0.1
ref_t = 300 300












6.5.9 Cystein removals with Rosetta
The alanine substitution is performed in 4 cycles with the packages Design and Re-
lax of Rosetta software (version 2015.19.57819 bundle). Three input ﬁles are requested:
OPTIONS, PARAMETERS and RESFILE.




atabase @flag1.txt -s INPUT.pdb -ex1 -ex2 -ex1aro -ex2aro -linmem_ig 10 -packing:extrach




















<FastRelax name=fast_relax scorefxn=s task_operations=ifcl/>






RESFILE OctaVII 06: design.resﬁle
NATAA
START
92 A PIKAA S
98 A PIKAA S
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RESFILE OctaVII 07: design.resﬁle
NATAA
START
89 A PIKAA S
92 A PIKAA S
178 A PIKAA S
209 A PIKAA S
217 A PIKAA S
219 A PIKAA S
RESFILE OctaVII 08: design.resﬁle
NATAA
START
42 A PIKAA S
59 A PIKAA S
97 A PIKAA S
119 A PIKAA S
125 A PIKAA S
191 A PIKAA S
RESFILE OctaVII 09: design.resﬁle
NATAA
START
32 A PIKAA S
93 A PIKAA S
98 A PIKAA S
128 A PIKAA S
157 A PIKAA S
RESFILE OctaVII 10: design.resﬁle
NATAA
START
29 A PIKAA S
70 A PIKAA S
90 A PIKAA S
103 A PIKAA S
153 A PIKAA S
209 A PIKAA S
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6.6 HMM physical-chemical features
List of the 17 features selected for the training of the HMM software. The ﬁrst 16 are
obtained from Aaindex (www.genome.jp/aaindex), while the last one is obtained from
DynaMine analysis.
1. Hydrophobicity coeﬃcient in RP-HPLC
2. Amino acid abundance
3. Normalized positional residue frequency at helix termini C
4. Unfolding Gibbs energy in water
5. Information measure for extended without H-bond
6. Information measure for N-terminal turn
7. Zimm-Bragg parameter sigma x 1.0E4
8. Normalized relative frequency of coil
9. Normalized positional residue frequency at helix termini
10. Average relative fractional occurrence in AL(i)
11. Relative preference value at C
12. STERIMOL length of the side chain
13. Alpha-helix indices for beta-proteins
14. Weights for coil at the window position of 6
15. Relative preference value at C1
16. Electron-ion interaction potential
17. DynaMine predicted backbone dynamics

OctarellinVII
A new generation of de novo designed (β/α)8 - barrel proteins
De novo protein design is a growing ﬁeld in protein chemistry, aiming at the production of
artiﬁcial proteins. On a purely fundamental basis, the design of proteins from scratch allows
testing the accuracy of the current protein knowledge and, possibly, to improve it. A deep
knowledge of the sequence, structure, function relationships in proteins is necessary to design
new proteins with speciﬁc functions. This facet of de novo protein design has numerous appli-
cations in biotechnology and biomedicine. On the other hand, in the context of a post-genomic
era, advanced computational methods for protein analysis, modelling and design are needed to
decode the massive amount of genomic data.
There is a long tradition at the University of Lie`ge in the design of artiﬁcial (β/α)8-barrel
proteins, called Octarellins. This fold, also known as TIM-barrel, is widespread in nature, partic-
ularly in enzymes, and represents an interesting target for therapeutic or biological applications.
Several generations of Octarellins were designed with the help of very diﬀerent approaches.
Lessons from these previous works has served as a rational basis for this study, which consists in
the design of a new generation of artiﬁcial TIM-barrels, termed OctaVII. This thesis is divided
in four sections that are shortly described hereafter:
The ﬁrst section describes a pool of natural TIM-barrels, which structural features were
analyzed in order to extract useful information for the following steps of design and validation.
The second section is dedicated to the design of OctaVII models. Backbone structures were
designed with the use of the modelling software Rosetta and Modeller. This led to the selection
of 28 backbones structures, which were used for the design of sequences, using Rosetta. Finally,
more than 8000 artiﬁcial sequences were designed.
The third section includes the in silico validation of the design. Information obtained from
natural TIM-barrels was used to screen the 8000 artiﬁcial sequences and to select 10 of them for
experimental characterization. Various structural features were tested, including hydrogen bond
content and amino acid composition, and both secondary structure predictions and molecular
dynamic simulations were performed.
The fourth section is dedicated to the experimental validation of the design through pro-
tein expression, puriﬁcation and biophysical characterization. In addition to the ten original
sequences that were designed in this work, ﬁve additional variants were tested for their possibly
improved properties (collaborations at the Vrije Universiteit Brussel, Belgium, and at the Van-
derbilt University, USA).
This thesis contributes to the development of the de novo design of proteins as an emerging
methodology for both a better understanding of proteins and the design of new functional
proteins with applications in biomedicine and nanotechnology.
